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Chapter 1 General Introduction
Alzheimer Disease
Alzheimer’s disease (AD) is the most common type of dementia, it is estimated that more 
than 35 million people worldwide suffer from it. As the average age of the world population 
is increasing, it is estimated that the prevalence of AD will double in the next 20 years (dos 
Santos Picanco et al. 2018)(Duthey 2013). AD is characterized by an irreversible and progres-
sive deterioration of brain regions, with a typical etiology of pathological events; the first 
alterations occur in the temporal lobe and the dentate gyrus of the hippocampus, which 
has a direct correlation with short-memory problems. Later the parietal lobe is affected, 
altering spatial visualization processes and resulting in the loss of knowledge of daily habits 
and uses. Finally, the frontal lobe is affected, which leads to behavioral alterations (Iacono 
et al. 2014). Several molecular lesions have been reported in AD, being the accumulation 
of misfolded proteins the most extensively described feature in the AD brain, as well as ox-
idative stress, inflammatory damage, energy failure, and synaptic dysfunction which finally 
inducing cell death pathway activation (Heppner, Ransohoff, and Becher 2015b).
Two forms of Alzheimer’s disease are known, familial and the sporadic forms, and they have 
diverse genetic components; familial AD has been associated with mutations in the amyloid 
precursor protein (APP) gene, and in genes for presenilin 1 (PSEN 1) and presenilin 2 (PSEN 
2), which are the most commonly mutated genes in familial AD (Landman et al. 2006). A 
range of genes has been associated with the sporadic AD, including the E4 allele of the apo-
lipoprotein gene (APOE), which increases the risk for AD 3-fold in heterozygotes and 15-fold 
in homozygotes. In addition, it is known that APOE is associated with the processing and 
accumulation of AB peptide (J.-B. Zhu et al. 2017). The ApoE gene is located on chromosome 
19 (4 exons); has 3 common isoforms: APOE2 (8%), APOE3 (78%) and APOE4 (14%); APOE 
is a lipid transport molecule; APOE2 and APOE3 bind to (HDL) and ApoE4 (LDLR) (Stocker et 
al. 2018). Alterations in APOE4 lead to an increase in cholesterol levels. In the brain, APOE 
is mainly expressed by astrocytes. It is suggested that APOE facilitates amyloid beta (Aβ) 
aggregation by converting an α helix in Aβ into a β sheet (Rebeck 2017). APOE also has an 
important role in the redistribution of lipids during regeneration of neurons after brain after 
excitotoxicity events (Rebeck 2017). There is evidence that the stability of synapses is relat-
ed to APOE activity. Consequently, it was shown that the APOE E4 allele induces a reduction 
of synaptic enzymes such as choline acetyltransferase and glutaminase which contribute to 
the increased risk of nel uurodegeneration (Uddin et al. 2018; Lai et al. 2006). 
The main pathological characteristics of AD are plaques consisting of Aβ peptide, dystroph-
ic neurites in the neocortex, neurofibrillary tangles (NFTs) of tau protein in structures of 
the medial temporal lobe, neuronal loss in white matter, inflammation, among others  (dos 
Santos Picanco et al. 2018). Alzheimer dementia is related to the density of NFTs in the ne-
ocortex and hippocampus, and it is due to the accumulation of soluble tau, while plaques 
are less clearly related to the severity of dementia (Kametani and Hasegawa 2018). Another 
important characteristic of AD is the response of glial cells, where the size and number 
of processes of astrocytes are increased in the white and gray matter. Microglia activity is 
also increased in gray matter containing Aβ plaques and NFTs, with increasing processes 
size and expression of the major histocompatibility class 2 complex (MHC-II), and increased 
expression levels of lysosomal enzymes and complement receptors (Heppner, Ransohoff, 
and Becher 2015b). Furthermore, microglia activation has been associated with inflammas-
ome complex formation, which includes the production of Apoptosis-associated speck-like 
protein (ASC specks). ASC specks protein are released by microglia and have a high binding 
affinity to Aβ fragments, which facilitates the formation of Aβ oligomers and aggregates, 
acting as inflammation-driven cross-seed for Aβ pathology (Venegas et al. 2017; Bamberger 
et al. 2003).
Neuropathological hallmarks
AD has been characterized by the accumulation of specific proteins in neurons or in the 
brain parenchyma. Two main histopathological markers such as Aβ aggregates (amyloidop-
athy), and NFT (tauopathy). Furthermore accumulations of intracellular lipid granules sur-
round Aβ plaques which were included as an AD histopathological marker as well (Sato and 
Morishita 2015). Amyloidopathy has been described widely in AD cases, it is characterized 
by the aggregation of Aβ, resulting from the aberrant cleavage of the amyloid precursor 
protein (APP) by the enzyme β-secretase 1 (BACE1) and γ-secretase enzyme complex, which 
Figure 1. Alzheimer Disease is a multifactorial disorder, at the gross anatomical level, AD brains have atrophy 
associated with neuronal apoptosis, resulting in loss of brain volume. At the molecular level, loss of synapses, 
protein aggregation, of Aβ fragments and tau hyperphosphorylated is observed. In association with glia cell reac-
tion, since, microgliosis and astrogliosis have been reported. Graphics source (CREATIVE COMMONS LICENCE and 
Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License n.d.).
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generates the formation of extracellular and intracellular prone Aβ fragments (Hardy 2002). 
An imbalance between production and degradation, and accumulation of β-amyloid pep-
tide causes an excess of Aβ-plaques which has been pointed as a main initiating factor and 
neuropathological marker in AD. This process is called “amyloid hypothesis,” describing that 
Aβ-42 peptides accumulation is toxic to brain cells and experimental evidence suggest that 
it accumulation precedes and induce tau aggregation (Bloom 2014b) (Figure 1).
Amyloidopathy in Alzheimer Disease
The amyloid precursor protein (APP), 695 to 770 amino acids in size, is a type I membrane 
glycoprotein, particularly expressed in neurons where it is anterogradely transported in ves-
icles to different cellular compartments including synapses (Kamal et al. 2001). It is mainly 
involved in cell signaling, growth and differentiation (Nalivaeva and Turner 2013), and the 
structural and functional alteration of this protein has been related to carcinogenesis, type 
II diabetes and neurodegeneration as AD (Venkataramani et al. 2010; Takayama et al. 2009).
There are two divergent pathways in the natural metabolic processing of APP, known as 
the non-amyloidogenic and amyloidogenic pathways, respectively (Figure 1) (Barage and 
Sonawane 2015). The first pathway processes around 90% of APP, via the cleavage by the 
zinc-binding metalloproteinase α-secretase, whose activity is mainly regulated by protein 
kinase C (PKC), this enzyme cleaves APP in the peptide domain known as Aβ, and the re-
sulting fragment is the precursor protein of α soluble amyloid protein precursor (sAPPα) 
(LeBlanc, Koutroumanis, and Goodyer 1998; Mattson, Guo, and Geiger 1999). This fragment 
is taken up by the membrane enzyme complex γ-secretase, which consists of five subu-
nits: 1) presenilin 1 (PS1), 2) presenilin 2 (PS2), 3) APH1 (anterior pharynx-defective 1), 4) 
enhancer presenilin 2 (PEN2) and 5) nicastrin, and these proteins together perform the in-
tramembrane proteolysis of the sAPPα fragment (Selkoe and Kopan 2003; Wolfe 2010). The 
activation of this pathway has not been associated with any pathology; on the contrary, its 
activation is considered as neuroprotective (Lichtenthaler 2012; Obregon et al. 2012).
The amyloidogenic pathway starts with the cleavage of the APP by the integral membrane 
protein type 1 known as BACE1(Ben Halima et al. 2016), which cleaves at aspartate (Asp) 
amino acid residues. In neurons, APP cleavage occurs specifically at Asp624 (Barao et al. 
2016), releasing a fragment called soluble amyloid β precursor protein (sAPP-β) which in-
duces differentiation to neurons during embryonic development (Freude et al. 2011) and 
the truncated fragment of APP known as C99 or Carboxy-terminal β fragment (β-CTF) (Zhang 
et al. 2012). The latter can be processed at different sites by the γ-secretase complex to gen-
erate the intracellular domain of APP (AICD: transcriptional regulator mainly of proteins of 
the membrane) and 2 Aβ fragments of 40 and 42 amino acids in size, respectively (Koelsch 
2017) (Figure 2).
There is extensive scientific evidence that Aβ fragments, and predominantly Aβ1-42, have 
a hydrophobic structure which favors aggregation and extraneuronal accumulation in in-
soluble plaques, deposited in the parenchyma and cerebral vasculature. This phenomenon 
disturbs the cell homeostasis, affecting neuronal synapses and memory processes, charac-
teristic events in AD (Bignante et al. 2013; Lefort, Pozueta, and Shelanski 2012). This process 
occurs mainly in lipid rafts where the association and cleavage APP by BACE1 has been de-
scribed, and consequently high levels of cholesterol the (main component of lipid rafts) in-
creases the proteolytic activity of BACE1 resulting in increased generation of Aβ fragments. 
These findings suggest that lipids are implicated in the production of Aβ and that the under-
standing of this role will allow a more comprehensive approach to the complex neuropatho-
logical processes that occur in AD, as well as facilitating the generation of novel therapeutic 
strategies aimed at recovering neuronal homeostasis (Ma et al. 2007; Evin and Hince 2013).
Figure 2. Processing of Amyloid Precursor Protein (APP). The non-amyloidogenic pathway start with α-secretase 
activity which results in the cleavage of APP to produce the soluble fragment sAPPα. The terminal fragment of APP 
(α-CTF) is cleavage by ϒ-secretase to produce non amyloidogenic peptide 3 (p3) and the intracellular APP fragment 
(AICD). In the amyloidogenic pathway APP is cleaved by β-secretase at short distance to the transmembrane do-
main, which release a soluble fragment sAPPβ. However, the β-CTF is cleavage by ϒ-secretase to generate the am-
yloidogenic peptide fragments of different lengths such as Aβ 40 or 42 amino acids. Independently of the pathway, 
CTF is released into the cytosol and it migrate to the nucleus to activate gene transcription. Taken and modified 
from “Alzheimer’s disease: the lipid connection” (T Hartmann, Kuchenbecker, and Grimm 2007).
Tauopathy in AD.
Tauopathy is characterized by the aggregation of neurofibrillary tangles (NFT) of hyperphos-
phorylated tau protein. Under physiological conditions, tau protein induces stability during 
the polymerization and depolymerization of microtubules and vesicle transport, however, 
it is also demonstrated that tau is the major antigenic component of neurofibrillary tangles. 
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The property of tau to bind to microtubules is established by post-translational modifica-
tions, mainly by phosphorylation of serine/threonine residues, which modulate the affinity 
of tau for microtubules. The ability of tau protein to modulate the dynamics of microtu-
bules, give tau an important role in the maintenance of axonal transport, allowing the mo-
bilization of signaling molecules, trophic factors and other essential cellular components 
such as mitochondria (Mandelkow et al. 2003; Shahpasand et al. 2012) and vesicles, which 
are determinants for neuronal function and viability (Ballatore, Lee, and Trojanowski 2007). 
However, under pathological conditions, the hyperphosphorylation of tau causes loss of as-
sociation with microtubules promoting toxic aggregates, NFTs, that are one of the most im-
portant neuropathological markers of the severity of AD (Congdon and Sigurdsson 2018b). 
Formation of NFTs begins with tau detachment from microtubules; this detachment is in-
duced by the increase of phosphorylation rate and/or decreasing of dephosphorylation in 
the cytosol (Jouanne, Rault, and Voisin-Chiret 2017). Subsequently, small deposits of non-fi-
brillar tau are formed, called pre-tangles, which undergo conformational changes resulting 
in the formation of paired helical filaments (PHFs) to finally form the neurofibrillary tangles. 
Additionally, it has been established that the malfunction and alterations in the activity of 
tau phosphatases are direct causes of neurofibrillary tangle formation (Bloom 2014b; Mor-
ris et al. 2011). 
The phosphorylation of tau in different sites has different impacts on biologic and pathogen-
ic functions. Quantitative in vitro studies demonstrate that tau phosphorylation at Ser262, 
Thr231, and Ser235, inhibit microtubule binding between 10 and 35%; Studies of binding 
kinetics between hyperphosphorylated tau and normal tau show that Ser199 / Ser202 / 
Thr205, Thr212, Thr231 / Ser235, Ser262 / Ser356, and Ser422, are critical phosphorylation 
sites, which convert tau into an inhibitory molecule, which recruit normal tau and micro-
tubule-associated proteins such as MAP1 and MAP2, producing microtubular disassembly 
(Stoothoff and Johnson 2005). On the other hand, phosphorylation’s in Thr231, Ser396, and 
Ser422 promote auto-aggregation of tau forming fibrillar tau; tau mutations in Ser396 and 
Ser404, are fibrillogenic; phosphorylation in regions rich in proline, inhibit microtubule as-
sembly activity and promote tau aggregation; tau phosphorylation in the C-terminal tail 
increases its activity and strongly promotes its aggregation; phosphorylation’s at the C-ter-
minus and in nearby regions to microtubule binding sites, decreases its activity and desta-
bilizes microtubules. In fact, the NFT and Aβ aggregation levels are tightly correlated with 
low scores during cognitive tests on human AD patients and AD mice models. Despite this 
correlation has been described, the precise mechanism that relates these two proteinopa-
thies still remains poorly understood for AD (Bloom 2014a; Congdon and Sigurdsson 2018a).
Interestingly recent studies have been shown the lipid accumulation as third hallmark, being 
a potential and important link to understand the etiopathology of AD, since it is relevant 
during the aggregation process of Aβ and NFT.
The link between lipids and Alzheimer’s
Lipids in AD have been the least studied factor by the scientific community, despite several 
studies have shown in AD brains that the levels of lipid aggregation were increased compared 
to healthy CNS, suggesting an aberrant modification of lipid metabolism. Furthermore, bio-
chemical alterations have been reported in the composition of lipids in post-mortem brains 
diagnosed with AD (Hirsch-Reinshagen, Burgess, and Wellington 2009). The nervous system 
has a high lipid content and the neuronal lipid composition regulates the traffic and activ-
ity of membrane-anchored proteins that can control cellular Aβ levels, such as the BACE1 
enzyme and the γ-secretase complex, which are regulated by cholesterol, sphingomyelin 
(SM) and phospholipids (Kalvodova et al. 2005; Walter 2012). Furthermore the extreme 
aggregation of Aβ also causes toxic effects by altering the membrane lipid composition, 
affecting the activity of phospholipases A, D and C (Desbène et al. 2012; Sanchez-Mejia and 
Mucke 2010; Jang et al. 2013). Additionally, has been established that the main genetic risk 
factor for sporadic AD (ApoE4) is related with alterations in lipid metabolism in the CNS. This 
is supported by the observation that the level of phosphoinositol biphosphate (PIP2) was 
reduced in postmortem human brain tissue of ApoE4 carriers, in the brain of ApoE4 knock-in 
(KI) mice, and in primary neurons expressing ApoE4 alleles. In contrast, in neurons with high 
ApoE3 levels, phospholipid levels were increased. (Schreiber et al. 2017; Bu 2009; Rebeck 
2017; L. Zhu et al. 2015). 
The influence of lipids on proteinopathies is proposed through the processing of APP and 
production of Aβ, as the proteolytic enzymes involved in this process are integral membrane 
proteins, implying that the lipid environment of these enzymes modulates their catalytic 
activity as well as their translocation to the plasma membrane. Therefore the metabolism of 
cholesterol, as well as other membrane lipids, aroused interest to understand the complex 
development of AD (Ma et al. 2007). In addition, different lines of evidence related lipid 
species such as ceramide, cholesterol and triglyceride levels with Aβ aggregation (Panchal et 
al. 2014; Tall 2008; Listenberger et al. 2003). However, the relationship between lipid metab-
olism and alterations therein, and its potential contribution to AD is still poorly understood.
Cholesterol, metabolism and Alzheimer’s disease.
Cholesterol is a multifunctional molecule. The brain is the organ with the highest cholesterol 
content, containing approximately 25% of the total human body cholesterol, which is locat-
ed in only 2% of the total weight of the human body. It is the main component of the plasma 
membrane of neurons, glia cells as well as myelin, and plays an essential role in the main-
tenance of the structure, plasticity and neuronal functionality (Pfrieger 2003; Salter and 
Beggs 2014). The metabolism of cholesterol is a key factor in the successful maintenance of 
neuronal functions and that its alteration triggers neurodegenerative pathologies such as 
AD (Amira Zarrouk et al. 2018). 
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Most of the cerebral cholesterol is synthesized de novo since the blood-brain barrier (BBB) 
prevents the free passage of cholesterol from the blood plasma to the brain, BBB allows 
the limited passage of chemically modified cholesterol molecules such as 27-hydroxycho-
lesterol and the 24- hydroxycholesterol. However, the cholesterol exchange rate is very low, 
estimated at 1% per day (H.-L. Wang et al. 2016b). It has been shown that the ability of 
mature neurons to synthesize cholesterol is low, which makes glial cells the main source of 
this molecule in the brain (Giudetti et al. 2016). Therefore, the metabolism of cerebral cho-
lesterol is complex and must be finely regulated by various proteins that control processes 
such as synthesis, storage, removal and transport. Failures of this complex metabolism plays 
a crucial role in major human diseases (Lin et al. 2015).
Hydroxy-Methyl-Glutaryl CoA-Reductase (HMG-CoA-R), is a key enzyme in the cholesterol 
synthesis pathway since it catalyzes the production rate of 3-hydroxy-methyl-glutaryl CoA 
to mevalonate which is the precursor molecule for cholesterol (Sharpe and Brown 2013). 
In fact one pharmacological strategy against alterations in cholesterol metabolism focuses 
on HMG-CoA-R inhibitors such as statins which decrease hypercholesterolemia and reduc-
ing the risk of developing amyloidopathy as well (Ostrowski et al. 2007), this is supported 
by epidemiological studies that have demonstrated a correlation between high cholesterol 
levels and AD (Kivipelto et al. 2001; Tobias Hartmann, Kuchenbecker, and Grimm 2007). At 
the molecular level, it has been demonstrated that statins such as simvastatin and lovastatin 
significantly decrease the levels of Aβ40 and 42 peptides in primary cultures of hippocampal 
and cortical neurons, and this effect is repeated in cerebrospinal fluid and brain homoge-
nates of murine models treated with high doses of simvastatin (Fassbender et al. 2001; 
Saeedi Saravi et al. 2017). Other pharmacological inhibitors of the cholesterol pathway, such 
as BM15.766, inhibit the activity of the enzyme 7 dehydrocholesterol reductase that acts in 
one of the final steps of cholesterol biosynthesis, reducing cholesterol and Aβ levels (Reid et 
al. 2007; Fonseca et al. 2010; Alonso, Mata, and Mata 2005).
On the other hand, the pharmacological inhibition of the enzyme Acetyl-Coenzyme A acet-
yltransferase 1 (ACAT1) reduces the levels cholesterol esters and indirectly Aβ aggregation, 
since this protein regulates the excess of free cholesterol by storing cholesterol esterified in 
structures known as lipid drops, which demonstrates that hypercholesterolemia and ACAT1 
activity increase Aβ levels in neuronal cultures (Chang et al. 2006; Huttunen et al. 2010). 
Consequently, the genetic deletion of ACAT1 increases the 24s-hydroxycholesterol levels al-
lowing cholesterol excesses to cross the blood-brain barrier and be carried to the peripheral 
blood flow avoiding its accumulation in the brain, which correlate with Aβ reduction and 
improves the cognitive capacity in AD murine models (S. R. Murphy et al. 2013; Bryleva et al. 
2010). These data suggest that the balance between free cholesterol and cholesterol esters 
play a key role in the development of amyloidopathy.
Role of lipid rafts in AD
Lipid rafts are microdomains of cell membranes, composed mainly of stable associations 
of cholesterol, sphingolipids and specific membrane proteins, their composition makes it a 
dense membrane structure, allowing specific interaction between lipid-lipid, protein-lipid 
and protein-protein interaction (Lingwood and Simons 2010). Multiple functions for lipid 
rafts have been identified, among which its role in signaling, angiogenesis, cellular structure, 
regulation of enzymatic activity and cholesterol homeostasis are highlighted (Marin et al. 
2017).
On the other hand, whether cholesterol levels or sphingolipids of membranes enriched in 
phosphatidylcholine are increased, the over-activation of γ-secretase is observed, indicating 
that the lipid environment in the membrane directly regulates the proteolytic activity of 
enzymes such as BACE1 and indirectly the production of aberrant peptides. However, the as-
sociation between BACE1 and cellular membrane can occur inside or outside the lipid rafts, 
however, aberrant sections of APP occur mainly in the proteolysis performed within these 
microdomains (Choi et al. 2017). Probably due to the preferential formation of co-clusters 
between BACE1, γ-secretase and APP in cholesterol-enriched environments as in lipid rafts, 
rapid endocytosis of these clusters is observed, favoring the conformation of aggregates of 
intracellular Aβ (Bharadwaj et al. 2018; Marquer et al. 2011). These findings demonstrate 
that the composition of membrane lipid structures induce pathological processes and that 
the reestablishment of the levels and physiological conditions of cholesterol, sphingolipids, 
phospholipids and others are an interesting therapeutic target to reduce the formation of 
amyloidogenic aggregates and stop the progress of AD as these data suggest that an imbal-
ance in lipid metabolism favors the proteolytic activity over APP by BACE1 and γ-secretase, 
reinforcing the importance of lipids in the pathogenesis of AD.
Sphingolipids and Alzheimer’s disease
Sphingolipids represent one of the main lipids in cell membranes linked to cell signaling, its 
main fraction is sphingomyelin (SM) with 85% of all sphingolipids and is characterized by the 
presence of phosphocholine and ceramide (Cer). In the metabolism of lipids, Cer is the most 
important branch point in the synthesis of sphingolipids since from this lipid different me-
tabolites are derived as glycosphingolipids (GLs) better known as gangliosides (GM) (Noel, 
Ingrand, and Barrier 2017; Dinkins, Wang, and Bieberich 2017).
High levels of SM reduce the levels of Aβ by inhibiting the activity of γ-secretase, this was 
verified in experiments where the activity of the enzyme sphingomyelinase (SMase) was 
inhibited, this enzyme converts the SM to Cer, and this inhibition results in a significant in-
crease SM levels, decreased levels of Cer and amyloid peptides (Figure 3) (M. M. Mielke et 
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al. 2011; He et al. 2010). Interestingly, there has been an increase in the activity of SMase 
in the brains of patients diagnosed with a familial AD with PSEN1 mutations (Fonteh et al. 
2015). On the other hand, decreasing Cer levels can have a beneficial effect, since a signif-
icant increase in Cer has been reported during the early stages of AD, as this lipid favors 
the processing of the APP protein by BACE1, giving stability during BACE1 activity, creating 
platforms enriched by Cer (Panchal et al. 2014) However, the complete inhibition of sphin-
golipids biosynthesis by down-regulation of the enzyme palmitoyltransferase (precursor of 
the metabolic pathway of sphingolipids) induce increasing of Aβ 1-42 synthesis. Interesting-
ly, this phenomenon can be reversed since the addition of exogenous sphingosine restores 
the ratio between the synthesis of amyloid peptides in neuronal cultures, which suggests 
that sphingolipids can regulate the proteolytic activity of BACE1 and γ-secretase(Grimm et 
al. 2011).
Other sphingolipids associated with AD are the gangliosides or glycosphingolipids. Several 
studies indicate that the total ganglioside pattern is significantly altered in AD brains, which 
highlights the importance of glycosphingolipids (Fukami et al. 2017b). For example, the in-
crease in monoganglioside 1 (GM1) and the increase in the enzymatic activity of sialidase 
(glycolipid regulator) in AD (Fukami et al. 2017a). In histopathological analyses performed 
on senile plaques, it was observed that both cholesterol and GM1 bind to Aβ, this result 
suggests that the GM1/Aβ complex could function as a starting point in the aggregation of 
the peptide, since Aβ levels increase up to 10 times in the presence of GM1, with respect to 
control groups(Yanagisawa 2005), since GM1 enhances the catalytic activity of γ-secretase 
while decreasing the activity of α-secretase. Consequently, the inhibition of enzymes that 
process these gangliosides decreases the levels of Aβ, in vitro and in vivo models. (Yuyama 
and Yanagisawa 2010). However, more studies are needed to clarify the cellular role of GM1 
in both physiological and pathological conditions.
On the other side, Aβ peptide interact with the sphingolipids through a sequence of bind-
ing to sphingolipids. This characteristic confers affinity for sites where the concentration 
of sphingolipids is high, as lipid rafts which enhance the amyloidogenesis, both extra and 
intracellular (Yahi and Fantini 2014; Mahfoud et al. 2002). These data together confirm the 
relationship between SMase, Cer, gangliosides, enzymes, and AD, however, further research 
is still needed to fully understand the mechanisms of lipid regulation and its influence on AD.
Phospholipids and Alzheimer’s disease
Different studies in the brains of patients diagnosed with AD showed alterations in the me-
tabolism and composition of phospholipids, among which the phosphorylated derivatives of 
phosphatidylinositol (phosphoinositide) stand out, as well as alterations in the production 
and activity of the enzymes phospholipase A2 (PLA2), C (PLC) and D (PLD), phosphoinositide 
kinase and various phosphatases (A Zarrouk et al. 2017; Amira Zarrouk et al. 2018). In both 
in vitro and in vivo models have been showed that the use of phospholipid inhibitors such 
as phosphatidylinositol-3 kinase (PI3K) causes a significant decrease in the levels of Aβ in 
the brain (Jimenez et al. 2011). In addition, phospholipids closely related to signaling, regu-
lation of ion channels, membrane structure, endocytosis and exocytosis such as Phosphati-
dylinositol-4, 5-bisphosphate (PtdIns (4, 5) P2) negatively regulate the production of the Aβ 
peptide since it is substrate of the γ-secretase enzyme that effectively competes with APP, 
therefore in the presence of PtdIns (4, 5) P2 reduces the production of Aβ42 in cell cultures. 
The metabolism of PtdIns (4,5) P2 is regulated by PLC, therefore blocking this phospholipase 
indirectly reduces the non-amyloidogenic activity of α-secretase and promote the amyloi-
dogenic pathway, in the absence of PtdIns (4, 5) P2 (Uranga et al. 2017b). However, other 
researchers found that the inhibitory effect of PLC is anti-amyloidogenic, since it decreases 
the levels of Aβ42 and prevents the excessive intake of calcium into the neuron through the 
NMDAR receptors preventing the loss of intracellular calcium homeostasis and decreasing 
the loss of synapses, both events observed in the AD (Uranga et al. 2017a). There is still an 
Figure 3. Cholesterol induces the activity of BACE1 and γ-secretase within lipid rafts. The rafts are small and highly 
dispersed at the cell surface, because they contain only a few proteins, such us APP, ϒ-secretase, and BACE1. In ad-
dition, the cholesterol at lipid rafts give stability to BACE1 activity, which is necessary to cleave APP. Graphic source 
(CREATIVE COMMONS LICENCE and Servier Medical Art by Servier is licensed under a Creative Commons Attribu-
tion 3.0 Unported License n.d.)A close correlation has been established between high cholesterol levels and the 
activity of BACE1 and γ-secretase enzymes, which promotes amyloidogenesis (Figure 3)(Díaz et al. 2014). In vitro 
studies show that a reduction in membrane cholesterol levels through the use of components such as β-methyl cy-
clodextrin (βMCD), causes a decrease in the activity of β and γ secretases, reduction of Aβ peptide levels, and there 
is evidence of a loss of association between BACE1 and membranes enriched with cholesterol (Rituper et al. 2013).
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extensive debate that defines the pros and cons of using PLC inhibitors as a therapy against 
AD. However, it seems that phospholipases are a key point in the understanding of different 
neurodegenerative diseases.
On the other hand, phospholipase D has also been related to the generation of amyloid 
peptides. From the DNA sequence coding for PLD, 3 isoenzymes PLD1, PLD2 and the most 
recent one associated to mitochondria called mitoPLD1 have been identified, however the 
studies have focused mainly on PLD1 and PLD2 which share motives that are essential in 
phospholipid catalysis. These enzymes have a phosphate binding motif for appropriate tar-
geting, they also contain a phosphatidylinositol-bisphosphate binding motif (PIP2) which is 
critical for catalytic activity (Frohman 2015; Oliveira et al. 2010). However, PLD1 has a motif, 
which is a negative regulatory element of this catalytic activity. PLD1 and 2 hydrolyze phos-
phatidylcholine (PC) to generate phosphatidic acid (PA) and choline (Oliveira et al. 2010). PA 
is a bioactive molecule that allows the formation and fusion of membranes in the secretory, 
lysosomal and autophagy pathways. The action of PA phosphatases originates diverse mol-
ecules such as diacylglycerol (DAG) and lysophosphatidic acid (LPA) which are found mainly 
in the membranes of transport vesicles (Liu et al. 2013).
Overexpression of PDL1 in hippocampal neurons increased the transport of APP towards 
the plasma membrane, and the growth of neurites and these events do not occur in neu-
rons with AD, on the contrary, under physiological conditions PDL1 negatively regulates the 
catalytic activity of PS1 (γ-secretase) and its transport to the cell surface, preventing the 
formation of Aβ42. On the other hand, the derivatives of this protein allow the formation 
of intracellular transport and degradation vesicles favoring the maintenance of neuronal 
homeostasis(Cai et al. 2006). These studies support the action of different phospholipids 
(phosphoinositols, PA and DAG) in AD specifically in the formation of amyloid aggregates 
and the subsequent intracellular ion imbalance among other molecular events that lead to 
the loss of synapses and finally to neuronal death, which turns these molecules into poten-
tial therapeutic targets to be explored against this disease (Tanabe, Nakajima, and Ito 2014).
Arachidonic Acid, PLA, Docosahexaenoic Acid (DHA) and Alzheimer’s
Arachidonic acid (AA) is one of the main omega-6 fatty acids present in food of animal origin. 
In addition, the body synthesizes AA by transforming linoleic acid present in cereals, nuts 
or vegetable oils. AA has been considered as a lipid that activates inflammatory pathways 
(Bazinet and Laye 2014). AA is located in the cell membranes and it is found mainly in neu-
rons. Its function is associated with cell signaling, favoring neuronal activity and long-term 
potentiation (LTP) a cell model for learning and memory (Bazinet and Laye 2014). Pharma-
cological inhibitors of AA decrease memory and learning capacity in behavioral tests such as 
the Morris water maze, and the mechanism by which AA and PLA2 (AA regulatory enzyme) 
activates neurons is through the recruitment and stabilization of receptors AMPA to the syn-
aptic membrane surface, which favors the increase of calcium currents increasing the firing 
rate of neuronal action potentials. Opposite effects are observed by inhibiting PLA2, or by 
decreasing AA levels. These results do not negate the possibility that excess AA and PLA2 
cause abnormal activity in neurons, in fact, over activity of PL2A is reported in AD (Zárate 
et al. 2017).
AA directly modulates neuronal activity and indirectly through its metabolites. When a le-
sion occurs in the membrane of neurons, AA is released and PLA2 produces two metabo-
lites, such as Prostaglandins and Leukotrienes (Chen et al. 2008). These metabolites exert 
pro-inflammatory activities, glutamate excitotoxicity, decreased synaptic plasticity and ox-
idative stress. Which agrees with the increased levels of cytosolic PLA2 immunoreactivity, 
decreased levels of AA in the brain and the loss of learning capacity and memory retention 
(Rao et al. 2012; Luo, Long, and Chen 2015). In AD model mice, deletion of GIVA-PLA2 (a 
phospholipase specific for neurons) improved the performance of mice in behavioral tests. 
The probable mechanism that regulates synaptotoxicity generated by hyperactivity of GI-
VA-PLA2 is through the excess of calcium influx since the membrane NMDA receptors levels 
increase drastically the activity of this phospholipase during chronic exposure to the oli-
gomers of Aβ (Bate 2017; Sanchez-Mejia et al. 2008).
The polyunsaturated fatty acid DHA, commonly known as omega-3 (C22: 6 n-3), is essential 
for the maturation of the central nervous system and the preservation of brain functions 
during the course of life, however is a lipid that should be ingested in the diet, in fact the 
satisfactory intake DHA has become a challenging goal, due to the deficiency in the western 
diet of n-3 fatty acids, which can be considered as a risk factor for the AD (Mohaibes et al. 
2017; Cunnane et al. 2013). Therefore, DHA is considered as a neuroprotective molecule, 
several authors point out that AA and DHA have antagonistic effects, when DHA increases 
AA decreases exerting an anti-inflammatory role, its activity depends on PLA enzymes, they 
process DHA from α-Linoleic acid (Abdullah et al. 2017).
Enhancing the activity of these enzymes is proposed as a therapeutic strategy that reduces 
the levels of amyloid peptides, since epidemiological studies showed that populations with 
high intake of DHA reduce the risk of suffering some dementia, consequently low levels 
of DHA have been found in the blood of patients with AD (Yassine et al. 2017; Freund-Le-
vi et al. 2006). In-vitro and in-vivo studies show that the presence of DHA in the nervous 
system reduces the levels of Aβ, improves the synapse and cognitive capacity in murine 
models. Additionally, it has been shown DHA increase the expression of genes that promote 
cell survival through the regulation of lipid function such as cellular communication, signal 
transduction, neuronal plasticity, neurotransmitter release, and vesicle formation, providing 
homeostasis (Zhao et al. 2011). However, it is necessary to perform studies in appropriate 
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models for AD, which allow to fully understand the molecular mechanism that regulates 
these neuroprotective effects, since DHA is a potential anti-inflammatory therapeutic target 
(Heras-Sandoval, Pedraza-Chaverri, and Pérez-Rojas 2016).
AD and Neuroinflammation
Inflammation in the brain (Neuroinflammation) is a biological response which involves sev-
eral changes of local immune cells such as microglia and astrocytes around the damaged 
or inflamed area, with release of inflammatory molecules and increased oxidative stress 
(Glass et al. 2010a). Neuroinflammation has been described as a pathological contributor in 
many neurodegenerative diseases. Some of these diseases are defined as proteinopathie, 
due to abnormal aggregation of specific protein species. In vitro and in vivo models have 
been shown that proteinopathies increased the immune response at the brain. The brain 
has been considered an “immunologically privileged” organ, since, the immune cells from 
peripheral are unable to cross the Blood-brain barrier, then the glia cells (microglia and as-
trocytes) are the neuroimmune system.
In the CNS, microglia constantly regulate the tissue environment by producing factors that 
influence their surrounding brain cells, particularly in response to stimuli such as pathogen 
invasion or tissue damage, promoting tissue repair. However, this inflammation response 
may become detrimental to the tissue if it persists resulting in excessive production of neu-
rotoxic molecules, such as cytokines and interleukins amplifying the inflammatory process-
es (W. Y. Wang et al. 2015). In facts neurotoxic molecules have been associated with neuro-
degenerative diseases like AD and Parkinson Disease. These diseases have proteinopathies, 
defects in axonal transport, mitochondrial dysfunction and apoptosis in common. The in-
flammatory response in neurodegenerative diseases is not clearly described as an initiating 
factor, nonetheless, increasing evidence shows a close relation with disease progression 
suggesting important roles of glia cells and their effectors of inflammatory processes at the 
brain.
Microglia cells
Microglia are the macrophages cell population in the central nervous system (CNS) making 
up around 10% of all glia cells. In 1932, Pio Hortega del Rio described the morphology of 
microglia in the CNS, as cells that extend long processes and branches from the soma, and 
was called “ramified microglia”. However, later it was shown that the morphology of mi-
croglia is diverse and that these processes are highly motile. In fact, that properties help to 
sense signals, and interactions with epithelial cells, neurons, astrocytes, oligodendrocytes, 
and blood vessels. This is essential to function as a primary innate immune cell in the CNS. 
Microglia cells respond to any alteration in brain homeostasis, such as infections or protein-
opathies, for instance amyloid-β aggregations. The response is called microglia activation 
and it includes morphological, gene expression, and functional changes. Activated microglia 
can adopt an amoeboid morphology which is usually accompanied by microglia proliferation 
(microgliosis) (Keren-Shaul et al. 2017). While on the molecular level have been described 
the overexpression of specific molecules, such recognition receptors, e.g., toll-like receptors 
(TLRs), CD14, CD36, triggering receptor expressed by myeloid cells 2 (TREM2), and CD33 
(Hickman, Allison, and El Khoury 2008a).
The proinflammatory response is followed by myeloid differentiation primary protein 88 
(MYD88) and Nuclear factor-κB (NF-κB) pathway, triggering cytokines production such as 
IL-1β and IL-6. This cellular process involves multiple molecular mechanisms such as inflam-
masome to control the inflammatory response (Wu et al. 2017).
Microglia function
Microglia are play critical roles in brain development by supporting neurogenesis, pruning 
synapses, and removal of excess neurons and inflammatory response. During development 
the Microglia cells arrive in the brain around embryonic day 9 in mice. guiding the neural 
circuit formation trough realizing neurotrophins like Bdnf. It was demonstrated since mi-
croglia Bdnf depletion, induced impaired learning and memory behavior by reduction of 
synapse formation on mice (Parkhurst et al. 2013). Microglia are also involved in synapses 
engulfed and elimination (pruning) during normal brain development, as well as phagocy-
tosing apoptotic cells, modulating neurogenesis, and regulating synapse plasticity and mye-
lin formation.  All these different functions are often accompanied by regional differences in 
microglia morphology and region distribution, which change depending of maturation stage 
of the brain (Schafer and Stevens 2015; Hammond et al. 2018).
On the other hand has been reported that immune activation in the CNS, present in infec-
tions, immune disorders, and neurodegeneration, involves microglia and astrocytes which 
constitute the resident immune cells of the CNS of the brain during development, adult-
hood, and aging (Akiyama et al. 2000). Like macrophages, the microglia cells destroy strange 
materials in the CNS as innate immune player through the phagocytic and cytotoxic mech-
anism. Furthermore, microglia can act as antigen-presenting and contribute to inflamma-
tion by secreting molecules, such as cytokines (Interleukins), Tumoral Necrosis Factor-alpha 
(TNF-α), free radicals (Nitric Oxide), and polyunsaturated fatty acids (Eicosanoids) (Heppner, 
Ransohoff, and Becher 2015b). In the CNS, the microglia constantly produce molecules that 
influence surrounding cells such as astrocytes and neurons, however, peak activity occurs 
in response to homeostasis alterations commonly due to viral or bacterial infections, free 
radicals, loss of ion homeostasis, as well as neurotoxins and innate immune dysfunction, 
furthermore it has been shown that protein aggregations such as beta-amyloid also activate 
the fully phagocytic form of microglia (Glass et al. 2010b).
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Although the inflammation is a response to recover homeostasis, it can also produce neu-
ro-toxic factors, which can amplify the alteration, generating pathological tissue, depending 
on the persistence of inflammatory stimuli or failure in compensation mechanisms (Hep-
pner, Ransohoff, and Becher 2015a). The main neurotoxic factors are cytokines and inter-
leukins. These neurotoxic mediators, in general, are associated with several neurodegener-
ative diseases including AD, which are commonly linked to intracellular mechanisms failures 
such as protein degradation, mitochondria dysfunction, defects on axonal transport, and 
apoptosis. Inflammation is not related as initiating factor of the neurodegenerative disease. 
However, the emerging evidence on the sustained inflammatory response from microglia 
and astrocytes in disease progression, suggest important roles of neuroinflammation effec-
tors in neuronal dysfunction and death (Heneka et al. 2015a). Neurodegeneration induced 
by protein aggregations is relevant, since it refers an imbalance in homeostasis mechanism 
kept by CNS, recent evidence suggests an important role of immune response in neurode-
generation.
Microglia in AD
Chronic activation of microglia affects brain homeostasis, inducing injuries and death of 
neurons through constant release of cytotoxic factors, including inflammatory cytokines, 
complement components, chemokines, reactive nitrogen species (RNS), reactive oxygen 
species (ROS), and fatty acids. All those mediators have been suggested to contribute to 
AD pathogenesis. The cytokines are divided into two main groups according to the effect: 
pro-inflammatory and anti-inflammatory, basically, both have antagonist effects as pro-in-
flammatory cytokines amplify the inflammatory response while anti-inflammatory limit the 
inflammatory response. IL-1, IL-6, and TNF-α are the most common pro-inflammatory cy-
tokines, which have been found increased in the CSF and brain of AD patients (Zheng, Zhou, 
and Wang 2016), being described as a relevant factor in AD pathophysiology. On the other 
hand, anti-inflammatory cytokines such as interleukins (IL’s) 4, 10 and 13, are also elevat-
ed to negatively modulate the inflammatory response. Interestingly has been reported the 
increasing levels of those IL’s reduced the Aβ aggregation and inflammatory response ob-
served surrounding senile plaques (Szczepanik et al. 2001) (figure 4).
In AD, microglia is binding to all types of Aβ such as soluble amyloid β, oligomers, and Aβ 
fibrils via microglia receptors including class A scavenger receptor A (SR-A)  1, CD36, CD14, 
α6β1 integrin, CD47 and toll-like receptors (TLR2, TLR4, TLR6 and TLR9) which are involved 
with inflammatory response in AD (Bamberger et al. 2003). The binding process is followed 
by engulfment of Aβ by microglia to degrade it via endosomes/lysosomes. Although ear-
ly microglial recruitment promotes Aβ clearance, the constant accumulation of microglia 
on the time exacerbate the cytokines release, due to two events: increasing levels of SR-A 
at the cell membrane (Hickman, Allison, and El Khoury 2008b), and Aβ plaques are highly 
resistant to enzymatic degradation, both trigger a general failure of Aβ clearance (Heneka 
et al. 2015a; Hickman, Allison, and El Khoury 2008a). (Mawuenyega et al. 2010). This has 
been suggested, that increased cytokine release has an antagonist effect on phagocytosis 
by microglia cells via negative regulation of Aβ phagocytosis receptors. Recently have been 
described mutations on the microglia receptor TREM2 (triggering receptor expressed in my-
eloid cells 2) and apoE4, which increased the AD risk (Yuan et al. 2016). TREM2 is a surface 
receptor highly expressed by microglia and it regulates the phagocytosis of brain debris. 
TREM2 activity is mainly detected on microglia and reactive astrocytes surrounding apoptot-
ic brain cells and Aβ plaques (Jay, von Saucken, and Landreth 2017). On the other hand, the 
overexpression of apoE4 has been described to reduce the clearance of Aβ and increase its 
deposition in plaques, however, the precise mechanisms by which apoE4.confers increased 
Figure 4. Inflammation in Alzheimer’s Disease. Amyloid-β peptide, produced by cleavage of the amyloid precursor 
protein (APP), aggregates forms that activate microglia, in part by signaling through Toll-like receptors (TLRs). These 
receptors induce the transcription factors NF-κB, which produce reactive oxygen species (ROS) and drive the ex-
pression of inflammatory mediators such as cytokines. These inflammatory factors act directly on neurons and also 
stimulate astrocytes, which amplify proinflammatory signals to induce neurotoxic effects.; resulting in neuronal 
apoptosis. Microglia also play protective roles by mediating clearance of Aβ through phagocytosis mechanisms. 
Graphic source (CREATIVE COMMONS LICENCE andServier Medical Art by Servier is licensed under a Creative Com-
mons Attribution 3.0 Unported License n.d.).
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AD risk are not well understood yet (Castellano et al. 2011). Interestingly the activity of 
both receptors together plays a key role to facilitate microglial phagocytosis of apoptotic 
neurons, debris, and aggregates such as Aβ (Atagi et al. 2015).  c by differentially regulating 
clearance of Aβ from the brain, which is directly related with inflammatory cytokines-medi-
ated neurotoxicity induced by excess Aβ (Carmona et al. 2018).
Transcriptomic analysis of Aβ-plaque-associated microglia has revealed a special pheno-
type, which is related with disease environmental. This phenotype is not observed in mi-
croglia in non Aβ-plaque areas, indicating that the neuroinflammation phenotype mainly 
occurs in plaque-associated microglia, also known as disease-associated microglia (DAM) 
(Butovsky and Weiner 2018). These microglia cells have up-regulated genes included Axl, 
Apoe, Clec7a, Itgax, Lgals3 and Cst7, which have been reported by several groups to be part 
of common neurodegenerative diseases. Microglia lose the homeostatic molecular func-
tions, related with synaptic stability and become into a chronical inflammatory source, how-
ever, more investigations are needed to probe if the microglia can show specific phenotypes 
and functions depending of the disease and the stages of the disease (Butovsky and Weiner 
2018; Yuan et al. 2016).
Mediators in AD inflammation
As it has mentioned before, Aβ aggregation alone can induce inflammatory response; main-
ly by microglia over activate which release pro-inflammatory cytokines during long-term 
that subsequently inducing neuronal apoptosis which contributes to cognitive decline and 
AD progression (Shabab et al. 2017). These results were also supported in AD mice models, 
where the pro-inflammatory cytokines such as IL-1 IL-1β and TNF-α increased proportionally 
with the Aβ plaques burden. Furthermore, these cytokines levels were elevated in cerebro-
spinal fluid (CSF) and plasma of AD patients compared with healthy controls or patients with 
mild cognitive decline. In addition, in vitro experiments showed that exposition of microglia 
primary cultures to Aβ 41-42 oligomers increased the production of IL-1, IL-1β, and TNF-α 
(Spangenberg and Green 2017). To produce these cytokines, the microglia activates several 
molecular pathways which involve enzymes such as caspases. IL-1β maturation requires the 
activation of caspase-1; interestingly high levels of caspase-1 are reported in the brains of 
patients with AD (Flores et al. 2018). Consequently, the levels of IL-1β are also increased es-
pecially around the Aβ plaques and CSF, as well as the in vitro evidence showed the release 
of IL-1β after the stimulation with Aβ oligomers (W. Y. Wang et al. 2015). Furthermore, has 
been shown those cytokines can affect the neuronal function altering the action potentials 
of synaptic transmission in AD model mice. Recently has been reported microglia, mac-
rophages, and dendritic cells coexist in the CNS at steady state which change to activated 
state after an inflammatory stimulus, during aging and in Alzheimer animal models (Mrdjen 
et al. 2018).
Aβ plaques activates NRLP3 inflammasome complex via lysosome disruption, the NLRP3 
regulates the caspase-1 dependent maturation and secretion of pro-inflammatory cytokines 
(Nakanishi et al. 2018). Since during the oligomerization of NLRP3 two adaptor molecules 
such as ASC and the pro-form of caspase-1 are recruited, leading to the activation (cleavage) 
of caspase-1. Activated caspase-1, in turn, catalyzes the maturation of IL-1β. Consequently, 
has been shown that deficient of caspases-1 and NRLP3 reduce  Aβ plaque burden, fur-
thermore reduce the altered synaptic plasticity, the spatial memory affection and behav-
ioral alteration in AD mice models (Nakanishi et al. 2018). Caspase 3 is also activated in 
over-reactive microglia which have a positive regulation over the nuclear factor-κB (NF-κB), 
which is a transcription factor for pro-inflammatory mediators such as IL-1β, TNFα, and ni-
tric oxide (NO) (Wu et al. 2017). Consequently, deletion of caspases 1 and 3 in mice models 
also showed negative regulation on microglia activation and AD progress (de Calignon et 
al. 2010). These results suggest that pro-inflammatory cytokines from microglial activate 
surrounding the Aβ plaques are potentially detrimental for brain homeostasis increasing 
the AD pathology.
The pro-inflammatory cytokines via surface receptors activate the enzyme inducible nitric 
oxide synthase (iNOS) in microglia, which increase the production of NO that in high con-
centration is neurotoxic (Sierra et al. 2014). The levels of iNOS are up-regulated in AD pa-
tients favoring the posttranslational nitration on tyrosine amino acids of Aβ peptides which 
increase their disposition to aggregate, interestingly the nitration has been found in the core 
of Aβ plaques, suggesting nitrated Aβ is able to initiate the plaque formation and transform-
ing the plaque into insoluble stage being NO relevant during the early stage of development 
of AD (Heneka et al. 2015b). In contrast, the genetic ablation of iNOS reduces the Aβ burden 
and inflammatory response in AD mice models. This indicates posttranslational modification 
causes structural damage to AD brain (Nathan et al. 2005).
Therapeutic strategies to treat AD.
Diagnose Alzheimer’s dementia, is the first obstacle to understand the disease since is dif-
ficult to have an accurate diagnosis. The clinical diagnosis needs the association of neuro-
logical and psychiatric history of the patient; furthermore, neuropathology, neuroimaging, 
computed tomography and the clinical phase called moderate cognitive impairment (MCI, 
Mild Cognitive Impairment), are determining factors to differentiate Alzheimer’s disease 
from other causes of dementia (dos Santos Picanco et al. 2018). Currently, new promising 
diagnostic tests are emerging, such as positron emission tomography (PET), biomarkers and 
determination of atrophy of medial temporal lobe by magnetic resonance imaging (MRI), 
which basically seeks identify with a high sensitivity, patients with Alzheimer’s disease, how-
ever still without clear results as well as the clinical treatments (dos Santos Picanco et al. 
2018).
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There is a high unmet medical need for effective treatment of AD. Despite all the therapeu-
tic approaches, the treatments are still palliative, without blocking the cause of the disease. 
In recent years, some drugs have been proposed for the treatment of AD, the goal of current 
pharmacologic therapies is to delay the progression of symptoms of neurocognitive and 
physical decline mainly focusing on early stages of AD. However most of them are in the 
experimental phase and currently, the approved treatments have different molecular brain 
targets (Cummings et al. 2018).
AD brains have reduced the levels of Acetylcholine neurotransmitter and their function 
which is involved on cognitive impairment. The overactivity of cholinesterase enzyme (AChE) 
degrade the acetylcholine from the synaptic cleft, which decreases the signal transmission 
between neurons. There have been developed specific inhibitors of cholinesterase avoiding 
reversibly their activity on Acetylcholine, thereby increasing cholinergic transmission be-
tween neurons. However, after several years of clinical trials, the benefits of this treatment 
on clinical symptoms of AD patients seems not too relevant. Since, the cognitive decline 
decreased 3.15 points less than placebo on a 78-point assessment scale over 4 years with a 
delay on the AD progression of 6 months, as long as vitamin E is included with the treatment 
(Epperly, Dunay, and Boice 2017). There is also approved partial inhibitor of N-methyl-D-as-
partate (NMDA) receptors, Memantine, which reduce the toxic effect from Glutamate excess 
on hippocampal neurons, this inhibitor has been used on several dementia types, showing 
benefits in cognition functional and global status, however the benefits can be classified as 
moderate and not consistent results between patients. The magnitude of benefit was: 2.97 
points on a 100-point cognitive assessment scale, 1.27 points on a 54-point ADL scale, and 
2.76 points on a 144-point behavior scale (Epperly, Dunay, and Boice 2017).
Other medications that have been investigated include statins, non-steroidal anti-inflam-
matory to limit the aggregation and inflammation induced by of Aβ plaques in AD patients, 
however, were not found a beneficial effect on the cognitive process and functional status. 
On the other hand, the poly-unsaturated fatty acid Omega-3 has been tested on AD patients 
and healthy controls having not beneficial effects on AD patients, nonetheless this fatty acid 
is still a potential target because observational studies have suggested the intake of dietary 
omega-3 reduce the incidence of dementia, being a potential preventive treatment against 
dementia due to their anti-inflammatory effects (Ajith 2018).
To control the inflammatory processes that result from the disease, several therapeutic 
strategies have been tried, which are basically aimed at inhibiting cyclooxygenase 2 (COX2), 
prostaglandin E2 receptors (PGE2), stimulation of phagocytosis by microglia, immunization 
with Aβ, blocking complement factors and TNF-α, among others; the results of those thera-
pies are still controversial. The possible explanations for the absence of success with anti-in-
flammatory therapy with more established dementia include a failure to stop the spread of 
fully established tauopathy and failure to rescue neuron loss (Heneka et al. 2015b).
In addition, some drugs have been designed to act on the activity of amyloid-producing 
enzymes, however most of them are in the experimental phase; within these we have: the 
activators of α-secretase and the inhibitors of β and γ secretase, as therapeutic candidates, 
which prevent production and aggregation of Aβ and favoring their elimination; Aβ-immu-
notherapy, either by passive or active immunization, seeks to generate anti-Aβ antibodies, 
which bind to the senile plaques, inducing elimination by the microglia or alternatively join-
ing the soluble Aβ in the periphery, facilitating its exit from the brain; inhibitors of fibrillation 
of Aβ, base their mechanism of action, by interfering with Aβ-Aβ and Aβ-ApoE interactions, 
preventing conformational changes in their structure and subsequent fibrillation; however, 
the results are controversial. Inhibitors of BACE-1 such as Verubecestat showed efficiency 
to reduce the Aβ level in the cerebrospinal fluid, but no effect on cognitive or functional 
decline of patients with Alzheimer’s disease (Egan et al. 2018), in contrast, AZD3293- BACE1 
inhibitor had prolonged suppression of plasma and cerebrospinal fluid Aβ, and Two “Phase 
III” studies are now ongoing to know the effects on cognitive decline (Cebers et al. 2016). 
Furthermore, comparative studies have been shown BACE1 inhibitor treatments more ef-
fective than immune therapies, since, results showed that AZD3293 is a better therapeutic 
agent for treating AD than Solanezumab (Hassan et al. 2018). Currently, clinical trials of 
Figure 5. RNAi natural process. Drosha cleaves the Pri-miRNA to generate a pre-miRNA or short hairpin RNA (shR-
NA) it requires the activity of endogenous Exportin 5 for nuclear export. Ago2 (Argonaute 2) is recruited by the role 
of DICER binding partner (TRBP), that forms a dimer with Dicer, and then receives the pre-miRNA. The shRNA is 
cleaved in one step by DICER generating a 19-22 nucleotides duplex siRNA. After identification of the “guide strand” 
in the siRNA duplex, the “passenger strand” is cleaved by Ago2. The “guide strand” is integrated into the RISC that 
contains different argonautes and argonaute-associated proteins. The siRNA guides RISC to the target mRNA. The 
target mRNA is cleaved by Ago2 and degraded. Graphic template  source (CREATIVE COMMONS LICENCE and Serv-
ier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License n.d.).
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gamma-secretase inhibitors, aggregation blockers, vaccination with Aβ, vaccination with 
monoclonal antibodies against Aβ epitopes are ongoing. Finally, other candidates have been 
proposed for their potential as a therapy, such as genetic therapies by neutralizing targeted 
mRNA molecules of β or Ω secretase, however, they are still in development stages (Diego 
Piedrahita et al. 2016; Villamil-Ortiz et al. 2016).
RNA interference (RNAi) a therapeutic alternative to treat Alzheimer’s disease
A wide variety of factors can induce AD and it is hard to understand what the functions of 
these factors are and how they work together to triggering AD; however, RNAi may make 
it easy to determine these. Since RNAi can be used to bind and allow the degradation of 
specific mRNA, which make evident endogenous biological pathways, is can be a potential 
therapeutic strategy, by decreasing the expression of genes and observe the changes on a 
specific molecular pathway, as well as biological and pharmacological effects in cell cultures 
and animal models for several diseases (Chakraborty et al. 2017b; Bobbin and Rossi 2016). 
Compared with other therapeutics, the advantage of RNAi is that the targets include those 
that are not easy to be targeted with drugs might be amenable for RNAi targeting. This is 
because in theory any transcript may be targeted by RNAi. However, stability and the re-
lease of RNAi in vivo, low intracellular uptake and non-specific stimulation of the immune 
system are critical points to be resolved in order to develop therapeutic RNAi for clinical use. 
Currently, RNAi is being used in basic bioscience, to solve the specific problem of several 
diseases such as AD. To date, approximately 20 clinical trials have been initiated using RNAi 
based therapeutics. Several other RNAi therapeutics are in the preclinical stage and aiming 
to enter clinical trials (Chakraborty et al. 2017a).
RNAi regulates the synthesis of protein with a posttranscriptional modification, which is 
a gene-silencing mechanism. miRNA maturation involves two cleavages mediated by RNa-
seIII enzymes DROSHA and DICER (Ipsaro and Joshua-Tor 2015). DROSHA works inside the 
nucleus on pri-miRNA releasing a hairpin of 65 nucleotides, being transported into the cy-
toplasm as a double strand pre-miRNA. There pre-miRNA is cleaved by DICER enzyme lib-
erating ∼22-nucleotides mature miRNA duplex, called small interfering RNA (siRNA), later 
the siRNA is incorporated in an enzymatic complex called RNA-induced silencing complex 
(RiSC), where the sense strand of siRNA is cleavage by Argonaute 2 (Ago2). The RISC com-
plex beside containing DICER, is also constituted by other proteins such as Argonauts, TRBP, 
PACT, Gemin3 and KSRP, the last one, is part of both Dicer and the Drosha complex, joining 
the precursors of the miRNAs with a high affinity, facilitating its maturation. The anti-sense 
RNA strand induces RiSC complex to bind with the mRNA target, which is complementary 
to the antisense strand and degrading it. In addition, the activated RiSC-siRNA complex can 
then be recycled for the degradation of identical mRNA targets by RNases (Li and Patel 2016) 
(figure 5).
Currently, Pharma companies are designing clinical trials for RNAi therapeutics. Based on 
several biomedical studies, which has been developed different computer models and 
mathematical algorithms for the prediction and design of interference RNA, establishing 
general principles; such as: 1) both the sense and anti-sense strand are composed of 21 
nucleotides, with 2 protruding nucleotides in the 3’; 2) to select the target sequence, it must 
be taken from 50 nucleotides downstream of the stop codon of the target mRNA; 3) the 
sequence must have low Guanine/Cytosine content (not exceeding 50%); 4) the sense band 
must have a low internal stability in the 3’.
 
These rules are important to create RNAi with high efficiency; for example, silencing effects 
in C. elegans can be disseminated and transmitted to several generations. The conversion 
of dsRNA to a siRNA fragment of 21-23 nucleotide can by itself provide amplification, which 
can explain the potential of RNAi strategy. Another possible explanation is the RISC com-
plex, where a simple active center can catalyze multiple reactions with catalytic targets and 
cleavage activities. The amplification process also involves RNA-dependent RNA polymerase 
(RdRP) (Chakraborty et al. 2017b). As the primers can be linked in a random manner to tar-
get sequences, where siRNA, serves as a primer for a RdRP reaction, where siRNA-primer 
converts the mRNA into dsRNA so that DICER degrades it to siRNA and thus starts a chain 
reaction. Therefore, target specificity and wide spectrum give RNAi advantages respect to 
traditional small molecules and protein drugs. However, the biological barriers are present 
especially when the brain cells are the target, which raised function versatility requirements 
to RNAi therapies, since; the right design and efficacy of RNAi are determinants to break 
down the barriers to target tissues in local or systemic therapies delivery (Chakraborty et 
al. 2017a).
BACE1 is considered an excellent therapeutic target for the treatment of AD, since, in addi-
tion to being a key enzyme in the production of Aβ, BACE1 knockdown reduces APP levels, 
catalytic activity is reduced and mice have no detectable abnormalities (D Piedrahita et al. 
2015), Recently, RNAi appears as an attractive mechanism to induce a knockdown and over-
come the problems of specificity presented by different approaches, such as, the design 
of BACE1 inhibitors which has presented undesirable side effects (Hu et al. 2008; Moussa 
2017). Consequently, our most recent findings have validated the potential of BACE1 si-
lencing in neuroprotection, since it causes specific BACE1 decreasing levels and it has been 
correlated with the decrease in protein aggregation (D Piedrahita et al. 2015). Additionally, 
macro-autophagy was stablishing how the main NFT degradation pathway after shBACE-
1miR treatment. Interestingly the BACE1miR-mediated soluble hyperphosphorylated tau 
downregulation was only blocked by 3-MA (a class III PI3K inhibitor) in vitro. Together, these 
data suggest a role for BACE1miR in the double-membrane vesicles and in membrane fusion 
to form autophagosomes, which requires phosphatidylethanolamine, suggesting an interac-
tion between BACE1 activity and lipid metabolism to induce the reduction of NFT (Piedrahita 
et al. 2016). Supporting that the silencing of BACE1 is a good target to prevent the formation 
of Aβ and NFT.
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The alteration in lipid metabolism can influence the development of AD, influencing the 
production and accumulation of Aβ in membrane microdomains rich in saturated fatty acids 
(SFA) (H.-L. Wang et al. 2016a; Panchal et al. 2014). In addition, cellular SFA levels modulate 
the metabolism of APP; trough increasing the stability of APP-BACE1 interaction, leading 
to increasing in Aβ levels and accelerates the AD pathology (Xiang, Lam, and Shui 2015). 
In rodents, high cholesterol levels in neurons cause an increase in BACE1 levels, and accu-
mulation of Aβ1-42 peptide; furthermore, it is correlated with tau hyperphosphorylation 
(Moussa 2017). Have been reported in mice AD model and AD human that Aβ is finding in 
cellular structures with a high content of SFA such as lipid rafts, indicating that lipids are 
an important player involve on AD development mainly influencing the plaque formation 
(Hong 2015).
 
In addition, recent studies show direct correlation between AD and neuroinflammation 
showing that this correlation is being modulated by lipid metabolism. Due to several lipid 
species have diverse biological activities, in order to maintain tissue homeostasis including 
regulation of inflammation and its resolution (Heppner, Ransohoff, and Becher 2015b; Han-
nun and Obeid 2008). The alteration of lipid homeostasis, trigger, thereby increasing the 
pro-inflammatory response in the CNS (Gualtierotti et al. 2017). Have been reported that 
families of bioactive lipids like lysophospholipids and sphingolipids as well as several ele-
ments of their complex metabolism and signaling (i.e., enzymes and receptors) are mainly 
dysregulated chronic inflammatory diseases and AD (Di Paolo and Kim 2011; Buckley, Gilroy, 
and Serhan 2014). Indicating that lipids are essential on inflammatory processes as well as in 
protein aggregation disorders, which suggest that the modulation of lipids; could be a future 
and promising therapeutic strategy to be undertaken.
For all the above, we propose as an alternative to potentiate the homeostasis recovery of 
the brain affected by AD, developing a knockdown of BACE1 mRNA at the CA1 hippocampal 
area using RNA interference as a therapeutic strategy, which would reduce the Aβ aggre-
gation levels. On the other hand, the homeostasis recovery involves several molecular fac-
tors, including lipid metabolism and inflammatory response when our therapy is in the CNS. 
BACE1 protein levels are reduced could it modify the lipid composition of cell membranes? 
And whether the membrane lipid composition is modified, would these lipid changes mod-
ulate the neuro-inflammatory mediators at the AD mice brain and primary neuron cultures? 
HYPOTHESIS
BACE1 mRNA silencing induces recovery of cell homeostasis, through the regulation of fatty 
acid metabolism and pro-inflammatory response in the hippocampus region in the 3xTg-AD 
mouse model (in vivo) and primary cortical neuron cultures (in vitro).
MAIN AIM
Establish the effect of BACE1 silencing on fatty acid metabolism and neuroinflammation 
using an AD mice model and primary neuron cultures.
SPECIFIC AIMS
• Examine the effect of the silencing of BACE1 on the hippocampus lipid profile in 3xTg-AD 
mice and primary cortical neuron cultures.
• Evaluate the relationship between the lipid profile induced by the silencing of BACE1 and 
pro-inflammatory mediators in 3xTg-AD model and cortex primary neuron cultures.
• Establish the ratio of membrane lipid profiles in the brains of patients diagnosed with 
Alzheimer’s disease. In order to propose critical points of therapeutic intervention for the 
early-onset AD and late-onset AD.
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β-amyloid (Aβ) is produced by the β-secretase 1 (BACE1)-mediated enzymatic cleavage of 
the amyloid precursor protein through the amyloidogenic pathway, making BACE1 a ther-
apeutic target against Alzheimer’s Disease (AD). Alterations in lipid metabolism are a risk 
factor for AD by an unknown mechanism. The objective of this study was to determine 
the effect of RNA interference against BACE1 (shBACEmiR) on the phospholipid profile in 
hippocampal CA1 area in aged 3xTg-AD mice after 6 and 12 months of treatment compared 
to aged PS1KI mice. The shBACEmiR treatment induced cognitive function recovery and re-
stored mainly the fatty acid composition of lysophosphatidylethanolamine (LPE) and eth-
erphosphatidylethanolamine (ePE), reduced the cPLA2’s phosphorylation, down-regulated 
the levels of arachidonic acid (AA) and COX2 in the hippocampi of 3xTg-AD mice. Together, 
our findings suggest, for the first time, that BACE1 silencing restores phospholipids compo-
sition which could favor the recovery of cellular homeostasis and cognitive function in the 
hippocampus of triple transgenic AD mice.
 
Key words: Alzheimer’s disease, phospholipids, BACE1, RNA interference, hippocampus, 
cognitive function.
Abbreviations: PA, phosphatidic acid; PC, phosphatidylcholine; LPC, lysophosphatidylcho-
line; ePC etherphosphatidylcholine; PS, phosphatidylserine; ePS, etherphosphatidylserine; 
PE, phosphatidylethanolamine; LPE, lysophosphatidylethanolamine; ePE, etherphosphati-
dylethanolamine, PI, phosphatidylinositol; PG, phosphatidylglycerol; SM, sphingomyelin; 
CE, cholesterol esters; AA, arachidonic acid; SCR, scrambled; B, shBACE1miR; cPLA, cytosolic 
phospholipase A; m, months.
Introduction
Alzheimer’s disease (AD) is a disabling neurodegenerative disorder that impacts millions of 
people worldwide and is recognized as the most common form of dementia (Querfurth and 
LaFerla, 2010). The aggregation of three main neuropathological markers—senile plaques 
(SP), neurofibrillary tangles (NFT) and lipid granules—is characteristic of AD. Current evi-
dence suggests that senile plaques trigger the amyloid cascade and that the deposition of 
β-amyloid (Aβ) is the first step in the development of AD, leading to the formation of SP, NFT, 
neuronal loss, and finally, clinical dementia  In AD, neuronal loss alters the cellular composi-
tion and macrostructure of cerebral regions, either moderately, as observed in the prefron-
tal cortex, or severely, as in the entorhinal cortex and hippocampus. Progressive cell death 
in these regions is tightly linked to dementia due to the reduction in the number of neurons 
found in the hippocampus and cerebral cortex of individuals with AD but not asymptomat-
ic subjects (Andrade-Moraes et al., 2013). Accordingly, AD patients show significantly less 
activation in the hippocampal formation, which is associated with progressive memory loss 
(Sperling et al., 2003). 
Aβ is generated by the enzymatic processing of the amyloid precursor protein (APP). This 
process involves the cleavage of APP by the β-site APP cleavage enzyme 1 (BACE1) and the 
γ-secretase complex, which contains presenilin 1 or 2 (PS1 or PS2) as the catalytic subunit 
to generate the Aβ40 and Aβ42 peptides (Thinakaran and Koo, 2008). BACE1 is a type I 
transmembrane aspartic protease that is related to pepsins and retroviral proteases. The 
subcellular localization of BACE1 is within the trans-Golgi network and the endosomal com-
partment. Although BACE1 reaches the plasma membrane due to vesicle trafficking, it is 
quickly recycled. Only a limited amount of APP cleavage by BACE1 takes place at the plasma 
membrane; the primary BACE1-mediated APP processing occurs in endocytic vesicles where 
the low pH environment favors the enzymatic activity (Kandalepas and Vassar, 2012).
 
Cellular lipid composition also regulates the catalytic activity of enzymes such as BACE1, as 
observed in cholesterol-rich membrane domains known as lipid rafts (Ehehalt et al., 2003). 
The cholesterol content of these membrane domains also seems to affect the enzymat-
ic activity of BACE1 on APP (Kalvodova et al., 2005). However, although cholesterol is the 
best-studied brain lipid in AD, many other lipids are involved in the Aβ-lipid regulatory sys-
tem, and some of these lipids exhibit stronger effects than cholesterol on Aβ production (Di 
Paolo and Kim, 2011).
The association between an aberrant lipid balance and AD is supported by the fact that the 
neuronal lipid composition regulates the trafficking and activity of the membrane proteins 
involved in Aβ production, such as APP, BACE1 and presenilin 1 and 2 (Grimm et al., 2005;). 
It has also been found that high levels of Aβ modulate the activity of enzymes such phos-
pholipases A2, C and D and thus alter membrane homeostasis (Berman et al., 2008;Oliveira 
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and Di Paolo, 2010;Sanchez-Mejia and Mucke, 2010). In addition, several genes related to 
AD, such as APOE, ABCA7, CLU, and BIN1, are tightly connected to lipid metabolism and 
cellular membrane dynamics (Hollingworth et al., 2011;Karch and Goate, 2014;Rosenthal 
and Kamboh, 2014) 
Although the link between lipid metabolism and AD was suggested years ago, many aspects 
of this relationship have remained elusive due to the lack of technology and analytical meth-
odologies to understand the molecular mechanisms of lipid alterations in AD. The advent 
of lipidomics has allowed researchers to detect and quantify the lipid species and FAs of 
cerebral structures, thus facilitating the analysis of the lipid classes involved in cell signaling, 
membrane structure and trafficking. These techniques have been used to establish the lipid 
compositions of brain tissues from healthy individuals and AD patients (Han et al., 2001;Fa-
belo et al., 2014), revealing changes in the levels of plasmalogens, such as, ether-phosphati-
dylethanolamine (ePE), sulfatide, ceramide, galactosylceramide, cholesterol and alkyl-acylg-
lycerophosphocholine (Han et al., 2001;Han et al., 2002;Cutler et al., 2004).
Nevertheless, there is also evidence suggesting that some of enzymes involved in AD, can 
regulate lipid homeostasis. Thus, postmortem analysis of frontal cortices from AD patients 
revealed a 47% increased activity of BACE1 compared with samples from cognitively normal 
individuals. They found a positive significant linear correlation between BACE1 activity and 
the levels of 4-hydroxynonenal (HNE) and malondialdehyde (MDA) (Borghi et al., 2007). This 
study hints to the fact BACE1 may have a direct effect on regulating lipid homeostasis, which 
is also supported by the work of Meakin and colleagues who used mice lacking BACE1 gene 
to evaluate the effect of this enzyme on the body weight, as well as lipid and glucose metab-
olism. They found that the knockout animals had decreased production of lipids in the body 
and showed increased insulin sensitivity compared to their littermate controls, which may 
be an indicative of high energy expenditure. Furthermore experiments demonstrated that 
the absence of BACE1 in brown adipose tissue and skeletal muscle led to increased levels of 
the uncoupling protein 1, which seems to be involved in protection against oxidative stress 
and fatty acid handling (Gallagher et al., 2012). 
In addition, our previous results showed that the silencing of BACE1 produces reduction of 
tauopathy in old 3xTg-AD mice, and part of the effect was autophagosome lipidation-de-
pendent (Piedrahita et al., 2015). Therefore, supported in those previous evidences about 
the role of BACE1 in lipid homeostasis; our hypothesis is that BACE1 down-regulation affects 
the phospholipid composition of hippocampus in an AD model. In this study, we present the 
lipidomic profiles of hippocampal tissue obtained from a commonly used transgenic mouse 
model of AD (3xTg-AD) treated with RNA interference (RNAi) against BACE1 for 6 and 12 
months and compared them with control groups, using mass spectrometry, we detected 
and analyzed 12 different lipid classes and subclasses, including phospholipids (PLs), sphin-
golipids, lysophospholipids, plasmalogens, covering over 402 lipid subspecies. 
Materials And Methods
RNAi design
We designed the shRNAi sequences for silencing BACE1 (shBACE1miR). The scrambled 
RNAi sequences used as control (shSCRmiR) were based on previously published sequences 
(Chang et al., 2006). These sequences were cloned into human miR-30-based stem-loops 
by polymerase extension of overlapping DNA oligonucleotides. The following primers 
were used for polymerase extension to clone the RNAi into the lentiviral shuttle plasmid 
(pCMV-GIN-ZEO.GFP) for transfection in HEK-293T cells: shBACE1miR forward primer, 5’…
CAGAAGGCTCGAGAAGGTATATGCTGTTGACAGTGAGCGCGGACTGCAAGGAGTACAACTATAGT-
GAAGCCACAGATGTA…3’ and shBACE1miR reverse primer, 5’…CTAAAGTAGCCCCTTGAAT-
TCCGAGGCAGTAGGCATGGACTGCAAGGAGTACAACTATACATCTGTGGCTTCAC…3’; shSCRmiR 
forward primer, 5’…CAGAAGGCTCGAGAAGGTATATGCTGTTGACTAGCACACATCAGGAAG-
CGCTCGACAGTGATAGTGAAGCCACAGATGTA…3’, and shSCRmiR reverse primer, 5’…CTAAA-
GTAGCCCCTTGAATTCCGAGGCAGTAGGCA CCTAGCACACATCAGGAAGCGCTCGACAGTGA-
TACATCTGTGGCTTCAC…3’. The extension products were digested with XhoI and EcoRI for 
directional cloning into the pCMV-GIN-ZEO.GFP vector (Open Biosystems, Pittsburg, USA). 
To clone the RNAi vectors for adeno-associated virus (AAV) production, the following 
primers were used for polymerase extension: shBACE1miR forward primer, 5’…AAAACTC-
GAGGAGCTCGTGAGCGCTGGACTGCAAGGAGTACAACTCTGTGAAGCCACAGATGGG…3’ and 
shBACE1miR reverse primer 5’… TTTTGGATCCATTAATAGGCAATGGACTGCAAGGAGTA-
CAACTCCCATCTGTGGCTTCACAG…3’; shSCRmiR forward primer, 5’…AAAACTCGAGTGAGCG-
CACCATCGAACCGTCAGAGTTACTGTAAAGCCACAGATGGG…3’ and shSCRmiR reverse primer, 
5’…AAAAACTAGTAGGCGTACCATCGAACCGTCAGAGTTACCCATCTGTGGCTTTACAG…3’. These 
extension products were digested with XhoI and SpeI for directional cloning into a U6 ex-
pression plasmid that was cut with XhoI and XbaI (Boudreau et al., 2009).
 
Viral particle production and neuronal culture transduction
The AAV particles were obtained by the large-scale production of heterologous proteins 
from Sf9 insect cell cultures that were co-infected with recombinant baculovirus derived 
from the Autographa californica nuclear polyhedrosis virus (Urabe et al., 2002). The shBACE-
1miR expression cassettes—driven by the mouse U6 promoter—were cloned into pAAV.
CMV.hrGFP, which contained AAV serotype 2/5 inverted terminal repeats and a CMV-hu-
manized Renilla GFP (hrGFP)-simian virus 40 poly (A) reporter cassette (Urabe et al., 2002;). 
The AAV titers were determined using quantitative PCR and/or DNA slot blot analysis. The 
AAV particles were dialyzed before use.
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We used 3xTg-AD mice containing PS1 (M146V), APP (Swe), and tau (P301L) mutations 
(Oddo et al., 2003), as well as the PS1KI mice containing the PS1 (M146V) mutation, named 
as “control group”, because PS1KI is the genetic background of the 3xTg-AD mice, do not de-
velop intracellular and extracellular β-Amyloid and do not exhibit LTP deficits.  Furthermore, 
those mice are viable, fertile, normal in size and do not display any gross physical or behav-
ioral abnormalities (Oddo et al., 2003). Both mice strains were kindly donated by Dr. Frank M 
LaFerla from the University of California (Irvine, CA, USA). The animals were bred in-house 
in a specific pathogen-free (SPF) colony at the vivarium at SIU (Sede de Investigación Univer-
sitaria, University of Antioquia, Medellin, Colombia), maintained with a 12 h:12 h dark:light 
cycle, and received food and water ad libitum. The animals were handled in accordance with 
the Colombian standards (Law 84/1989 and resolution 8430/1993) and NIH guidelines for 
animal welfare and care (Public Law 99-158, November 20, 1985, “Animals in Research”). 
Specific care was taken to minimize animal suffering and minimize the number of animals 
used. A total of 42 3xTg-AD mice (6 and 12 months old, 20-30 g), 20 PS1KI mice (6 and 12 
months old, 20-30 g) were used. 28 male and 14 female mice were aleatorily assigned, us-
ing three males and two-three females per group. One side of the hippocampi was used for 
lipidomic analysis and the other for biochemical analysis.
The animals were anesthetized (5% ketamine and 2% xylazine, 50:5 dosage mg/kg) and 
bilaterally injected with 1μL of AAV2-shSCRmiR (shSCRmiR) or AAV2-shBACE1miR (shBACE-
1miR) into both hippocampi (bregma coordinates were -1.7 anteroposterior, 0.8 (right) and 
-0.8 (left) lateral, and 2.5 mm dorsoventral). The injections were performed with a 10-μL 
syringe (Hamilton, Reno, USA) at 0.1 μL/min, and 10 min elapsed after the infusion before 
the syringe was withdrawn. The following experimental groups were used: Short-term treat-
ment group, PS1KI and 3xTg-AD mice were injected with shBACE1miR (B12m) or scrambled 
miR (Scr12m) at an age of 12 months old and evaluated 6 months later; and Long-term 
treatment group, PS1KI and 3xTg-AD mice injected with shBACE1miR (B6m) and scrambled 
miR (Scr6m) at an age of 6 months and evaluated one year after injection (Fig. 1). The an-
imals were evaluated by the Morris water maze test and later sacrificed for biochemical 
measurements (Fig. 1). The hippocampi were dissected, immediately frozen on dry ice and 
stored at -80°C until use. 
Morris water maze test
Morris water maze testing was performed at 6 and 12 months following the shBACE1miR 
and shSCRmiR injection in the PS1KI and 3xTg-AD mice. A circular pool (1-m diameter and 
0.5-m height) was filled with water at 22 ± 2°C, with an escape platform with a diameter 
of 20 cm submerged 2 cm below the water surface. The platform was hidden in the water, 
which was painted with non-toxic white color and opaque paint to facilitate video recording. 
The test procedure consisted of four stages: 1) Visible: 2 days, 2 trials per day, 60 seconds 
per trial with the platform 2 cm above the water level; 2) Learning: 5 days, 2 trials per day 
(10 trials in total), 60 seconds per trial to find the hidden platform; 3) Retention: 48 hours af-
ter the last training day (1 day, 1 trial per day, 60 seconds per trial without platform); and 4) 
Transference (changing location of the platform to the opposite side of the pool): A second 
learning trial of 2 days, 2 trials per day (4 trials in total), 60 seconds per trial to find the hid-
den platform (Fig. 1). The animal behavioral tests were recorded and analyzed individually 
using View Point software (Lyon, France).
Lipid analyses
The total lipids from the mouse hippocampus were extracted according to the FOLCH tech-
nique (FOLCH et al., 1957) using a mixture of 2 mL of chloroform (CHCl3) and 1 mL of meth-
anol (MeOH) in a 2:1 (v/v) ratio. Then, 0.005% butylated hydroxytoluene (BHT) was added, 
and this mixture was used to homogenize the hippocampus. Subsequently, 1 mL of 0.9% 
NaCl was added, and the mixture was centrifuged at 3000 rpm for 3 minutes. The organic 
layer (lower layer) was removed and transferred to a new glass tube. This procedure was 
performed in an oxygen-free using enriched nitrogen environment to avoid lipid oxidation 
processes and was repeated three times. The solvents were evaporated, and the extract was 
lyophilized to remove the excess of humidity. Finally, the lipid composition was analyzed by 
mass spectrometry.
 
Figure1. Experimental design. AAVshSCRmiR and AAVshBACEmiR were injected in the hippocampus of 6 and 12 
months-old PS1KI and 3xTg-AD mice. After 6 and 12 months’ post-injection respectively, behavioral analyses using 
Morris water maze test were performed. First and second days’ visible test; learning and memory were evaluated 
during 5 days (10 trials); after 48 h retention test was realized. Afterward, the transfer test was performed over 2 
days (four trials).
Lipid analyses
The total lipids from the mouse hippocampus were extracted according to the FOLCH tech-
nique (FOLCH et al., 1957) using a mixture of 2 mL of chloroform (CHCl3) and 1 mL of meth-
anol (MeOH) in a 2:1 (v/v) ratio. Then, 0.005% butylated hydroxytoluene (BHT) was added, 
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and this mixture was used to homogenize the hippocampus. Subsequently, 1 mL of 0.9% 
NaCl was added, and the mixture was centrifuged at 3000 rpm for 3 minutes. The organic 
layer (lower layer) was removed and transferred to a new glass tube. This procedure was 
performed in an oxygen-free using enriched nitrogen environment to avoid lipid oxidation 
processes and was repeated three times. The solvents were evaporated, and the extract was 
lyophilized to remove the excess of humidity. Finally, the lipid composition was analyzed by 
mass spectrometry.
Mass spectrometry
An automated ESI-MS/MS approach was used and data acquisition and analysis carried out 
at the Kansas Lipidomics Research Center using an API 4000™ and Q-TRAP (4000Qtrap) de-
tection system as described previously (Sparkes et al., 2010;Zhou et al., 2011) This protocol 
allowed the detection and quantification of low concentrations of the polar lipid compounds. 
The molecules were determined by the mass/charge ratios, which were compared with the 
respective internal standard to determine which species of lipids were present in the eval-
uated extract: 0.66nmol di14:0-PC, 0.66 nmol di24:1-PC, 0.66 nmol 13:0-lysoPC, 0.66 nmol 
19:0-lysoPC, 0.36 nmol di14:0-PE, 0.36 nmol di24:1-PE, 0.36 nmol 14:0-lysoPE, 0.36 nmol 
18:0-lysoPE, 0.36 nmol 14:0-lysoPG, 0.36 nmol 18:0- lysoPG, 0.36 nmol di14:0-PA,0.36 nmol 
di20:0(phytanoyl)-PA, 0.24 nmol di14:0-PS, 0.24 nmoldi20:0 (phytanoyl)-PS,0.20 nmol 16:0-
18:0-PI, 0.16 nmol di18:0-PI, and 1 nmol 15:0 fatty acid. The system detected a total of 12 
different lipid species and their respective sub-species, which were identified by the number 
of carbons and degree of unsaturation of the chain. Lipid concentration was normalized by 
molar concentration across all species for each sample, and the final data are presented as 
mean mol%.
Western blotting analysis
The animals were sacrificed, and the cerebral cortices were dissected, immediately frozen 
in liquid nitrogen, and stored at -80°C prior to use. The samples were lysed in 10 mM Tris 
(pH 7.4), 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1% NP40, 1 nM orthova-
nadate, 5 mM NaF, 1 mM phenylmethylsulfonyl fluoride, and a protease inhibitor cocktail 
(Sigma-Aldrich) (Cardona-Gomez et al., 2004). The lysates (containing approximately 40 µg 
of proteins, quantified using the Bradford method) were loaded onto 8% and 10% polyacril-
amide gels and transferred onto nitrocellulose membranes (GE Healthcare) at 250 mA for 2 
h using an electrophoretic transfer system. The membranes were incubated overnight at 4°C 
in anti phospho-cPLA2 (Ser505) (rabbit polyclonal. 1:1000; Cell Signaling), anti-COX2 (rabbit 
polyclonal. 1:500; abcam), and mouse anti-βIII tubulin (1:5000; Promega). IRDye 800CW 
goat anti-rabbit (LI-COR; 1:5000) were used as the secondary probes. The blots were devel-
oped using the Odyssey Infrared Imaging System. To minimize inter-assay variation, samples 
from all of the experimental groups were processed in parallel.
Statistical analysis
In the behavioral test were used 10-15 animals/group. The escape latency during the hidden 
platform training sessions and transference tests were determined using repeated-meas-
ures ANOVA. The latency and the number of platform crosses in the hidden platform trials 
and in the probe, trials were analyzed by One-way ANOVA, also ANOVA per day followed by 
Fisher’s post hoc test were realized. The analyses were performed using SPSS 18.0 software 
(Chicago, IL, USA). The values were expressed as the means ± SEM. The results were consid-
ered to be significant at * p<0.05, and ** p<0.01. All of the sample groups were processed 
in parallel to reduce inter-assay variation. 
The lipid levels for each sample were calculated by summing the total number of moles of 
all lipid species measured and then normalizing that total to mol%. Comparisons between 
groups were assessed either by one-way ANOVA, followed by the Tukey post-hoc test or the 
Kruskal-Wallis test, depending on the homoscedasticity and normality of the experimental 
data. Multivariate statistics were performed using principal component analysis (PCA) and 
a partial least squares-discriminant analysis (PLS-DA) (Barker et al., 2003). PLS-DA was in-
cluded because it is particularly suitable for the analysis of datasets with a small number 
of samples and a large number of variables. The  PLS-DA analysis was carried out using the 
routines described in (Ballabio and Consonni, 2013). For both techniques, an index repre-
senting the importance of the variables according to the first components was estimated. 
PCA used an index (denoted as ρ) that considers the entries of the principal directions and 
the variance of each component to determine the weight that every lipid species has in the 
estimation of the principal directions (Jolliffe, 2002). In contrast, for PLS-DA, the index used 
is called the variable importance in projection (VIP) (Mehmood, 2012), which analogously 
to ρ, determines the importance of each variable that is reflected by each component and 
also considers the variance explained by each PLS component (for a detailed description of 
VIP, please refer to Mehmood and the references therein). The confidence ellipsoids per 
group and treatment are also included. The data from the univariate and bivariate statistics 
are expressed as the mean ± the standard error of the mean. The statistical significance is 
indicated in the figures and tables.
Results
BACE1 gene silencing prevents learning and memory impairments in 3xTg-AD mice after 6 
and 12 months of treatment
During the visible platform test, the shBACE1miR-treated 3xTg-AD mice did not show dif-
ferences compared to the controls after either 6 or 12 months of treatment (Fig. 2A). How-
ever, the learning task performance of the shBACE1miR-treated mice at 6- and 12-months 
post-injection was better than that of the corresponding shSCRmiR-treated 3xTg-AD control 
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mice (Fig. 2B). These observations supported a memory improvement because the shBACE-
1miR-treated mice spent less time finding the hidden platform and showed preferences 
in the trajectory for the quadrant of the platform (Fig. 2C, D) at both post-injection time 
points. Additionally, reversal learning skills were improved in the 3xTgAD mice treated with 
shBACE1miR, which spent less time looking for the second platform location in the transfer 
test than the shSCRmiR-treated 3xTgAD mice (Fig. 2E). PS1KI mice treated with shBACE1miR 
did not show changes respect to the untreated control in both evaluated time lines (Fig. 2).
The phospholipid profile of the hippocampus is altered in 3xTg-AD mice
To determine whether the transduction with shBACE1miR or the scrambled version induced 
lipid changes in the 3xTg-AD mice, we characterized the hippocampal phospholipid composi-
tion of the transgenic animals at two different post-injection time points (6 and 12 months). 
These profiles were compared with shBACE1miR or the scrambled treated PS1KI mice, 
which were evaluated at the same post injection times. At a glance, the analysis revealed 
two types of variations in the phospholipid contents of the 3xTg-AD mouse hippocampus. 
The first set of changes seems to be related to the pathological condition, while the second 
type is associated with the shBACE1miR treatment.
The lipid profiling of the all control groups PS1KI and 3xTg-AD mice hippocampus shows 
that the lipidome is primarily composed of high abundance glycerophospholipids, such as 
PC (47.5% and 47.2%), PS (5.1% and 5.8%), PE (18.6% and 20.0%), and PI (1.9% and 1.8%); 
sphingolipids, such as SM-DSM (8.0% and 8.3%); low abundance glycerophospholipids, such 
as PA (0.3% and 0.4%) and PG (0.07% and 0.6%); lysophospholipids, such as LPC (0.2% and 
0.4%) and LPE (0.9% and 1.0%); and etherphospholids, such as ePC (1.4% and 1.6%), ePS 
(0.02% and 0.11%) and ePE (1.4% and 1.6%) (Fig. 3A).
The treatment of 3xTg-AD mice with the shBACE1miR or shSCRmiR for 6 or 12 months result-
ed in distinctive lipid profiles compared with the control animals (Fig. 3A). The disease-asso-
ciated changes in the phospholipid composition involve an overall decrease in PC (control vs 
AD mice, p<0.001), PS (control vs AD mice, p<0.01) PE (control vs AD mice, p<0.01), PI (con-
trol vs AD mice, p<0.01) and SM-DSM (control vs AD mice, p<0.05) (Fig. 3A). In contrast, the 
lipid profile obtained from the shBACE1miR-treated 3xTg-AD mice showed that the treat-
ment restored the LPE (p<0.001) and ePE (p<0.05) content to basal levels (Fig. 3A and 4A3), 
suggesting a regulatory role for BACE1 in the biosynthesis of these particular plasmalogens.
Figure 2. BACE1miR prevents cognitive dysfunction in 3xTg-AD mice. The learning and memory task performance 
of the PS1KI and 3xTg-AD mice were evaluated by the Morris water maze test after 6 months and 12 months 
of treatment with shBACE1miR and compared with the respective animal controls. A- Visible test, B- Learning 
test (First position of the platform), C-, D- Retention and representative trajectory images of the animals during 
the retention test, E- Transference test (Second position of the platform), The data are expressed as the group 
mean±S.E.M. *, **Significant differences: *P< 0.05, **P< 0.001; n= 12 to 10-15 animals/group.
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The results of the PCA analyses from the detected lipids indicate that nearly 82% of the 
total variance may be explained by the first 2 principal components (PC1 and PC2) (Fig.4A). 
The most relevant variables for these two components were related to the PC subclasses 
32:0 and PE subclasses 40:6, which demonstrated higher r indexes (13.6236 and 12.1049 
respectively) (Fig. 4A). PC 32:0 is composed of the saturated FA Palmitic acid (Fig. 4A). In 
contrast, PE 40:6 is composed of the polyunsaturated FAs DHA and saturated FAs stearic 
acid (Fig. 4A). The PLS-DA analyses indicate that nearly 86% of the total variance may be ex-
plained by factor 1. In this case, the most relevant feature according to VIP are PI 40:00 (VIP: 
2.0965) and PC 44:8 (VIP = 1.9355). Moreover, three of the first five most relevant features 
according to VIP belong to the LPE species. (Fig. 4A). This LPE subclass is composed of the 
monounsaturated FA such as Palmitoleic (16:1), Oleic (18:1) and polyunsaturated AA acids, 
as arachidonic (20:4). Both the PCA and PLS-DA analyses indicate that the control group is 
located in a different quadrant of the plane compared with the AD and treated AD animals, 
which are in the right quadrant of the graphic (Fig. 4A). In addition, the AD and treated AD 
groups also show a different distribution pattern, indicating that BACE1 silencing modifies 
the course of certain PLs in the disease (Fig. 4A).
shBACE1miR restores the basal levels of LPE and ePE of 3xTg-AD at 6- and 12-months 
post-injection
We demonstrated that shBACE1miR has a regulatory effect on the lipid profile in two specif-
ic lipid classes: LPE and ePE. The LPE levels increased (p<0.001) in the AD groups compared 
Figure 3. Lipid composition of the hippocampus from 3xTg-AD and control mice, grouped according to the time of 
treatment. Various lipid changes can be seen in the hippocampal tissue. A - The lipid class profiles are expressed 
as %Mol composition. All lipid species were measured (means), and the error bars represent the SEM. B. Multivar-
iate analyses of the lipid profiles from the hippocampus. PCA, Principal component analyses for the lipid classes 
and PLS-DA, Partial least squares analysis to discriminate between the lipid classes. The left panels illustrate the 
factor loadings for PC1 and PC2, with the indices of variance explained for each component. The right panels show 
the factor score plots for PLS-DA The data for the 3xTg-AD mice were significantly different from the control groups 
(*p< 0.05, **p< 0.01; ***p< 0.001 ANOVA followed by the Tukey post hoc test or Kruskal-Wallis test) Abbreviations: 
PA, phosphatidic acid; PC, phosphatidylcholine; LPC, Lysophosphatidylcholine; ePC etherphosphatidylcholine; PS, 
phosphatidylserine; ePS, etherphosphatidylserine; PE, phosphatidylethanolamine; LPE, Lysophosphatidylethanol-
amine; ePE, etherphosphatidylethanolamine, PI, phosphatidylinositol; PG, phosphatidylglycerol; SM, sphingomy-
elin. n=3-5 per group.
Figure 4. A- Multivariate analyses of the lipid profiles from the hippocampus. PCA, Principal component analyses 
for the lipid classes and PLS-DA, Partial least squares analysis to discriminate between the lipid classes. The left 
panels illustrate the factor loadings for PC1 and PC2, with the indices of variance explained for each component. 
The right panels show the factor score plots for PLS-DA. The variables in the analyses are the controls, AD (3xTg-AD 
without treatment) and AD+shBACE1-miR (3xTg-AD with 6 and 12 months of treatment). n=3-5 per group. 
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with the AD mice treated with the shBACE1miR and the control groups (Fig. 3A and5A). 
The PCA analysis showed that the AD+shBACE1miR group had a displacement to the left 
quadrant close to the control group, while the AD mice occupy a different region that is 
shifted to the right (Fig. 5A). This result indicates that nearly 97% of the total variance may 
be explained by the first 2 principal components (PC1 and PC2), which is LPE 18:1 accord-
ing to Rho=1.0208. However, three of the first five most relevant features according to VIP 
belong to unsaturated lipid species (22:6, 20:1 and 20:4) (Fig. 5A). In addition, these obser-
vations were confirmed by counter plot analyses, where the LPE content was increased in 
the AD groups (3xTg-Scr6m and 3xTg-Scr12m) and restored to the basal levels in the shBACE-
1miR-treated AD mice at 6- and 12-months post-injection (Fig. 5B). The PLS-DA analysis 
also revealed that the AD+shBACE1miR group on the graph had a displacement from AD to 
control group; however, the AD group exhibited a different distribution. The subclasses with 
major importance in data distribution, based on higher r index, were LPE 22:5 (docosapen-
taenoic acid) (1.0858) and LPE 20:2 (Eicosadienoic Acid) (1.0494) (Fig. 5A).
In addition, ePE also seems to be affected by the treatment because the levels of this plas-
malogen decreased (p<0.05) in AD compared with the AD+shBACE1miR and control groups 
(Fig. 3A). The PCA analysis confirmed this result and showed that all experimental groups 
occupy different areas in the quadrants, i.e., ePE species were able to differentiate among 
the experimental groups. The most relevant molecular species, such as ePE 40:6 (18:0 stear-
ic/22:6 DHA) and 38:6 (16:0 palmitic/22:6 DHA), had a higher r index (0,01470 and 1,1170, 
respectively) (Fig. 5C). Interestingly, the contour graphic showed changes in the same ePE 
subclasses and showed a decrease in AD groups, although their levels were recovered in 
the AD+shBACE1miR groups at 6- and 12-months post-treatment (Fig. 5D). The recovery of 
the basal levels may represent a modulatory effect of the shBACE1miR on the phospholipid 
profile in the 3xTg-AD mice. The PLS-DA analysis also demonstrated different distribution 
patterns for all groups on the plot. The subclasses with major importance in the data distri-
bution based on a high VIP index were ePE 38:6 (16:0 palmitic acid/22:6 DHA) (1.5995), ePE 
40:6 (22:6 DHA/18:0 stearic) (1.4983) and (Fig.5C).
A detailed analysis of the LPE’s FA composition revealed the presence of large chain fatty 
acyls (16C to 22C) with either monounsaturated or polyunsaturated FAs bearing 1, 4 or 
6 bonds. Interestingly, the shBACE1miR treatment modified the carbon-chain length and 
the degree of unsaturation of the LPE subspecies. shBACE1miR seemed to restore the ba-
sal levels of long fatty acyls chains, such as 16C, 18C, 20C and 22C, which were altered in 
the untreated AD groups (3xTg-Scr6m and 3xTg-Scr12m) (Fig. 6A). The same effect was also 
found for the degree of unsaturation, particularly in polyunsaturated FAs with 1, 4 or 6 
bonds, compared with the control groups (Fig. 6B). In contrast, the FA composition analysis 
of ePE showed that this plasmalogen was formed by very long fatty acyls chains (32C to 40 
C), whose levels did not show statistically significant differences among the experimental 
groups (Fig. 6C). In contrast, the analysis of the FA unsaturation number revealed changes 
in ePE FAs with 6 bonds (Fig. 6D). It was evident that the shBACE1miR treatment (3xTg-B6m 
and 3xTg-B12m) partially restored this type of unsaturation in the ePE FAs to that observed 
in all control groups (Fig. 6D).
BACE1 silencing reduces active cPLA2, ARA and COX2 levels.
The LPE and ePE level changes suggested a potential implication of a PLA2 isoform (Dennis 
et al., 2011), to understand this effect we evaluated the phosphorylation of cPLA, AA levels 
and COX2 protein levels in all experimental groups, after confirming the decreased BACE1 
protein levels (p<0.01) in the hippocampi from shBACE1miR treated mice respect to those 
treated with shSCRmiR (Fig. 7A). BACE1 protein levels tended to increase under PS1KI con-
dition, but without significant effect, as reported Giliberto et al., 2009.  cPLA2 is the main 
enzyme envolved in the production of both lipids species (Makide et al., 2009), inducing AA 
release, which trigger proinflammatory signalling through the  cyclooxygenases, as COX2 
(Lin et al., 1993;Kuwata et al., 1998). Our findings evidenced that the levels of phosphoryl-
ated cPLA2 in ser505 were decreased at 6 and 12 months post-injection in the shBACEmiR 
groups compared with Scr (p<0.01) and PS1KI controls group (p<0.05) (Fig. 7B). The AA lev-
els were increased in AD (3xTg-Scr6 and Scr12m) groups, how has been previously described 
(Sanchez-Mejia et al., 2010), while shBACE1miR6 and shBACE1miR12 decreased to control 
levels (p<0.001)  (Fig. 7C). Finally, we found that COX2 levels increased significantly in all 
Figure 5. shBACE1miR restores the basal levels of LPE and ePE at 6- and 12-months post-injection. A - PCA, Prin-
cipal component analyses for the LPE and ePE subclasses and PLS-DA, Partial least squares method to discriminate 
between the LPE and ePE subclasses. The left panels illustrate the factor loadings for PC1 and PC2, with the indices 
of variance explained for each component. The right panels show the factor score plots for PLS-DA. The groups in 
the analyses are controls, AD (3xTg-AD without treatment) and AD+shBACE1-miR (3xTg-AD with 6 and 12 months 
of treatment). B - Contour plots of the more influential subclasses of LPE and ePE (variables) in the discriminant 
analyses for each evaluated variable; all LPE and ePE subclasses were measured (means), and the error bars repre-
sent the SEM. n=3-5 per group. 
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the 3xTg-AD groups; however, this decreased only at the long-term shBACE1miR- treatment 
(12m) (Fig. 7D). Taken together, these results suggest that the BACE1 silencing reduces the 
composition of AA in LPE at 6 and 12 months of treatment, with a clear repercussion on 
anti-inflammatory response at 12 months by decrease of cPLA2 and COX2 levels in the hip-
pocampus from 3xTg-AD mice. 
Discussion
Recently, we validated the silencing of BACE1 in wild type and triple transgenic AD mice, 
where shBACE1miR treatment induced neuroprotection by reduction of CTF (carboxy-ter-
minal fragment) and 1-42 Ab levels. In addition, hyperphosphorylated tau was reduced 
through the regulation of some autophagy actors, which were blocked by phosphatidiletha-
nolamine (PE) lipidation inhibitor (3 Methyl-Adenine, 3MA) (Piedrahita et al., 2016). There-
fore, in the present study, we performed a deep lipid profile analysis of the hippocampal 
region of 3xTg-AD mice to evaluate the effect of BACE1 silencing in this AD model, whose 
treatment improved the spatial learning and memory skills at 6- and 12-months post-in-
jection. Although, BACE1 inhibition has several substrates involved in neurotransmission, 
excitability and synapses, as neuroregulin 1, APP, between others (Munro et. al., 2016), and 
its inhibition could be adverse (Vassar 2014, Ohno 2016); however, a reduction of BACE1 
protein under a pathological over-expressed BACE1 activity condition, could suggest an im-
portant benefit in neuroprotection, remyelination and plasticity (Farah et al., 2011; Piedra-
hita et al., 2016), supported by the recovery of the cognitive function in the shBACE1miR 
trearted aged 3xTg-AD mice. Also, BACE1 silencing did not affect to PS1KI mice and had a 
lipid profile very similar than C57BL6 mice (data not shown). 
We detected 12 lipid classes that covered over 402 lipid subclasses, observing changes in 
6 PL classes in the hippocampus of the 3xTg-AD mice compared to the control groups. In-
terestingly, we observed that treatment with shBACE1miR modifies the levels of LPE and 
ePE, restoring the amounts of these plasmalogens to the basal levels found in the control 
Figure 7. shBACEmiR decrease the levels of phosphorylated cPLA2, ARA and COX2 levels in the hippocampus of 
old 3xTg-AD mice. A- Representative bands from BACE1 protein levels and B- p-cPLA2 levels at long and short-term 
shBACE1miR´s post-treatment (6 and 12 months) by Western blotting. C- Arachidonic Acid composition levels in 
LPE lipid. Results are expressed as Mol % of total fatty acids. D- Representative immunoblot of COX2 protein levels. 
Results are expressed as relative units (RU) and. Data are shown as means ± SEM. For 3xTg-AD, results were sig-
nificantly different from the controls group (*p< 0.05, **p< 0.01, ***p< 0.001; ANOVA followed by Tukey post hoc 
test) n=3-5 per group.
Figure 6. Altered fatty acid composition of LPE and ePE in the hippocampal region from the 3xTg-AD mouse mod-
els and recovery by BACE1miR. Independent analyses of changes in lysophospholipid (LPE) and plasmalogen (ePE) 
chain lengths equal to the total number of carbon atoms in the fatty acid moieties A- and C-, and the LPE and ePE 
saturation equal to the total number of double bonds in the fatty acid moieties B- and D-. The data for the 3xTg-
AD mice were significantly different from those of the control groups (*p< 0.05, **p< 0.01, ***p< 0.001; ANOVA 
followed by the Tukey post hoc test or Kruskal-Wallis test). #p< 0.05, ANOVA with Tukey’s tests compared between 
3xTg-AD groups. Data are expressed as Mol %. n=3-5 per group. 
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animals, which may be associated with tissue homeostasis and cognitive function recovery. 
In addition, there were also changes in the individual lipid species of different subclasses, 
suggesting that the FA carbon chain and unsaturation number may play an important role in 
AD pathogenesis. These results suggest that the numerous changes that occurred in the PLs 
could be used as potential molecular target that facilitate understanding the biochemical 
mechanism involved in the neurodegenerative process in AD.
Alterations in membrane lipids are widely described in brains from AD and several neu-
rodegenerative disorders (Sagin and Sozmen, 2008). A tight relationship has been estab-
lished between lipid metabolism and lipotoxicity in neurons (Du et al., 2009). Trafficking and 
secretase activity of the key membrane-bound proteins controlling Aβ levels, including APP, 
BACE1, and presenilins, are regulated by membrane levels of cholesterol and sphingomye-
lin (SM). According to early studies, a general decline of SM content in AD brains has been 
described (Cunane et. Al., 2012), which was confirmed by decreased levels of SM in the 3xT-
gAD mice groups in our data. Also, different studies have reported decreased brain PL levels 
in neurodegenerative diseases, mainly PI (Prasad et al., 1998;Berman et al., 2008;Whiley et 
al., 2014); PC (Whiley et al., 2014) PE and its derivatives, such as LPE and ePE (Ginsberg et 
al., 1993;Ginsberg et al., 1995;Nesic et al., 2012); and PS (Shea, 1997), seeming to have mul-
tifactorial origins, including the hyperactivation of phospholipases, peroxisomal dysfunction 
and irregular FA composition of PLs. Our observations confirm those results, where alter-
ations in PL metabolism were close related to AD condition, whose aberrant metabolism 
could be reflected in the animal’s behavior alteration.
In the present study, we observed decreased levels of PC in all AD groups compared with 
the control groups, specially the subspecies 34:1 and 32:0. The alterations in the PC levels 
have been described as a deregulation in the diacylglycerol cholinotransferase-mediated 
biosynthesis and turnover of PC from DAG, which affects neurite and axonal outgrowth and 
synaptic plasticity by DAG accumulation and low levels of PC (Araki and Wurtman, 1997;Ma-
teos et al., 2010;Gaudin et al., 2012). However, the biological activity depends on the type of 
FA linked to the molecular structure. Previous works reported that these PCs are decreased 
in micro-extracted senile plaques from the post-mortem AD brain, and it could be linked to 
the roles of PLA2 and PLD1 in Aβ activation (Gaudin et al., 2012;Whiley et al., 2014;). Ad-
ditionally, these species are composed of monounsaturated omega-9 oleic acid (18:1 n-9) 
and saturated palmitic acid (16:0), and this composition of membrane lipids influences their 
biophysical properties, including fluidity, permeability and charge (Finkelstein et al., 2014). 
The loss of oleic acid has been reported to favor BACE1 activity and increase the Aβ 1-42/
Aβ 1-40 ratio, whereas dietary oleic acid supplements increased the Aβ 1-40/Aβ 1-42 ratio 
and reduced the levels of BACE and presenilin, as well as the number of amyloid plaques in 
AD brains (Amtul et al., 2011). Interestingly, our results confirm the aberrant biosynthesis 
of PC and the imbalance between the levels of saturated/unsaturated FAs affecting to the 
structure of PC could favor the abnormal destabilization of membrane in AD brains. 
Also, in our work, we found decreased PS and PE levels in the hippocampus from all AD´s 
experimental groups. Interestingly, we observed that the main decreased FA in both species 
was 40:6, which is composed of 22:6 (DHA) and 18:0 (stearic acid) chains. DHA is the best 
substrate for PS biosynthesis, and a decrease in this polyunsaturated acid has been related 
to cognitive impairment (Grimm et al., 2013;). Reduction in the DHA levels of hippocampal 
PS was demonstrated in senescence accelerated mice model, which has a short life span, 
memory and learning alterations, and increased amounts of hippocampal Aβ plaques. In 
addition, DHA content of PS and PE are 12% and 14% reduced in the human AD´s cortex 
respectively, and also it has been found less amount of PE subspecies 22:6 n-3 (DHA) in the 
cortex of 9-month-old AD mice (Cunnane et al., 2012;). In general, a reduction of PE, PE-de-
rived PUFAs in the brain (Ginsberg et al., 1993;Conquer et al., 2000;Dorninger et al., 2015;) 
and in plasma (Conquer et al., 2000) has been associated to AD. Therefore, our results are in 
agreement with the previous findings and suggest that altered PS and PE metabolism in the 
hippocampus could be implied in the cognitive impairment described in AD by affecting the 
signaling pathways modulated by PUFAs, such as DHA and AA.
PE accounts for approximately 25% of mammalian PLs and is significantly enriched in the 
brain, where the PE content is 45% of the total PLs. PE has been recently involved in the pos-
itive regulation of autophagy and longevity (Rockenfeller et al., 2015). PEs and/or PE-derived 
(LPE and ePE) are essentials in the cell function (Vance and Tasseva, 2013), LPE can be gen-
erated from PE via a phospholipase A-type reaction (Vance and Tasseva, 2013). Currently, 
the physiological significance of LPE in the brain is unknown. However, in non-mammalian 
species, it has been attributed to certain functions. For example, in the housefly, LPE has 
antifungal and antibacterial activity (Meylaers et al., 2004), and in the mushroom Grifola 
frondosa, it stimulates mitogen-activated protein kinase (MAPK) signaling. Furthermore was 
reported that LPE induced neuronal differentiation of PC12 cells (Nishina et al., 2006). And 
recently it has been reported that LPE has a direct relationship with the calcium influx (Lee 
et al., 2015), which is close related to cell death (Bezprozvanny and Mattson, 2008).  Inter-
estingly, our data indicated increased LPE levels in the hippocampus of AD animals (Scr6 m 
and Scr12 m), specifically, the AA (20:4), the DHA (22:6) and the oleic acid (18:1) composi-
tion. Surprisingly, BACE1 silencing for 6 and 12 months reestablished the levels of these FAs 
to the control levels, which suggested that LPE is accumulated in AD. In addition, The PLS-
DA analysis of the phospholipid species, also suggested that, the shBACE1miR treatment 
generated a displacement of lipid prolife from AD group to control group profile. According 
to PLS-DA, such displacement is explained in an important part by LPE (16:1, 18:1, 20:4), 
meaning a significant role of BACE1 silencing in neuroprotection.
Although DHA is widely reported as being beneficial for cells, the excess levels likely trigger 
a negative effect on the membrane balance because the DHA content in the plasma mem-
brane of T27A cells may be detrimental. This prediction was confirmed by observations of 
the reduced viability of cells incubated with 22:6/18:0 (Zerouga et al., 1996). In contrast, the 
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key enzyme involved in the turnover and degradation of LPE, phospholipase A2 (PLA2), is 
markedly increased in brains from AD patients (Farooqui, 2010;) and associated to AA pro-
duction in AD (Sanchez-Mejia et al., 2010).  Also, PLA2 activation has been linked to inflam-
mation process in a genetically model of neurodegeneration, since it showed that specific 
lysophospholipids were responsible for microglial activation and the cytosolic PLA2 (cPLA2) 
inhibition had neuroprotective effect (Lee et al., 2011a;Sundaram et al., 2012). According 
to our results, BACE1 silencing down-regulated the composition of AA in LPE at 6 and 12 
months’ post-treatment, and decreased the phosphorylation state of cPLA2, which could be 
involved in the cell membrane homeostasis of treated AD mice at 12 months post-injection, 
with the consequent down-regulation of AA levels and COX2 pro-inflammatory pathway in 
the same time-line (Fig. 7C and 7D), suggesting a more effective anti-inflammatory regula-
tion by the long-term BACE1 silencing. Which are in concordance with our recent data were 
BACE1 silencing reduced not only b-amyloid and Carboxy-terminal fragment (CTF), but also 
reduced MAPK activity and phosphorylated soluble tau (Piedrahita et al., 2016). MAPK regu-
lates cPLA2 activity down-stream under lipid peroxidation condition (Lee et al., 2011b). Also, 
cPLA2 activity has been involved in the hyperphosphorylation of tau during neuroinflamma-
tion (Sundaram et al., 2012). AA through COX2 activity is the precursor of pro-inflammatory 
eicosanoids, prostaglandin E2 and leukotriene B4 and also increases the production of in-
terleukin-1, tumor necrosis factor-α and IL-6 (SanGiovanni and Chew, 2005;Freund-Levi et 
al., 2014). 
On the other side, also it has been reported that 22:6 FA suppresses the production of 
AA-derived eicosanoids and thus exerts anti-inflammatory and immunosuppressive effects 
(Calder, 2012;). Decreased levels of 22:6 trigger oxidative stress, which is known as a prima-
ry factor in the pathogenesis of AD because of the high-metabolic rate of the brain, which 
makes it particularly susceptible to ROS (Migliore et al., 2005). Also, oxidative stress is re-
lated to the progressive degradation of brain PLs in AD because they are rich in readily oxi-
dizable AAs and DHAs (SanGiovanni and Chew, 2005;Calder, 2012). However, our data sug-
gest a membrane destabilization process showing an up-regulation of DHA 22:6 in the LPE 
composition, maybe contributing to the pathogenesis of AD. Interestingly our data suggest 
the BACE1 knock-down reverse this pathogenic environment, generating homeostasis on FA 
composition of LPE, and reducing pro-inflammatory pathway cPLA2/AA/COX-2.
On the complementary side, a deficiency in brain ePE, which constitutes up to 70% of the 
total plasmalogens, has been traditionally associated with AD development, and low levels 
have been detected in the brain (Braverman and Moser, 2012), in the cerebrospinal fluid 
(Brites et al., 2009;Andrade-Moraes et al., 2013;) and in the serum of patients (Lessig and 
Fuchs, 2009); supporting the importance of those ones to control the membrane instability 
during oxidative stress in AD. According to our results, the reduction in ePE levels resulted 
from a significant decrease in the polyunsaturated 22:6 (DHA) and 18:0 (oleic acid) FAs. Be-
cause plasmalogens function as “scavengers” of ROS in biological membranes, low levels of 
ePE are associated with reduced cell viability because of the cell loss of antioxidant capacity. 
Decreased concentrations of ePE may be correlated with peroxisomal alterations because 
the enzymes required for its biosynthesis are found in these organelles (Lizard et al., 2012;). 
Several studies have reported alterations in peroxisomes isolated from AD brains and re-
duced biosynthesis of plasmalogens composed of DHA (Kou et al., 2011;Fanelli et al., 2013). 
Furthermore, the main ePE degradation enzyme is PLA2, which is significantly increased in 
AD. Interestingly, in this work, we demonstrated that BACE1 silencing restored the amount 
of ePE in the hippocampus of 3xTg-AD mice to the control levels, suggesting that BACE1 
silencing may play a role in the regulation of PLA2 activity restoring the homeostasis of this 
plasmalogen and allowing it to reach effective concentrations for antioxidant activity. 
In summary, our study suggests that AD is associated with a general disruption of membrane 
properties and plasmalogens composition disbalance. The length and saturation number 
are important determinants of many membrane characteristics including membrane, flu-
idity, thickness and the local curvature, even molecular packing, which in turn regulate the 
activities of the enzyme membrane. Intramembrane proteolysis is likely to be exquisitely 
regulated by the thickness of the membrane (Hong 2015), which could have implications 
for β-secretase-mediated cleavage of APP. However, this work suggests by the first time that 
BACE1 is involved in FA composition of PE-derivates (LPE and ePE), and that the shBACE1miR 
treatment in 3xTg-AD mice restores the levels of lipid subspecies that are altered by the 
disease animal model, which could be associated with learning and memory improvement. 
However, further research is necessary to establish whether there is a direct or indirect cor-
relation between the BACE1 levels and the metabolic pathways of PE, LPE and ePE and to ex-
plain how BACE1 silencing favors the appearance of the PUFAs involved in neuroprotection 
or if the reduction of BACE1 attenuated cytotoxic bA production for restoring cellular func-
tion including lipid metabolism, anti-inflammatory pathway and cognitive function, and to 
verify which would be the correspondence of those data with the human AD pathogenesis.
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Lipids are considered important factors in the pathogenesis of Alzheimer Disease (AD). In 
this study we realized a comparative analysis of the phospholipid profile and phospholipid 
composition of the temporal cortex from E280A-familiar AD (FAD), sporadic AD (SAD) and 
healthy human brains. Findings showed a significant decrease of lysophosphatidylcholine 
and phosphatidylethanolamine formed by low levels of polyunsaturated fatty acids (20:4, 
22:6) in the AD brains. However, Phosphatidylethanolamine-Ceramide (PE-Cer) and Phos-
phoglycerol (PG) were significantly increased in SAD, conformed by high levels of (18:0/18:1) 
and (30/32/36:0/1/2) respectively. Together, the findings suggest deficiency in LPC, PE, and 
alteration in the balance between poly and unsaturated fatty acids in both types of AD, and 
a differential pattern of phospholipid profile and fatty acid composition between E280A FAD 
and SAD human brains. 
Key words: Alzheimer’s disease, phospholipids, fatty acids, temporal cortex, polyunsaturat-
ed fatty acids.
Abbreviations: DAG, diacylglycerol; TG, triacylglycerol; FA, fatty acid; FFA, free fatty acid; 
PL, phospholipid; PA, phosphatidic acid; PC, phosphatidylcholine; LPC, lysophosphacholine; 
ePC ether phosphatidylcholine; PS, phosphatidylserine; ePS, ether phosphatidylserine; PE, 
phosphatidylethanolamine; PE-Cer, phosphatidylethanolamine ceramide; LPE, lysophos-
phatidylethanolamine; ePE, ether phosphatidylethanolamine, PI, phosphatidylinositol; PG, 
phosphatidylglycerol; SM, sphingomyelin; CE, cholesterol esters; AA, arachidonic acid; cPLA, 
cytosolic phospholipase. SAD, Sporadic Alzheimer Disease; FAD, Familial Alzheimer Disease
Introduction
Alzheimer disease (AD) currently is suffered by 15 million of individuals worldwide [1], being 
the most common cause of dementia and one of the main sources of morbidity in the aging 
population. Its ethiopathogenesis is multifactorial, with a very slow progression in the spo-
radic type of AD, affecting 10% of the population over 65 years of age, and approximately 
50% over 85 years old. AD is characterized by severe neuronal loss, which alters the tissue 
composition and macrostructure of cerebral regions, in a moderate mode in the cerebral 
cortex, and severe mode in the hippocampus [2]. 
Most frequent of AD is sporadic type (SAD), however AD variants as autosomal dominant 
Familial Alzheimer Disease (FAD) have been described [3]. FAD explain the 0.5% of all AD 
cases, which is characterized by an early onset (<65 years old) and a fast-increased severity; 
around 50% of FAD patients presenting autosomal dominant inheritance of mutations in 
one of the associated three genes, namely, preseniline-1 (PS1), preseniline-2 (PS2) and APP 
(Amyloid precursor protein). These mutations are closely related with the increase of Aβ 
1-42 production, which is triggered in a younger age generating different types of early on-
set FAD (EO-FAD) [3]. Although FAD and SAD share some features, it is not clear if these are 
equivalent diseases. In facts, metabolomics, lipidomics, transcriptomics, and epigenomics 
are new approach searching complementary criteria for AD diagnosis, because some fea-
tures changes for FAD, in many but not all cases, seem similar to SAD [4]. 
Several lines of evidence suggest that lipid metabolism participate in the pathogenesis of 
AD. Epidemiologic studies suggest that increased plasma cholesterol levels are associated 
with the disease. Furthermore, cellular studies have shown that the levels and distribution 
of intracellular lipids affect the processing of amyloid precursor protein into A beta peptides, 
being toxic species for the brain [5][6]. Fatty acid composition of phospholipids, as poly-
unsaturated fatty acids (PUFAs), mainly docosahexaenoic acid (DHA) and arachidonic acid 
(AA) have crucial roles in the preservation of physiology and maintenance of central nerv-
ous system [7]; therefore, their alteration increases the risk for developing AD [8][9]. Also, 
saturated fatty acids (SFA) provide stability in the cell membrane structure and membrane 
proteins. But, altered levels are related with neurodegenerative diseases, and those high 
levels of SFA are associated with a high level of serum cholesterol, which is strongly corre-
lated with AD [10]. Nevertheless, the PUFA effects on the regulation of lipid metabolism and 
in the prevention of neurodegenerative diseases appear to be diverse [11]. Balanced PUFA 
and saturated fatty acids ratio was thought to be very important in regulating serum choles-
terol [12]. However, excessive increase of PUFA has undesirable effects on oxidative stress, 
because of the high susceptibility to lipid peroxidation [13][14]. Those evidences suggest 
that a sensitive balance between PUFAs and SFAs ratio allows a membrane homeostasis 
avoiding the cell death. 
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In the present study we realized a comparative analysis of the phospholipid profile and 
phospholipid composition of the inferior temporal cortex from E280A familiar AD (FAD), 
sporadic AD (SAD) and healthy human brains.
Materials And Methods
Human brain samples
All samples from AD and healthy individuals provided informed consent for research, and 
this study was approved by the bioethical committee for human studies from the University 
of Antioquia. We included 5 cases of Sporadic Alzheimer Disease (SAD), 5 cases of Familial 
Alzheimer Disease (FAD) (presenilin 1 mutation E280A) and 3 control cases obtained from 
the University of Antioquia´s Brain Bank (Table 1). On the table, we showed the post-mor-
tem index, as time lapse between patient´s death and sampling; Braak stage, to classify the 
degree of AD [15]; NIA-RI criteria, as pathological diagnosis of AD´s “high likelihood” [16], 
and Consortium to Establish a Registry for Alzheimer’s Disease (CERAD), is a neuropsycho-
logical battery developed for screening of Alzheimer’s disease and recently validated [17]. It 
comprises the following eight sub-tests: Mini-Mental State Examination (MMSE/30), Verbal 
Fluency (VF/24), Modified Boston Naming Test (BNT/15), Word List Learning (WLL/30), Word 
List Recall (WLR/10), Word Recognition Discriminability (WLRD/10), Constructional Praxis 
Copy (CP/11), and Constructional Praxis Recall (PR/11) [17]. Frozen samples were obtained 
from the inferior temporal cortex for biochemical analysis. 
Lipid analysis
The total lipids from the inferior temporal cortex were extracted according to the FOLCH 
technique [18] using a mixture of 2 mL of chloroform (CHCl3) and 1mL of methanol (MeOH) 
in a 2:1 (v/v) ratio. Then, 0.005% butylated hydroxytoluene (BHT) was added, and this mix-
ture was used to homogenize the tissue. Subsequently, 1 mL of 0.9% NaCl was added, and 
the mixture was centrifuged at 3000 rpm for 3 minutes. The organic layer (lower layer) was 
removed and transferred to a new glass tube. This procedure was performed in an oxy-
gen-free using enriched nitrogen environment to avoid lipid oxidation processes and was 
repeated three times. The solvents were evaporated, and the extract was lyophilized to 
remove the excess of humidity. Finally, the lipid composition was analyzed by mass spec-
trometry.
Mass spectrometry
An automated ESI-MS/MS approach was used and data acquisition and analysis carried 
out at the Kansas Lipidomics Research Center using an API 4000™ and Q-TRAP (4000Qtrap) 
detection system as it was described previously [19]. This protocol allowed the detection 
and quantification of low concentrations of the polar lipid compounds. The molecules were 
determined by the mass/charge ratios, which were compared with the respective inter-
nal standard to determine which species of lipids were present in the evaluated extract: 
0.66nmol di14:0-PC, 0.66 nmol di24:1-PC, 0.66 nmol 13:0-lysoPC, 0.66 nmol 19:0-lysoPC, 
0.36 nmol di14:0-PE, 0.36 nmol di24:1-PE, 0.36 nmol 14:0-lysoPE, 0.36 nmol 18:0-lysoPE, 
0.36 nmol 14:0-lysoPG, 0.36 nmol 18:0- lysoPG, 0.36 nmol di14:0-PA, 0.36 nmol di20:0 (phy-
tanoyl)-PA, 0.24 nmol di14:0-PS, 0.24 nmol di20:0 (phytanoyl)-PS, 0.20 nmol 16:0-18:0-PI, 
0.16 nmol di18:0-PI, and 1 nmol 15:0 fatty acid. The system detected a total of 12 different 
lipid species and their respective subspecies, which were identified by the number of car-
bons and degree of unsaturation of the chain. Lipid concentration was normalized by molar 
concentration across all species for each sample, and the final data are presented as mean 
mol%.
Table 1. Description of brain tissue samples.












SAD F 82 92 5,5 VI 3 C
SAD F 65 74 2,5 IV 3 C
SAD F 69 76 3,75 VI 3 C
SAD M NA 83 4,3 VI 3 C
SAD M 70 83 4,3 VI 3 C
FAD M 49 55 2,8 VI 3 C
FAD F 50 60 2,8 VI 3 C
FAD F 45 55 2,5 VI 3 C
FAD M 40 53 4,1 VI 3 C
FAD F 62 74 5,5 V 3 C
CONTROL F NAP 43 >24 0 0 0
CONTROL M NAP 60 >24 0 0 0
CONTROL F NAP 84 4,3 2 1 A
NA= not available; NAP= not applicable. 0 = No histological evidence of Alzheimer´s disease. A = Histological findings 
are UNCERTAIN evidence of Alzheimer´s disease. B = Histological findings SUGGEST the diagnosis of Alzheimer´s 
disease. C = Histologic findings INDICATE the diagnosis of Alzheimer´s disease.
Statistical analysis
The lipid levels for each sample were calculated by summing the total number of moles of 
all lipid species measured and then normalizing that total to %mol. Comparisons between 
groups were assessed either by one-way ANOVA, followed by the Tukey post-hoc test or the 
Kruskal-Wallis test, depending on the homoscedasticity and normality of the experimental 
data. Multivariate statistics were performed using a partial least squares-discriminant anal-
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ysis (PLS-DA) [20]. PLS-DA was included because it is particularly suitable for the analysis 
of datasets with a small number of samples and a large number of variables. The PLS-DA 
analysis was carried out using the routines described in [21]. An index representing the 
importance of the variables according to the first components was estimated, the PLS-DA 
index used is called the variable importance in projection (VIP) [22], which determines the 
importance of each variable that is reflected by each component and, similar to PCA, it also 
considers the variance explained by each PLS component (for a detailed description of VIP 
[22]. The confidence ellipsoids per group and treatment are also included. The data from 
the univariate and bivariate statistics are expressed as the mean ± the standard error of the 
mean. The statistical significance is indicated in the figures and tables.
Figure 1. Lipid composition of the temporal cortex from human FAD, SAD and healthy brains. A - The lipid class 
profiles are expressed as %mol composition. All lipid species were measured (means), and the error bars represent 
the SEM. The data for the FAD and SAD tissue were significantly different from the control groups (*p< 0.05, **p< 
0.01, ANOVA followed by the Tukey post hoc test or Kruskal-Wallis test). B - Multivariate analysis of the lipid profiles 
from the temporal cortex of FAD, SAD and healthy brains. PLS-DA, Partial least squares analysis to discriminate be-
tween the lipid classes. The right panels show the factor score plots for PLS-DA and VIP index. DAG, diacylglycerol; 
PA, phosphatidic acid; PC, phosphatidylcholine; LPC, Lysophosphatidylcholine; ePC ether phosphatidylcholine; PS, 
phosphatidylserine; ePS, ether phosphatidylserine; PE, phosphatidylethanolamine; PE-Cer, Phosphatidylethanola-
mine Ceramide; LPE, Lysophosphatidylethanolamine; ePE, ether phosphatidylethanolamine, PI, phosphatidylinosi-
tol; PG, phosphatidylglycerol; SM, sphingomyelin. n=3-4 per group. **p< 0.01. Data are expressed as %mol. n=3-5 
per group.
Results
At a glance, the lipidomic analysis of the temporal cortex revealed a type of changes related 
with the neurodegenerative condition of SAD and FAD compared with healthy brains, while 
a second type of changes presented differences between the both Alzheimer variants re-
spect to the control group.
Temporal cortex lipid profile was detected in fifteen lipid species, where PC (47%), PE (23%) 
and SM (20%) showed the higher Mol%. Although, LPC and PE concentrations showed a 
clear tendency or significant reduction in both AD entities. Interestingly, a lipid specie de-
rived from PE, the phosphosphingolipid PE-Cer, also known as N-(octadecanoyl)-tetrade-
casphing-4-enine-1-phosphoethanolamine (http://www.lipidmaps.org/data/LMSDRecord.
php?LMID=LMSP03020001), showed a significant increased concentration in SAD, whereas 
its concentration in FAD did not present changes compared with the control group. Also, PG 
concentration increased significantly in SAD, respect to a similar concentration in FAD and in 
the control group (Fig. 1A).
PLS-DA analysis indicated that the control group is located in a different quadrant of the 
Figure 2. PE levels in the temporal cortex from FAD, SAD and healthy brains. A - Contour plot of the more influ-
ential subclasses of PE in the discriminant analysis for each evaluated variable; all PE subclasses were measured 
(means). B - Multivariate analysis using PLS-DA, Partial least squares analysis, to discriminate between the PE sub-
classes. The table show the factor score plots for PLS-DA with the indices of variance explained for each component 
(VIP). C - Total number of carbon´s atoms in the fatty acid moieties of PE composition. D - PE species saturation 
equal to the total number of double bonds in the fatty acid moieties. *p< 0.05, **p< 0.01, ***p< 0.001. Data are 
expressed as %mol. n=3-5 per group.
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plane compared with the FAD and SAD groups (Fig. 1B). In addition, the FAD and SAD groups 
showed a different distribution pattern, indicating that phospholipids (PLs) profile were dif-
ferent for each AD´s type (Fig. 1B). 60.8 % of the total variance may be explained by factor 
1, that in according to the VIP the five more changing species were conformed mainly by 
saturated fatty acids were PG 32:0 (16:0/16:0) (VIP = 2.1285), PG (36:2) (18:1/18:1), PS 36:4 
(20:4/16:0) (VIP = 1.9358), PE 34:0 (16:0/18:0) (VIP = 1.8640), PA 32:0 (16:0/16:0) (VIP = 
1.8120) compared with control group (Fig. 1B).
PE and LPC levels are reduced in the temporal cortex from FAD and SAD brains
When we analysed each significant changing phospholipid, we found that PE levels present-
ed reduced concentration in FAD and SAD, and PLS-DA analysis indicated that nearly 73% 
(PE) of the total variance could be explained by factor 1 (Fig. 2). The most relevant molecular 
sub-lipidic specie was PE 40:6 (18:0/22:6) in AD, which had a higher VIP index (2,6757) (Fig. 
2A, B), also supported by the reduction in the fatty acids composition of 40C with 4 or 6 
unsaturations (Fig 2C, D). Together, FAD and SAD groups had the same distribution pattern 
of PE on the plane compared to the different quadrant distribution showed by the control 
group (Fig. 2B). 
Another phospholipid affected in both AD types was the LPC. In accordance with the 
PLS-DA analysis the main decreased lipid subclasses LPC 16:0 (VIP= 2.1285) and LPC 18:1 
(VIP=2.0949), and the significant reduction of those fatty acids composition (16,18C:0,1) 
(Fig 3A, B). Furthermore, AD group´s had the same distribution pattern on the quadrant of 
the graph opposed to the control group. These data were supported by the reduced dye in-
tensity in FAD and SAD groups observed in the contour plot (Fig. 3 A). Also supported by the 
reduction in the fatty acids composition of 16C, 18C and 22C with 0, 1, 4 and 6 unsaturation, 
respect to the control group (Fig 3C, D).
Figure 3.  LPC levels in the temporal cortex from FAD, SAD and healthy brains. A - the Contour plot of the more 
influential subclasses of LPC (variables) in the discriminant analysis for each variable evaluated; all LPC subclasses 
were measured (means). B - Multivariate analysis using PLS-DA, Partial least squares analysis to discriminate be-
tween the PL subclasses. The table show the factor score plots for PLS-DA with the indices of variance explained for 
each component (VIP). C – Total number of carbon´s atoms in the fatty acid moieties of LPC composition. D - LPC 
species saturation equal to the total number of double bonds in the fatty acid moieties. *p< 0.05, **p< 0.01, ***p< 
0.001. Data are expressed as %mol. n=3-5 per group. 
Figure 4. PE-Cer levels in the temporal cortex from FAD, SAD and healthy brains. A - Multivariate analysis using 
PLS-DA, Partial least squares analysis to discriminate between the PE-Cer subclasses. B - shown the Contour plot 
of the more influential subclasses of PE-Cer (variables) in the discriminant analysis for each variable evaluated; all 
PE-Cer subclasses were measured (means). C - Total number of carbon´s atoms in the fatty acid moieties of PE-Cer 
composition. D - PE-Cer species saturation equal to the total number of double bonds in the fatty acid moieties. 
**p< 0.01, ***p< 0.001. Data are expressed as %mol. n=3-5 per group.
Differential pattern of phospholipid profile in the temporal cortex from E280A-familial 
and sporadic Alzheimer´s disease brains
78 79
Chapter 3
PE-Cer and PG have a differential profile in SAD respect to FAD brains
PLS-DA analysis presented a 72,97% of the total variance explained by factor 1 between AD 
types and healthy groups (Fig. 4A). PE-Cer 18:0 subclass was the most determinant in the 
differential distribution pattern in the plane compared to the control group (VIP=3.5201), 
followed by PE-Cer 38:4 (18:0/20:4) (VIP=0,7512) and PE-Cer 40:4 (18:0/22:4) (VIP=0,7512) 
(Fig. 4A). PE-Cer concentration was significantly higher in the SAD group in comparison with 
FAD and healthy groups, and specifically the higher concentration of PE-Cer (18:0) in SAD 
supported by the contour plot (Fig. 4B). Complementarily, the fatty acid composition by 18C 
with 0 or 1 unsaturation was significant higher in SAD (Fig. 4C, D). Therefore, all evaluated 
groups had a differential distribution patterns in the graph, suggesting a divergence be-
tween FAD and SAD in that sub-lipidic specie.
Also, PG concentration increased in SAD, which was evidence in the contour plot (Fig 5A). 
The main lipid subclass was the PG 32:0 (16:0/16:0) (VIP=2.0949) according to PLS-DA anal-
ysis (Fig. 5B), supported by the increased of fatty acid composition by 30C, 32C, 36C with 
0 or 1 unsaturation (Fig. 5C, D). In addition, the distribution pattern in the plane showed 
divergent distribution between AD groups even the FAD group was closer to control group 
(Figure 5B).
Discussion
Our data suggest a deficiency of PE and LPC levels in the temporal cortex from AD-E280A 
and SAD brains respect to healthy brains, and a particular up-regulation of PE-Cer and PG 
levels in the SAD´s samples. The temporal cortex has been identified as an affected area by 
NFTs and bA plaques in AD, also presenting synaptic and neuronal loss [23][24][25]. Few 
studies have realized a comparative analysis of lipid profile between FAD and SAD by lipid-
omic approach. Nevertheless, the involvement of lipid alterations in AD brains have been 
well-established in the last years, in particular with reference to cholesterol and polyunsatu-
rated fatty acid contents [26] [27].
The reduction of PE and LPC levels have been previously described in AD brains [27]. PE is 
a precursor of several lipid sub-species, as essential component of mammalian cell mem-
branes; it has been reported its decrease in post-mortem AD brains and in closed correlation 
with Aβ accumulation in Tg2527 mouse model of AD [28], confirming our observations in 
FAD-E280A and SAD brains (table 1). Although, our data showed a reproducible reduction 
of PE (15 Mol%) and a slight increased conversion to ePE (0,5%) in  the inferior temporal 
cortex of AD, which have been demostrated as a compensatory phenomenon [29]. Those 
levels were very different respect to previous studies, where ePE deficiency was up to 50% 
in AD mid-temporal cortex [30]. However, other recent study showed 6 and 8 Mol% of PE 
and ePE respectively in the prefrontal cortex from human brains [27]; suggesting an intrinsic 
variation per study and/or per cerebral region. Maybe, it is possible that a factor affecting 
the ePE levels detected in our study be because of the diacyl lipids were used as standards, 
and do not ether-linked lipids. Data is supported by a similar detection levels in our recent 
lipidomic analysis in 3xTgAD mice model [31].
Also, a decrease of PC and LPC have been reported previously in peripheral blood samples 
[32], human brain tissue and animal models [27]. But, PC modulation in AD is not consist-
ent through the different studies [32] [33], as in our data, where PC levels did not change. 
Nevertheless, LPC could be a sensitive parameter to measure alterations in the PC turnover 
or breakdown, because although it is usually present in low concentration into the brain, 
it has more stable concentration [33]. This concentration is regulated by the catalytic en-
zyme phospholipase A2 (PLA2) and Lysophospholipid acyltransferase (LPCAT), which turn 
lysophospholipids to phospholipids. The PLA2 has been described to be significantly de-
Figure 5. PG levels in the temporal cortex from FAD, SAD and healthy brains. A- The Contour plot of the more in-
fluential subclasses of PG (variables) in the discriminant analysis for each variable evaluated; all PG subclasses were 
measured (means). The analyzed groups are the healthy (controls), FAD and SAD. n=3-5 per group. B - Multivariate 
analysis using PLS-DA, Partial least squares analysis to discriminate between the PG subclasses. The table show the 
factor score plots for PLS-DA with the indices of variance explained for each component (VIP). C -Total number of 
carbons atoms in the fatty acid moieties of PG composition. D - PG species saturation equal to the total number of 
double bonds in the fatty acid moieties.  Data are expressed as %mol. n=3-5 per group.
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creased in parietal and temporal cortices of patients with AD, existing a correlation between 
the reduction of PLA2 and the severity in AD [34].
Moreover, the failure of PE and LPC production in the temporal cortices from SAD and FAD 
brains have reduced composition of monounsaturated acid, as Linoleic acid (18:1) and pol-
yunsaturated fatty acids (PUFAs), as DHA (22:6) and AA (20:4). Which have been previously 
reported in the hippocampus, temporal cortex and mid-frontal cortex [35] [36] [37]. Fur-
thermore, the turnover of DHA towards the neuroprotective docosanoids, as resolvins and 
neuroprotectins, which are effectors of antioxidant, anti-inflammatory, and antiapoptotic 
actions, also are altered in AD [38]. Interestingly, a supplemental dietary of DHA (22:6n-3) 
reduces neurodegeneration in mouse models of AD [39] [40].  Other studies suggest a neu-
roprotective effect of PUFAs, as AA on cognitive function, preserving the synaptic plasticity 
[41][42]. Recently, it has been demonstrated that arachidonic or docosahexaenoic acid diet 
prevents memory impairment and reduces the Aβ production in Tg2576 Mice [43] [44]. 
On another hand, the findings showed that PE-Cer is increased in SAD brains. PE-Cer is a 
lipid analogue to sphingomyelin (SM), but in basal conditions is >300-fold lower [45], its 
increased levels are related with imbalance in SM synthase (SMS2) activity. SMS2 is a bi-
functional enzyme producing both PE-Cer and SM. SM synthase-related enzyme (SMSr) is 
the principal PE-Cer synthase in the brain [45]. PE-Cer has been described in insects [46], ex-
pressed in Golgi apparatus, with a widespread ocurrency in the animal kingdom [47].  It has 
been associated to synaptic vesicles [48]; and ceramide as a modulator of phosphatidyleth-
anolamine has been correlated in chronic disease, as diabetes, obesity and some cancers 
[49]. Elevation of ceramide levels in AD is highly correlated in mild cognitive impairment [50] 
and apoptosis [51][52]. Therefore, in our study we detected that SM presented a tendency 
to increase in both FAD and SAD groups (Figure 1), suggesting PE-Cer is a marker of chronic 
impairment in SAD condition.
Another change was obtained on PG, which is found in low concentrations in mammal cells, 
this is mainly synthesized by the mitochondria and regulates numerous biological functions, 
such as activation of the protein kinase C family and the stability of mitochondrial mem-
brane [53][54][55]. PG is catalyzed by phosphatidylglycerophosphate synthase (PGS) activity 
and its overexpression increase the cell content of PG and decrease the PA concentration 
[55], and also PG is inversely related to PE levels in synaptic dysfunction in an AD model [56], 
which is coincident with our data, suggesting mitochondrial dysfunction is associated to an 
advanced stage of SAD [57][58].
Complementarily, the main composition of PE-Cer and PG in the temporal cortex from SAD 
brains was composed by saturated fatty acids, as stearic (18:0), palmitic (16:0) acid and 
arachidonic acid (20:4). Epidemiological studies suggest that high fat diet increases the risk 
of AD and the degree of saturation of fatty acids is a critical risk factor for developing AD 
[52], mainly in the frontal gray matter and in hippocampus [34]. In addition, neurofibrillary 
tangles are associated to palmitic and stearic fatty acids enriched membranes in AD brains 
[52]. Palmitic acid causes up-regulation of the BACE1 enzyme and its amyloidogenic process-
ing of β-amyloid precursor protein (APP) [59][60][61], supporting the metabolic alteration 
in the sporadic condition. Also, this chronic neurodegeneration could be accompanied by a 
pro-inflammatory environment, since our data showed AA composition in PE-Cer and PG. 
AA is metabolized to eicosanoids, such as prostaglandins, leukotrienes, and thromboxanes, 
all of which are potent mediators of inflammation. This pathway also involves to cyclooxy-
genases (COX), particularly COX-2 leading to Aβ plaques formation and cognitive deficits in 
APP mouse model [9].
In summary, the results suggest a deficiency of PE and LPC phospholipids formed by low 
concentration of mono (18:1) and polyunsaturated fatty acid (22:6, 20:4) in the temporal 
cortex of E280A-FAD and SAD brains, suggesting a common loss of homeostasis in a neu-
rodegenerative process and the necessity of adequate balance between saturated and un-
saturated FA composition in the cerebral regions. In addition, SAD brains present a high 
composition of saturated fatty acid (18:0 and 16:0) in PE-Cer and PG, suggesting a context 
of Golgi and mitochondria dysfunction and pro-inflammatory environment during a longer 
chronic neurodegeneration. This differential metabolic profile could to help to define a di-
vergent pattern between AD types and healthy brains. However, more studies are necessar-
ies for understanding the role of the phospholipids in the dynamic of neurodegeneration 
and the recovering of cerebral homeostasis.
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Inflammation has been suggested to play early and perhaps causative roles in Alzheimer’s 
disease (AD) pathogenesis possibly in part by the overactivation of the aspartic acid 
protease named b-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1), which 
is responsible for the b-amyloid cascade. We have described that BACE1 is involved in 
the lysophosphatidylethanolamine (LPE) (18:1/20:4/22:6) upregulation associated with 
tauopathy and inflammation signaling (cPLA2/arachidonic acid/COX2) in a triple transgenic 
model of Alzheimer´s disease, where BACE1 silencing reversed the imbalanced profile and 
produced cognitive function improvement. In this study, we analyze the role of cPLA2 and 
desaturases (SCD1, FAD6) in the BACE1 knockdown-induced protective action under a 
glutamate excitotoxicity model. Glutamate (125 mM) produced hyperphosphorylation of tau 
in cortical primary cultures along with increased apoptotic nuclei, LDH release, and cPLA2 
expression, which were all reversed by BACE1-KD. This beneficial effect was reinforced by the 
silencing of cPLA2 but attenuated by the reduction in SCD1 and partially attenuated by the 
reduction in FAD6. Inversely, overexpression SCD1 and FAD6 recovered the neuroprotective 
effect produced by BACE1-KD, which was not achieved by the overexpression of each 
desaturase alone. These findings suggest that the hyperphosphorylation of tau and the 
creation of a pro-inflammatory cell environment are blocked in a desaturase-dependent 
manner by targeting BACE1. 
Key words: BACE1, hyperphosphorylated tau, excitotoxicity, cPLA2, desaturases, 
inflammation.
Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by senile plaques 
composed of amyloid-β (Aβ) peptides, intracellular paired helical filaments (PHFs) caused 
by abnormally phosphorylated tau protein, neuroinflammation and neuronal loss. Aβ is 
generated by the enzymatic processing of the amyloid precursor protein (APP). This process 
involves the cleavage of APP by β-site APP cleavage enzyme 1 (BACE1) and the γ-secretase 
complex, which contains presenilin 1 or 2 (PS1 or PS2) as the catalytic subunit to generate 
the Aβ40 and Aβ42 peptides (Karran, Mercken, and De Strooper 2011; D. J. Selkoe and Hardy 
2016). The amyloid cascade hypothesis suggests that synaptic toxicity and neurotoxicity 
mediate the creation of the multimeric amyloid-β peptide species and the consequent 
hyperphosphorylation of tau, PHF formation and cognitive impairment; however, the 
molecular etiopathogeneses leading to those events are not fully understood. Recent works 
suggest that systemic inflammation could exacerbate or even trigger neuronal dysfunction 
associated with dementia, including impaired insulin signaling, synapse degradation and 
memory disturbances associated with the release of cyclooxygenase-2 (COX-2) and inducible 
nitric oxide synthase (INOS) (Karran, Mercken, and De Strooper 2011; Qin et al. 2003; Shi 
et al. 2016). Elevated APP and COX2 production has been linked to calcium-dependent 
phospholipase A2 (cPLA2) upregulation in vivo and in vitro in cortical neurons exposed to 
Aβ (Sagy-Bross et al. 2015). cPLA2 upregulation is closely associated with inflammation (Tan, 
Ng, and Ong 2016), excitotoxicity in spinal cord neurons (Z. Zhao et al. 2011) and mood 
disorders (Kim, Rapoport, and Rao 2011). Additionally, pro-inflammatory arachidonic fatty 
acid released by cPLA2 is metabolized by COX2 (Leslie 2015). In addition, elevated cPLA2 
activity has been associated with increased tau hyperphosphorylation during inflammation 
(Sundaram et al. 2012), and MAPK regulates cPLA2 activity under lipid peroxidation 
conditions (Lee et al. 2011).
 
Alternatively, our previous studies have suggested that BACE1 may have a more direct action 
on tauopathy because it decreases the rate of tau phosphorylation, blocking the MAPK 
pathway in a triple transgenic AD mice model (Diego Piedrahita et al. 2016). Additionally, 
the reduction in the phosphorylation of tau by shBACE1miR was blocked by an inhibitor 
of autophagosome lipidation of phosphatidylethanolamine (PE), 3-methyladenine (3-MA) 
(Diego Piedrahita et al. 2016). However, our recent research showed that BACE1 silencing 
prevents cognitive impairment and inflammation; reduces arachidonic acid, cPLA2 and 
COX2; and recovers the mono- and polyunsaturations of the fatty acid composition of 
PE plasmalogens, such as lyso (LPE) and ether (ePE), in the hippocampus of 3xTgAD mice 
(Villamil-Ortiz et al. 2016).
Therefore, considering that cPLA2 is the main enzyme involved in the production of 
plasmalogens (Makide et al. 2009) and that stearoyl-coenzyme A desaturase 1 (SCD) and fatty 
Tauopathy offsetting induced by BACE1-KD is desaturase dependent
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acid desaturase 6 (FADS6) are responsible for fatty acid unsaturation; our next question was 
to analyze the role of cPLA2 and desaturases (SCD1, FAD6) in BACE1-KD-induced protective 
action and tau hyperphosphorylation reduction in a model of glutamate excitotoxicity.
Materials and methods
Primary neuronal cultures
Cortical samples from Wistar rat embryos (E18-19) were dissected, dissociated and cultured 
on poly-L-lysine (Sigma-Aldrich, St. Louis, MO, USA) precoated multiwell plates in Neuroba-
sal medium (Gibco, Rockville, MD, USA), which contained B-27 supplement (Sigma-Aldrich), 
albumin from a chicken egg (Sigma-Aldrich), N2 human supplement (GIBCO), and a penicil-
lin-streptomycin antibiotic mixture (GIBCO); the samples were cultured at 37°C in a 5% CO2 
humidified atmosphere for a maximum of 19 days in vitro (DIV19). Isolated primary neurons 
were plated at a low density (52 cell/mm2) for immunofluorescence and at a high density 
(1500 cell/mm2) for Western blotting to assay cPLA2, SCD1 and FADS6.
ShRNA-miR AAV viral vector, shRNA lentiviral particles, and transduction
The SCR (scrambled) or BACE1 shRNA-miRs (short hairpin RNA in a microRNA backbone) 
were designed and validated in our previous study (D Piedrahita, Castro-Alvarez, Boudreau, 
Villegas-Lanau, Kosik, Gallego-Gomez, and Cardona-Gómez 2015). The adeno-associated vi-
rus (AAV) particles were obtained from the Davidson Laboratory (University of Iowa Viral 
Vector Core). The AAV aliquots were dialyzed, and the cells were transduced with 2 µL AAV 
2/5 (10 genomes per mL) at a titer of 1012 vg/mL for 3 h at 37°C; the media were subse-
quently completed with B27 supplemented Neurobasal medium. The transductions were 
performed at DIV7 and maintained for 12 days posttransduction prior to the administration 
of inhibitor and the glutamate treatments. cPLA, SCD1 and FADS6 shRNA mouse (m) viral 
particles containing target-specific constructs that encode 19-25-nt (plus hairpin) shRNAs 
were used to knock down gene expression (Santa Cruz Biotechnology, Santa Cruz, CA, USA). 
Commercial control shRNA viral particles encoding a scrambled shRNA sequence that does 
not specifically degrade any known cellular mRNA were also used. At DIV12, the cultures 
were transduced for 7 days with lentiviral particles at a titer of 106 infectious units of virus 
in Dulbecco’s modified Eagle’s medium (DMEM) that contained 25 mM HEPES, pH 7.3.
Transfection and cotransfection of neuron cultures
Neurons were cotransfected with cPLA2, SCD1 and FADS6 CRISPR activation plasmid (m) 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) or with an empty vector in DMEM with 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). At 4 h, the transfection medium was 
replaced with DMEM containing 10% fetal bovine serum (FBS). Hippocampal neurons were 
transduced with SCR or BACE1 shRNAmiR at DIV7. Clustered regularly interspaced short pal-
indromic repeats (CRISPR) activation plasmid (m) and empty plasmid were transfected and 
cotransfected into cortical neurons with Lipofectamine 2000 (Invitrogen) in Neurobasal me-
dium at DIV17. An equimolar mixture of 0.4 µg of DNA with Lipofectamine 2000 was used. 
At 4 h, the posttransfection medium was changed for the supplemented Neurobasal medi-
um, and the DIV18 neurons were treated with 125 µM glutamate for 20 min (Sigma-Aldrich) 
to induce excitotoxicity. 
Treatments 
DIV18 neurons were treated with 125 µM glutamate for 20 min to induce excitotoxicity 
(Posada-Duque et al. 2013). After 20 min, the glutamate was washed out to evaluate the 
effects. At 24 h postglutamate, the media were collected for use in the LDH assay, and either 
the protein was collected or the cells were fixed.
Immunofluorescence
Immunofluorescence analysis was performed as previously described (Posada-Duque et al. 
2013). Briefly, the cells were incubated overnight at 4°C with the following primary anti-
bodies: anti-mouse cPLA2 (1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-goat 
SCD1 (1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-goat FADS6 (1:200, Santa 
Cruz Biotechnology, Santa Cruz, CA, USA), and anti-mouse phospho-tau (Ser202, Thr205) 
(AT8) (1:1000, Thermo Fisher, CA, USA) antibodies. The Alexa-594 fluorescent antibody was 
used as a secondary antibody (1:1000, Molecular Probes, Eugene, OR, USA). The nuclei were 
stained with Hoechst (1:5000, Invitrogen), and the cells were incubated with each primary 
antibody conjugated with Alexa 594 (1: 2000, Molecular Probes) for 1 h. The cells were 
washed 4 times in buffer, cover slipped using Gel Mount (Biomeda, Hatfield, PA, USA), and 
observed under an Olympus IX 81 epifluorescence microscope (Olympus Latin America, Inc., 
Miami, FL, USA) or a Disk Scan Unit (DSU) Spinning Disc Confocal microscope. No staining 
was observed when the primary antibodies were omitted. XY images were collected using 
an Olympus IX 81 microscope with 10X (NA, 0.4), 40X (NA, 1.3) or 60X (NA, 1.42) oil immer-
sion objectives.
Quantitative image analysis
The percentage of condensed nuclei was obtained using the following formula: [condensed 
nuclei/ (condensed nuclei + normal nuclei)] × 100. (Posada-Duque et al., 2013) The mean 
area, diameter and intensity of each nucleus were quantified using the automatic meas-
urement/spatial trace feature tool. Condensed nuclei were defined as those possessing an 
average area equal to or less than 40 μm2, a diameter equal to or less than 6 μm and a fluo-
Tauopathy offsetting induced by BACE1-KD is desaturase dependent
92 93
Chapter 4
rescence intensity equal to or greater than 120 (AU). Images were analyzed individually and 
calibrated to a micrometer scale using Image Scope Pro Plus software (Media Cybernetics 
Inc., Rockville, MD, USA). Analyses were performed for 15 neurons per treatment in each 
duplicate assay and for at least four independent experiments (n =3-5).
LDH release
A cytotoxicity detection kit (Roche) was used to assess the presence of cytotoxicity by meas-
uring the activity of lactate dehydrogenase (LDH) released by cultures. The culture medium 
was recovered one day after glutamate treatment (DIV 19); LDH activity was determined 
by measuring NADH absorption as the linear rate of consumption during pyruvate reduc-
tion to lactate using a spectrophotometer. The cytotoxicity was calculated for a given test 
condition using the following equation: cytotoxicity (%) = [(A − low control)/(high control 
− low control)] * 100, where A is the mean LDH activity measured in medium samples from 
three wells per duplicate that were subjected to the test condition, low control is the LDH 
activity released from untreated normal cells, and high control is the maximum LDH activity 
released in all cells (cells treated with 1% Triton X-100 for 24 h).
Western blotting
After treatment, neuronal cultures were homogenized in lysis buffer (150 mM NaCl, 20 mM 
Tris (pH 7.4), 10% glycerol, 1 mM EDTA, 1% NP40, and 1 mg/mL inhibiting cocktail pro-
teases). Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (12% SDS–PAGE) was 
performed using a mini-protein system (Bio-Rad) with low-range molecular-weight stand-
ards (Bio-Rad). Protein (40 μg) was loaded into each lane with a loading buffer containing 
0.375 M Tris (pH 6.8), 50% glycerol, 10% SDS, 0.5 M DTT and 0.002% bromophenol blue. 
Samples were heated at 95°C for 3 min prior to gel loading. After electrophoresis, the pro-
teins were transferred to nitrocellulose membranes (Amersham, Buckinghamshire, UK) us-
ing an electrophoretic transfer system (mini Trans-blot Electrophoretic Transfer Cell) at 250 
mA for 2 h. The membranes were then washed with TTBS (20 mM Tris–HCl, pH 7.5; 500 
mM NaCl; 0.05% Tween-20 containing TRIS-buffered saline solution, pH 7.4) and 5% nonfat 
dry milk and incubated overnight at 4 °C with the following primary antibodies: anti-rabbit 
cPLA2 and p-cPLA2 (ser505) (1:1000; Cell Signaling, Danvers, MA, USA), anti-rabbit BACE1 
(1:500; Merck, Millipore, Darmstadt, Germany), anti-rabbit Cox2 (1:1000; Merck, Millipore, 
Darmstadt, Germany), anti-mouse AT8 (1:1000; Thermo Fisher, CA, USA), anti-mouse TAU5 
(1:1000; Thermo Fisher, CA, USA); anti-mouse SCD1 (1:500; Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), anti-rabbit iNOS2 (1:250; Abcam Cambridge, UK), anti-goat FADS6 (1:250; 
Santa Cruz Biotechnology, Santa Cruz, CA, USA). Anti-βIII tubulin (1:5000; Promega) and 
anti-mouse actin (1:1000; Sigma-Aldrich) were used as loading controls. IRDye 800CW goat 
anti-mouse or IRDye 680 goat anti-rabbit 1:15000 (Li-COR), as well as peroxidase-conju-
gated anti-mouse IgG and anti-rabbit IgG 1:5000 (Pierce), were used as secondary probes. 
Images of fluorescent blots were analyzed using Odyssey Infrared Imaging System applica-
tion software version 3.0 (Li-COR). The results from each membrane were normalized to 
control values. Samples from all experimental groups were processed in parallel to minimize 
inter-assay variation.
SCD1 and FADS6 activation assays
To increase the expression of the SCD1 (mouse activation plasmid; Santa Cruz Biotechnolo-
gy, Santa Cruz, CA, USA); and FADS6 (mouse activation plasmid; Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) genes in the neuronal primary cultures, we used the CRISPR activation 
plasmid (m) as a system for SCD1 and FADS6 transcription activation as a synergistic activa-
tion mediator (SAM). We used the scrambled gRNA CRISPR activation plasmid as a negative 
control for experiments using a target-specific CRISPR activation plasmid; it encodes nontar-
geting scrambled gRNA that does not recognize any DNA sequence. This SAM complex will 
not bind DNA or activate the transcription of any specific gene. In a 24-well tissue culture 
plate, we seeded 2 × 104 cells in 0.5 ml of antibiotic-free standard growth medium per well 
24 h prior to transfection (DIV 17). For each transfection, we diluted 1 µg of plasmid DNA 
into plasmid transfection medium to bring the final volume to 100 µl. The cells transfected 
with the CRISPR activation plasmid were assayed 48 h after transfection. Overexpression 
was measured using an immunofluorescence cell assay.
Statistical analyses
The n values used for the in vitro experiments were 3–5. The parametric data were com-
pared using multivariable 2-way ANOVA followed by Tukey’s post hoc test for compari-
sons between several independent groups. The nonparametric data were analyzed using 
Kruskal–Wallis and Dunn’s multiple comparison tests. The comparisons between 2 groups 
were performed using Student’s t-test for parametric data or the Mann–Whitney test for 
nonparametric data. All sample groups were processed in parallel to reduce inter-assay vari-
ation. The data are expressed as the means +/- SEM. PRISM (La Jolla, CA, USA) software was 
used. The results were considered significant when p < 0.05 (* or #), p < 0.01 (** or ##), or 
p < 0.001 (*** or ###). The symbols * or # directly above the bars represent comparisons 
between each treatment and the control.




BACE1 silencing provides neuroprotection and reduces tau hyperphosphorylation induced 
by glutamate excitotoxicity in cortical primary cultures  
To confirm our model based on BACE1 silencing, we validated the effect of shBACE1miR 
on AAV2/5 transduced in cortical primary neurons for 12 days and observed a significant 
decrease in BACE1 protein levels with and without excitotoxicity by glutamate (p<0.01 and 
p<0.001, respectively) (Fig. 1A). These observations were supported by our previous stud-
ies, which demonstrated that BACE1 RNAi (BACE1-KD) reduces BACE1 protein levels in both 
primary neuronal cultures and the injected brain region of an Alzheimer´s mice model by 
approximately 50% (D Piedrahita, Castro-Alvarez, Boudreau, Villegas-Lanau, Kosik, Galle-
go-Gomez, and Cardona-Gomez 2015; Villamil-Ortiz et al. 2016). Glutamate (125 µM) in-
creased hyperphosphorylated tau (AT8) levels in the shSCRmiR (control) group (p<0.0001) 
(Fig. 1B). This increase was significantly reversed by shBACE1miR treatment (p<0.001), 
though it was still increased compared to shBACE1miR without glutamate (p<0.05) (Fig. 1B). 
These observations were supported by the altered morphology of the neurons (Fig. 1C), 
including greater percentages of condensed nuclei (p<0.0001) (Fig. 1D) and increased LDH 
release (p<0.05) (Fig. 1E) seen in glutamate-treated neurons. These effects were prevented 
by BACE1-KD treatment (p<0.001 and p<0.0001, respectively) (Fig. 1C-E). These data con-
firm that BACE1 silencing protects neuronal cells and reduces tau hyperphosphorylation in 
a glutamate-induced excitotoxicity model. 
BACE1-KD decreases glutamate-upregulated cPLA2, and cosilencing with shcPLA2 accen-
tuates the reduction in hyperphosphorylated tau and COX2 levels
Previous findings indicate that cPLA2 is involved in different forms of neurodegeneration 
(Villamil-Ortiz et al. 2016). cPLA2 is increased in AD brains and is associated with Aβ de-
posits and pro-inflammatory pathways, specifically, the production of arachidonic acid (AA) 
and the activation of the COX2 enzyme (Villamil-Ortiz et al. 2016). We observed that cPLA2 
protein levels increased in a glutamate-mediated excitotoxic environment (p<0.001) (Fig. 
2A) together with AT8 (p<0.05) (Fig. 2B) and COX2 (p<0.05) (Fig. 2C) levels. cPLA2 and AT8 
upregulation was prevented by the silencing of BACE1 (p<0.05) but not COX2 (Fig. 2A, B, 
C). Under exposure to shcPLA2, the silencing of cPLA2 in all groups was confirmed (p<0.01 
or p<0.001 respectively), including a significant reduction in cPLA2 under glutamate tox-
icity conditions (p<0.01) (Fig. 2A). In addition, AT8 (p<0.01) and COX2 (p<0.001) protein 
levels were decreased, indicating that cPLA2 silencing per se provided neuroprotection (Fig. 
2A, B, C). Interestingly, the co-silencing of cPLA2 accentuated the reduction in AT8 (Fig. 2B) 
achieved by BACE1-KD (p<0.05), and it had a weak tendency to reduce COX2 levels (Fig. 2C). 
Figure 1. BACE1-KD decreases tau hyperphosphorylation and protects against glutamate-mediated excitotoxicity. 
Primary cortex neurons were transduced with SCR or BACE1 shRNA-miR and treated with 125 µM glutamate for 
20 min. The proteins were collected after 24 h. In (A) and (B), the BACE1 and AT8 protein levels were detected by 
Western blotting. Actin and tau5 were used as the loading control. Relative Units = RU, n = 4. * represents com-
parisons for BACE, AT8, % LDH and % condensed nuclei, respectively. (C) Morphological characteristics indicate 
adeno-associated virus (AAV) vector viral eGFP-tagged SCR and shBACE1-miR (green) and AT8 (red). (D) Percentage 
of condensed nuclei to total nuclei in Hoechst-positive cells. (E) Neuronal cytotoxicity was presented as the per-
centage of lactate dehydrogenase (LDH) release at 24 h after glutamate application (n = 5), and each experiment 
was performed in duplicate. All values were normalized to the control neurons. ANOVA with Tukey’s test was used 
for comparisons. Scale bar= 20 µm, * Comparison between each treatment at 24 h. *p < 0.05, ** p < 0.01; *** p < 
0.001; **** p < 0.001. 
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In contrast, INOS protein levels were reduced by shBACE1miR or shcPLA2 alone under expo-
sure to glutamate (p<0.05) but not under the co-silencing condition (Fig. 2D). Those findings 
were supported by the reduction in LDH release by shBACE1miR or cPLA2 in the excitotoxic 
environment without a synergic effect of the co-silencing of BACE1 and cPLA2 on cell death 
(Fig. 2E). Taken together, these data suggest a direct action of shBACEmiR in decreasing the 
hyperphosphorylation of tau by its effect on the reduction in cPLA2 in an excitotoxic context 
via a pathway other than direct control of COX2 or INOS pro-inflammatory signaling.
BACE1 silencing needs SCD1 to reduce hyperphosphorylated tau under glutamate-medi-
ated excitotoxicity 
The amount of saturated fatty acids is regulated by desaturase enzymes such as SCD1, which 
catalyze the synthesis of monounsaturated fatty acids, and the indices of fatty acyl-CoA de-
saturase activity have been associated with cognitive dysfunction in Alzheimer’s disease 
(Fonteh et al. 2016). In this study, we confirm the upregulation of SCD1 protein levels in a 
glutamate-mediated excitotoxicity context (p<0.01- p<0.05) (Fig. 3A), which we previous-
ly observed in aged 3xTg-AD mice (Villamil-Ortiz et al. 2016). SCD1 silencing reversed the 
change in SCD1 protein expression (p<0.01- p<0.05) (Fig. 3A). Interestingly, SCD1 targeting 
did not reduce the AT8 and COX2 protein levels that were upregulated under glutamate ex-
citotoxicity (Fig. 3B, C) and even increased COX2 in the basal condition (p<0.01) (Fig. 3C). The 
silencing of SCD1 avoided the reduction in tau hyperphosphorylation usually resulting from 
BACE1-KD treatment, and the co-silencing of BACE1 and SCD1 had the clear tendency to 
increase or prevent the reduction in COX2 in all experimental groups (Fig. 3C). INOS was not 
statistically affected by any treatment (Fig. 3D); however, a clear tendency to be increased 
by glutamate, reversed by BACE1-KD, and slightly increased in all treatments was observed 
with silencing and co-silencing by SCD1-KD (Fig. 3D). Together, these data could mean that 
SCD1 is overregulated by glutamate, although its silencing produced a generalized pro-in-
flammatory cell environment, and that it affects the neuroprotection exerted by the silenc-
ing of BACE1, particularly in the reduction in hyperphosphorylated tau.
Overexpression of SCD1 reinforces the shBACE1miR-induced neuroprotection
To validate the role of SCD1 in neuroprotection, combined with BACE1 silencing, we cotreat-
ed the neuronal cultures with shBACE1miR, to knock down BACE1-mRNA (DIV 7), and with 
an activation plasmid (CRISP/Cas9), to induce SCD1 overexpression (DIV 17). Treatments 
were either in the presence or absence of glutamate, which could simulate stress. Treat-
ment groups were compared with their respective control, which were transduced with 
shSCRmiR and/or transfected with the SCD1 empty plasmid coupled to GFP. The control 
neurons exhibited typical hallmarks of glutamate excitotoxicity, including a severe loss of 
neuronal processes (Fig. 4A), an increased percentage of condensed nuclei (p<0.05) (Fig. 
Figure 2. cPLA2 silencing improved the BACE1-KD-induced reduction in tau hyperphosphorylation in a gluta-
mate-mediated excitotoxicity model. Primary cortical neurons were doubly transduced with SCR, BACE1 shR-
NA-miR and cPLA2 shRNA and were treated with 125 µM glutamate for 20 min. After 24 h, (A) cPLA2, (B) AT8, (C) 
COX2 and (D) INOS protein levels were detected by Western blotting. Actin was used as the loading control. (E) 
% LDH release. Relative Units = RU, n = 4, and each experiment was performed in duplicate. All values were nor-
malized to the control neurons. ANOVA with Tukey’s test was used for comparisons. * Comparison between each 
treatment in the same group. # Comparison between shScrmiR and shcPLA2miR groups. *, # p < 0.05; **, ## p < 
0.01; ***, ## p < 0.001.
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4C) and increased LDH release (p<0.05) (Fig. 4D). The overexpression of the SCD1 CRISPR 
plasmid was confirmed by the increased immunoreactivity (IR) of SCD1 with or without 
glutamate treatment (Fig. 4A), although the overexpression did not allow for recovery from 
the stressed cell environment per se (Fig. 4A, C, D). However, the fluorescence data confirm 
that the morphology of the neurons treated with glutamate was recovered by the silencing 
of BACE1 with or without overexpression of SCD1 (Fig. 4A), as shown by decreased nuclear 
condensation and LDH release under glutamate exposure (p<0.05) (Fig. 4C, D). SCD1 over-
expression reinforced the protected morphology of neurons (Fig. 4A) and the reduction in 
cell death achieved by the silencing of BACE1 (p<0.01) (Fig. 4C, D). 
In contrast, the targeting of SCD1 affected the reduction in hyperphosphorylated tau by the 
neuroprotective action of BACE1-KD (Fig. 3B). We then measured the fluorescence pattern 
of AT8 in the SCD1 overexpression condition and found that AT8 fluorescence increased 
in all the groups transfected with the SCD1 CRISPR plasmid compared to the transfected 
empty plasmid groups (Fig. 4B). However, the AT8 fluorescence was mainly distributed in 
thin neuronal projections. When BACE1 was silenced with the overexpression of SCD1 CRISP 
plasmid under a glutamate-mediated excitotoxicity context, an even healthier outcome was 
observed than the effect achieved by BACE1-KD alone. Inversely, an aggregation of AT8-
IR was observed in the cytoplasm of neurons exposed to glutamate with or without SCD1 
overexpression. These findings suggest that SCD1 is needed in the protection mechanism 
exerted by the targeting of BACE1 in a neuroexcitotoxic condition.
BACE1-KD requires a fine balance of FADS6 to generate neuroprotection in a gluta-
mate-mediated excitotoxicity model.
It was recently suggested that desaturases are pro-survival enzymes in neurons since they 
are essential in producing fatty acids with six unsaturations called PUFAS (polyunsaturated 
fatty acids), which are involved in the anti-inflammatory process in neurons (Calder 2012; 
Janssen and Kiliaan 2014). However, other PUFAS with pro-inflammatory properties exist, 
such as arachidonic acid (AA), indicating a need for finely tuned levels of PUFAS (Zárate et al. 
2017a). Next, we analyzed the role of FADS6 in the BACE1-KD-induced neuroprotection. We 
confirmed the silencing of FADS6 in all experimental groups, and we did not find increased 
FADS6 protein levels under the glutamate condition (Fig. 5A). Nevertheless, we found that 
the co-silencing of BACE1 and FADS6 with or without glutamate generated increased protein 
levels of AT-8 (Fig. 5B), which correlated with a clear downward trend or significant reduc-
tion in COX2 (Fig. 5C) and INOS (Fig. 5D) under the same conditions, showing apparently 
opposite results.
Figure 3. SCD1 silencing increased AT8 and COX2 levels after BACE1 silencing in glutamate-mediated excitotoxicity. 
Primary cortex neurons were doubly transduced with SCR, BACE1 shRNA-miR and cPLA2 shRNA and treated with 
125 µM glutamate for 20 min. After 24 h, (A) SCD1, (B) tAT8, (C) COX2 and (D) INOS protein levels were detected by 
Western blotting. Actin and β-III tubulin were used as loading controls. Relative Units = RU, n= 4, and each experi-
ment was performed in duplicate. All values were normalized to the control neurons. ANOVA with Tukey’s test was 
used for comparisons. * Comparison between each treatment in the same group. # Comparison between shScrmiR 
and shcPLA2miR groups. *, # p < 0.05; **, ## p < 0.01; ***, ## p < 0.001.
However, when we analyzed the state of neuronal cultures after the overexpression of 
FADS6 (Fig. 6), we found altered neuronal morphology mainly consisting of a decrease in the 
neuritic processes (Fig. 6A); furthermore, we found that AT8 aggregated in the cytoplasm 
(Fig. 6B), in addition to a major percentage of condensed nuclei (Fig. 6C). These effects were 
reversed by BACE1 silencing (Fig. 6A, B, C). Taken together, these findings suggest that the 
neuroprotective action induced by BACE1-KD requires FADS6 expression; however, the re-
duction in or overregulation of FADS6 alone altered the healthy cells, indicating a need for 
finely balanced expression in homeostasis.
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Figure 4. Overexpression of SCD1 induces neuroprotection together with BACE1 silencing. The morphological char-
acteristics are shown for the cortical neurons transduced with GFP-tagged shBACE1miR and shscrmiR (green). The 
primary cultures were also transfected with an activation plasmid (CRISP/Cas9) for SCD1 overexpression. Nuclei 
were stained with Hoechst (blue), and SCD1 and AT8 were labeled with Alexa 594 dye (red). (A) SCD1 empty plas-
mid group, (B) SCD1 CRISP plasmid. Magnification was 40X. Scale bar is 20 µm (n = 5) (C) Percentage of condensed 
nuclei relative to the total nuclei of transfected neurons. Data are presented as the mean+/-SEM (n = 3), and each 
experiment was performed in duplicate. (D) Percentage of lactate dehydrogenase (LDH) release. All values were 
normalized to the control neurons. ANOVA with Tukey’s test was used for comparisons. Scale bar= 20 µm, * repre-
sents comparisons between each treatment in the same group. # Comparison between SCD1 empty plasmid and 
SCD1 CRISPR plasmid groups. *, # p < 0.05; **, ## p < 0.01; ***, ## p < 0.001. 
Figure 5. FADS6 silencing increased AT8 and COX2 levels after BACE1 silencing in glutamate-mediated excitotoxicity. 
Primary cortex neurons were doubly transduced with SCR, BACE1 shRNA-miR and FADS6 shRNA and treated with 
125 µM glutamate for 20 min. After 24 h, the proteins were collected. In (A) the SCD1, (B) the AT8, (C) COX2 and 
(D) the INOS protein levels were detected by Western blotting. Actin and β-III tubulin were used as the loading 
controls. Relative Units = RU, n= 4 and each experiment was performed in duplicate. All values were normalized to 
the control neurons. ANOVA with Tukey’s test was used for comparisons. * Comparison between each treatment in 
the same group. * p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 6. Over-expression of FADS6 induces neuroprotection in combination with shBACE1miR treatment. The 
morphological characteristics are shown for the cortical neurons transduced with GFP-tagged shBACE1miR and 
shSCRmiR (green). The primary cultures were also transfected with an activation plasmid (CRISP/Cas9) for FADS6 
overexpression. Nuclei were stained with Hoechst (blue), FADS6 and AT8 were labeled with Alexa 594 dye (red). 
(A) FADS6 empty plasmid group and (B) FADS6 CRISP. Magnification is 40X. The scale bar is 20 µm (n = 5). (C) 
Percentage of condensed nuclei relative to the total nuclei of transfected neurons. (D) Percentage of lactate dehy-
drogenase (LDH) release. Data are presented as the mean+/-SEM (n= 3), and each experiment was performed in 
duplicate. All values were normalized to the control neurons. ANOVA with Tukey’s test was used for comparisons. 
Scale bar= 20 µm, * represents comparisons between each treatment in the same group. # Comparison between 
SCD1 empty plasmid and SCD1 CRISPR plasmid groups. *, # p < 0.05; **, ## p < 0.01.
Discussion 
Our study suggests for the first time a more direct action of BACE1 on the phosphorylation 
state of tau that is mediated through cPLA2 and desaturase modulation during glutamate 
excitotoxicity. 
Despite the large body of evidence supporting the amyloid hypothesis of AD pathogenesis, 
efforts to develop agents that safely and unambiguously reduce CNS concentrations of Aβ 
in mice and humans have not been successful to date (Kennedy et al. 2016). Perhaps it is 
necessary to further understand the etiopathogenesis by BACE1 dysregulation and its role 
in the impairment of the neurovascular unit, inflammation and vascular dementia (Meakin 
et al. 2018; Botteri et al. 2018). Inhibition of this enzyme has been viewed as an Aβ-lowering 
therapeutic intervention, but several problems have prevented BACE1 inhibitors from 
advancing to pivotal clinical trials, especially because BACE1 has multiple functional subunits 
(Barao et al. 2016). However, we and others have found that BACE1 targeting improves long-
term spatial memory and prevents Aβ plaques and tau aggregation (Yu et al. 2014; Sierant 
et al. 2009; Villamil-Ortiz et al. 2016), with a reduction of 50% compared to the upregulated 
condition in neurodegeneration (Barao et al. 2016).
BACE1 activity is exacerbated under a saturated lipid environment caused by metabolic 
disorders (Hattori et al. 2006; Marwarha et al. 2017). Additionally, BACE1 is associated with 
neuroinflammation disorders (Stertz et al. 2018), and systemic inflammation may trigger 
neuronal dysfunction associated with dementia, including neuronal impairment, insulin 
signaling, synapse degradation, and memory disturbances associated with the release of 
cyclooxygenase 2 (COX-2) and INOS (Karran, Mercken, and De Strooper 2011; Qin et al. 
2003; Shi et al. 2016). High cPLA2 activity, as well as high expression of APP protein, was 
observed in primary rat cortical neuron cultures exposed to Aβ and in the cerebral cortex of 
mice infused with human cerebral β1-42 amyloid. The prevention of the regulation of cPLA2 
and its activity prevented the increase in APP protein levels and the high production of COX-
2 (Sagy-Bross et al. 2015), emphasizing a close relationship between cPLA2 and COX-2 since 
the arachidonic pro-inflammatory fatty acid is released by cPLA2, which is metabolized by 
COX-2, and since COX-2 levels also decrease without cPLA2 activity (Leslie 2015). 
Reviewing related pathological actors, cPLA2 has been widely involved in inflammatory 
responses, and it has been associated with tauopathy in AD since reduced activity of 
phospholipase A2 (PLA2), specifically of cPLA2 and calcium-independent intracellular PLA2 
(iPLA2), has been positively correlated with a reduction in neurofibrillary tangle density 
in the cerebral cortex and hippocampus (Sundaram et al. 2012; Schaeffer et al. 2011). 
Additionally, the isoform of PLA2-IVA is Ca2+ dependent, is highly expressed in the brain and is 
hyperactivated in AD (Sanchez-Mejia and Mucke 2010). Genetic ablation of cPLA2 improved 
cognition, viability and behavior in the context of the J20 APP transgenic model, despite 
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the elevated Aβ burden (Sanchez-Mejia and Mucke 2010). This finding is in agreement 
with our current study where BACE1 silencing provided neuroprotection and reduced 
glutamate-induced tau hyperphosphorylation through a reduction in cPLA2 protein levels. 
These effects were greater than the downstream control of COX2 or INOS pro-inflammatory 
signaling. These findings support our previous observations where BACE1 silencing 
prevented pro-inflammatory signaling through cPLA2/AA/COX2, which was upregulated 
by the accumulation of the saturated fatty acid (18:0) and mono- and polyunsaturated 
FA (18:1, 20:4, 22:6) composition of LPE (lysophosphatidylethanolamine) and ePE (ether 
phosphatydylethanolamine) plasmalogens of PE (phosphatydylethanolamine), which is 
associated with tauopathy and cognitive impairment in old 3xTgAD mice (Villamil-Ortiz et 
al. 2016).
Additionally, we found a reduction in the mono- and polyunsaturated fatty acids 
composition of PE and PC (phosphatidylcholine) (20:4, 22:6) and LPC (16:0/18:1) in human 
brains with sporadic and familial Alzheimer’s dementia compared with that in healthy 
controls, suggesting an alteration in the mono- and polyunsaturation rate associated with 
dementia. The synthesis and release of monounsaturated fatty acids are carried out by 
desaturase enzymes, such as stearoyl-CoA desaturase-1 (SCD-1), which changes with the 
cellular lipid metabolism (Poloni, Blom, and Schwartz 2015). Therefore, oleic acid (18:1) 
promotes neuron migration (Tabernero et al. 2001; Polo-Hernandez et al. 2014), but there 
is also increased expression of SCD1 in Alzheimer’s disease (Astarita et al. 2011; Fraser, 
Tayler, and Love 2010). Alternatively, our current study suggests the necessity of SCD1 for 
the neuroprotective action of BACE1-KD, but in a fine balance, as its upregulation under 
the excitotoxic condition was associated with tauopathy, LDH release and condensed 
nuclei. However, the reduction in SCD1 was also associated with high levels of COX2. Basal 
levels of SCD1 were necessary for the BACE1-KD action on the hyperphosphorylation of 
tau, although SCD1 overexpression did not protect neurons per se, suggesting the need for 
balanced production of monounsaturated fatty acids with respect to polyunsaturated fatty 
acids (18:1/20:4, 22:6) for healthy functioning of the brain (Bazinet and Laye 2014; Lei, Vacy, 
and Boon 2016), which could be regulated by sensible and homeostatic levels of BACE1.
PUFAs (polyunsaturated fatty acids) are synthesized by FADS6. The enzyme activity is 
regulated by the levels of PUFAs inside the cells, mainly DHA (docosahexaenoic acid, 22:6), 
(Hofacer et al. 2011), which has been linked to neuroprotective properties and which 
represents a potential treatment for a variety of neurodegenerative and neurological 
disorders, such as Alzheimer´s disease (J. J. Liu et al. 2015). Consequently, we showed that 
the silencing of FADS6 increased the hyperphosphorylated tau levels, although shBACE1miR 
was present and therefore prevented the protective effect of BACE1 silencing in neuronal 
primary cultures under excitotoxicity, These results could be supported by previous reports 
about β-amyloid oligomers significantly increasing active c-Jun N-terminal kinase (JNK) and 
phosphorylation tau in cultured hippocampal neurons, whereas DHA inhibited JNK and the 
tau phosphorylation (serine-422) in cultured hippocampal neurons (Q. L. Ma et al. 2009). 
Additionally, endogenous production of DHA reduced the level of phosphorylated tau, which 
has implications in AD pathogenesis and provides additional mechanistic arguments toward 
a beneficial effect of n-3 PUFA in AD (Oster and Pillot 2010). In addition, DHA treatment of 
cortical neuronal cultures resulted in enhanced axonal outgrowth (Mita et al. 2016). The 
beneficial effects of dietary DHA and n-3 PUFA have been described as decreasing the level 
of phosphorylated tau (Arsenault et al. 2011; Green et al. 2007), which supports the idea 
that FADS6 expression is necessary for the neuronal survival and neuroprotection induced 
by BACE1 silencing.
Furthermore, we have previously shown that AA and DHA are unbalanced in the 3xTg-
AD Alzheimer mouse model, while BACE1 silencing recovered the balance between both 
fatty acids after 6 and 12 months of treatment, suggesting that the inflammatory pathway 
involving COX2 and INOS proteins could be regulated by BACE1 targeting (Villamil-Ortiz et 
al. 2016). Indeed, the ratio of AA to DHA may affect cellular homeostasis associated with 
neurodegenerative diseases (Farooqui, Horrocks, and Farooqui 2007; A Zarrouk et al. 2017). 
However, the BACE1 and FADS6 double silencing decreased the levels of COX2 protein mainly 
under an excitotoxic stimulus, suggesting that BACE1 could influence the COX2 molecular 
pathway and induce an inflammatory response in neurons. In fact, epidemiological evidence 
has demonstrated that long-term treatment with nonsteroidal anti-inflammatory drugs 
reduces the risk of AD by inhibiting the expression of COX-2 (Lim et al. 2000). Although 
the levels of COX-2 and its metabolic product, prostaglandin, are elevated in the brain of 
AD patients, the mechanisms for the development of AD remain unknown. However, some 
evidence suggests that COX-2 could have reciprocal regulation with IL-1β and Aβ between 
glial and neuronal cells, particularly in the signaling pathways for IL-1β and BACE-1 synthesis 
(P. Wang et al. 2014). It is also supporting the idea that shBACE1miR treatment not only 
suppresses the expression of BACE1 but also suggests that it inhibits the formation of 
hyperphosphorylated tau through downregulation of the pro-inflammatory pathway. 
Few previous studies point toward the relevance of BACE1 in inflammation and as an 
immunoregulator (C. H. Chen et al. 2012). BACE1 expression is upregulated by pro-
inflammatory stimuli, whereas BACE1-KD induced neuroprotection in neuron primary 
cells. Additionally, desaturase, COX2 and BACE1 signaling expression was increased in 
response to excitotoxic stimuli, and there is evidence that those molecules are relevant in 
immunoregulation and inflammation processes (Park et al. 2016; C. H. Chen et al. 2012; 
P. Wang et al. 2014). However, crosstalk between these three pathways had not been 
previously demonstrated.
In conclusion, our data suggest that the silencing of BACE1 controls cPLA2 and is 
desaturase dependent in offsetting the hyperphosphorylation of tau and cell death in 
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an excitotoxic context. Therefore, the potential therapeutic effects of BACE1 silencing 
on neurodegenerative pathologies may involve multiple mechanisms, such as fatty acid 
metabolism regulation, which suggests that an approach with BACE1 knockdown combined 
with fatty acid regulation may represent a potential strategy for cell therapy. Importantly, 
our study does not provide a complete mechanism by which BACE1 reduction leads to a 
decrease in tau hyperphosphorylation. Therefore, our results can only explain part of the 
molecular pathways altered in this model, and further studies are needed regarding the 
mechanism necessary to reestablish cellular homeostasis.
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CHAPTER 5
Dimethyl Sulfoxide reduces LPS-induced 
inflammatory gene expression in primary 
microglia and BV-2 cells
Javier G Villamil1,2, Emma Gerrits1, Bart J.L Eggen1




Dimethyl sulfoxide (DMSO) is a widely solvent for a range of both polar and nonpolar com-
pounds and can cross cell membranes. In addition, DMSO has been studied in pharmaco-
logical studies as an anti-inflammatory compound. Based on these anti-inflammatory prop-
erties of DMSO, the objective of this study was to evaluate the effects of DMSO (0.1-10% 
v/v) on the viability and the LPS-induced inflammatory response of microglia, the innate 
immune cells of central nervous system. Effects on cell viability, proinflammatory mRNA 
and protein production were assessed in primary mouse microglia and BV-2 cells. Here we 
report that DMSO at high concentrations (10% v/v) reduced the viability of both primary 
microglia and BV-2 cells. As expected, LPS (100ng/mL) induced an inflammatory response 
through increased production of mRNA levels of IL-1Β, IL6 and COX2 in both cell cultures. 
Treatment with DMSO significantly reduced the LPS-induced production of IL-1β, IL6, nu-
clear factor kappa B1 (NF-κB1), cyclooxygenase (COX2) and induced nitric oxide synthase 
(iNOS) in BV-2 cells in a dose-dependent manner. In primary microglia, this effect was also 
observed although less pronounced. In addition, at low concentrations (0.2 to 1% v/v), 
DMSO reduced IL-1β and IL-6 protein levels. Taken together, at low concentrations, DMSO 
reduced the LPS-induced inflammatory response of primary microglia and BV-2 cells.
Introduction
Dimethyl sulfoxide (DMSO), a highly polar organic solvent, is an amphiphilic molecule with 
one hydrophilic sulfoxide group and two hydrophobic methyl groups (Brayton 1986). This 
dipolar nature facilitates its ability to interact with biological membranes since DMSO is 
able to solubilize polar and nonpolar substances and cross hydrophobic barriers such as 
cell membranes (Fernández and Reigada 2014). Due to these properties, DMSO serves as 
a cryoprotectant and vehicle for intracellular pharmacotherapies (Yoganantharajah et al. 
2018). Consequently, a wide number of studies have reported on other biological activities 
of DMSO, addressing the potential use of DMSO in a variety of medical conditions such as 
arthritis, scleroderma, musculoskeletal disorders, cancer and CNS disorders (Brayton 1986; 
Jacob and de la Torre 2009).DMSO is considered a low cytotoxicity molecule at low con-
centrations (Brayton 1986; Gad and Sullivan 2014), and it can be used up to 10% v/v in cell 
cultures without changing culture viability, however high DMSO concentrations can change 
cellular activity are and are cytotoxic for glial cells (Kloverpris et al. 2010). In vitro experi-
ments on rat liver cells treated with DMSO (25% v/v) showed increased activity of lysosomal 
enzymes(Sumida et al. 2011), while DMSO (40% v/v) increased the expression of selectins 
and the phosphorylation of proteins involved in intracellular activation pathways(de Abreu 
Costa et al. 2017). DMSO can reduce the inflammatory response of C-28/12 human chon-
drocytes (Kloesch et al. 2011) as well as Caco-2 cells treated with proinflammatory stimuli, 
resulting in reduced cytokine levels (Hollebeeck et al. 2011a). DMSO can also affect cell via-
bility, mouse macrophages treated with 2% DMSO displayed increased apoptotic cell death 
(Hollebeeck et al. 2011b). 
Different studies addressed the influence of DMSO on the expression of proteins in cells to 
understand their role on different biological pathways. Interestingly, the anti-inflammatory 
effect of DMSO is the most consistent among several studies, and low concentrations of 
DMSO (0.5 to 2% v/v) can reduce the proinflammatory cytokines/chemokines and prosta-
glandin E2 expression during stress challenging conditions in human. The same effect was 
shown in an arthritis C57BL/6 mouse model, where topical exposure to DMSO reduced the 
expression of pro-inflammatory cytokines (Elisia et al. 2016). Despite these studies, little 
is known about the effect of DMSO on microglia, the tissue resident macrophages of the 
central nervous system. Microglia form the primary immune defense in the CNS and con-
tinuously surveil the brain parenchyma (Salter and Beggs 2014) Microglia are increasing-
ly implicated in neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease 
(Perry and Holmes 2014; Salter and Beggs 2014). Microglia activation is observed in neuro-
degenerative disorders, with increased activity of intracellular enzymes as Cox2, iNOS, and 
transcription factors like NF-κB. Although the anti-inflammatory effect of DMSO has been 
demonstrated in peripheral immune cells, little information is available concerning the ef-
fects of DMSO primary microglia and BV-2 cells which was investigated in this study. 





C57BL/6J mouse pups were obtained from the animal facility (Centrale Dienst Proefdieren, 
CDP) of the University Medical Center Groningen. All animal work was approved by the An-
imal Ethics Committee of University of Groningen, and adhered to the European Directive 
(2010/63/EU) on the protection of animals used for scientific purposes.
Microglia were derived from primary mixed glia cell cultures originating from 1- or 2-day 
old mice-pup brains. After isolation, the brains were kept in cold medium A (HBSS with 0.6% 
glucose [D-(+)-glucose solution, Sigma, G8769], 15 mM HEPES buffer (Lonza BE17-737E), 1% 
penicillin/streptomycin). The meninges, cerebellum and olfactory bulb were removed and 
the remaining brain was minced into small pieces and suspended in medium A. Trypsin me-
dium (0.25% trypsin; 0.1 mg/mL DNase I in medium A) was used to get a single-cell solution. 
This reaction was stopped with trypsin inhibition medium (20% fetal bovine serum (FBS); 0.1 
mg/mL DNase I; 0.1 mg/mL trypsin inhibitor in medium A) and the cells were rinsed with 
wash medium (10% FBS; 0.1 mg/mL DNase I in medium A). The cell suspension was carefully 
titrated with glass pipettes of decreasing diameter and centrifuged in order to get a pellet of 
cells. The homogenized cells were supplied with microglia medium (10% FBS; 1 mM sodium 
pyruvate; 100 U/mL penicillin; 100 mg/mL streptomycin in DMEM) and were seeded at a 
density of 1.5 brains per T75cm2 flask, which were kept in the incubator 37°C and 5% CO2. 
When there was a confluent layer of astrocytes present in the flasks, the cultures were en-
riched with L929 fibroblast-conditioned medium to increase microglial proliferation. Conse-
quently, primary microglia were de-attached from the culture by one or two shake-offs. The 
primary microglia were seeded in well plates for experiments. The cultures were regularly 
checked under the microscope and enriched with fresh microglia medium if necessary, to 
remove debris and supply the cells with new nutrients.
BV-2 cells were cultured in Dubelcco’s Modified Eagle Medium (DMEM) (Lonza BE12;604F) 
supplemented with 10 % FBS (GIBCO, Cat# 10500064); 100 U/mL penicillin; 100 mg/mL 
streptomycin at 37°C and 5% CO2. DMSO was obtained from Merck Millipore, to Avoid 
batch variations in experiments of different LPS lot numbers, one batch of lipopolysacharide 
(LPS) was used in all experiments (E. coli 0111:B4, Sigma-Aldrich, cat# L4391).
Cell viability assays
Mitochondrial activity was determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay (Riss et al. 2004). Primary microglia and BV-2 cells 
were plated in 96-well plates (20,000 cells/well), treated with DMSO (0-10% v/v) and/or 
LPS (100ng/mL) for 3 h after which they were incubated with MTT solution (0.5 mg/mL in 
DMEM) for 2 h at 37°C. MTT conversion was determined by absorption at 570 nm.
Lactate dehydrogenase (LDH) release was measured to determine the cytotoxic effects of 
the DMSO and LPS treatments. Supernatant of primary microglia or BV-2 cells was mixed 1:1 
with LDH-assay reagent mix (5% assay buffer). After incubation for 30 min, the absorption 
was measured at 490 nm. As a positive control, cell lysates were used as a reference for 
maximal LDH release.
Quantitative real-time PCR
Primary microglia and BV-2 cells were seeded in 24-well plates (50.000 cells/well). The cells 
were treated with PBS, DMSO (0-1% final concentration) and/or LPS (100ng/mL final con-
centration) for 3 h. Total RNA was isolated from primary microglia and BV-2 cells using TRIzol 
(ambion). 0.3-0.5µg of total RNA was used for cDNA synthesis by reverse transcriptase using 
random hexamers (Fermentas), M-MuLV Reverse Transcriptase and Ribolock RNAse inhibi-
tor (Fermentas) and dNTPs. Quantitative PCR reactions were carried out using 2xiTAQ SYBR 
supermix (BIORAD) and a real-time thermal cycler (ABI7900HT, Applied Biosystems) with 
different set of primers (table 1). For each gene, measurements were performed in triplicate 
in a minimum of three independent experiments. Primers specific for the evaluated genes 
were designed in PRIMER EXPRESS 2.0 and tested for efficiency. The housekeeping genes 
Hmbs or Hprt1 were used as an internal standard to calculate relative gene expression levels 
with the 2−∆∆CT method (Livak and Schmittgen 2001) which is depicted as fold-induction 
of control samples. Data were extracted from QuantStudioTM Real-Time PCR Software v1.3 
(Thermofisher).
ELISA
Microglia supernatants were collected and used is ELISA analyses. IL-6 and IL1β protein lev-
els were determined using the mouse IL-6 ELISA MAX™ Deluxe kit, Biolegend, cat# 431304, 
and mouse IL1β ELISA MAX deluxe kit, Biolegend cat# 432606 according to the manufactur-
er’s instructions. For IL1β Elisa, ATP (1mM) was added during the last 15 min of the last LPS 
treatment to induce secretion.
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Table 1. qPCR primer information






















All data are presented as means ± SEM. Data were analyzed using an unpaired Student’s 
t-test when 2 groups were compared or by one-way ANOVA followed by a Tukey’s multiple 
comparison test post hoc to compare several groups. Asterisks indicate *p ≤ 0.05, **p ≤ 
0.005 or ***p ≤ 0.001, respectively. 
Results
High concentrations of DMSO are cytotoxic for microglia
DMSO can be cytotoxic for cells at concentrations higher than 1% v/v (Yi et al. 2017)(León-
García et al. 2017). However, little is known about the cytotoxic and anti-inflammatory ef-
fects of DMSO on microglia. First, we determined the cytotoxic effects of DMSO on on BV-2 
cells and primary microglia using cell viability assays. The cytotoxic effects were determined 
by MTT and LDH assays to measure mitochondrial activity and cellular integrity, respectively. 
Our results showed that treatment of BV-2 cells for 3 h with DMSO concentrations of 5 and 
10% significantly decreased the conversion of MTT (p ≤ 0.001) compared with cells treated 
with 0, 0.1, and 1% DMSO (Figure 1 A-B). LDH activity was significantly increased in BV-2 cells 
treated with 10% DMSO (p≤ 0.001) but not at DMSO concentrations of 5% and lower (Figure 
1B). Similar results were obtained in primary microglia, where 10% DMSO significantly de-
creased MTT conversion (p≤ 0.001) significant increased LDH activity (p≤ 0.001) (Figure 1C 
and 1D). These data show that at 5% DMSO, mitochondrial activity was compromised (MTT) 
in BV-2 cells and that cellular integrity (LDH release) was affect at concentrations of 10% 
DMSO in both BV-2 cells and primary microglia.
DMSO modulates pro-inflammatory gene expression by microglia cells.
Stimulation with an inflammatory cocktail and treatment with low concentrations of DMSO 
(0.1 to 0.5% v/v) reduced the expression of inflammatory cytokines in peripheral blood 
mononuclear cells (Elisia et al. 2016). However, it is unclear whether DMSO also has anti-in-
flammatory effects on microglia. LPS was used to induce pro-inflammatory gene expression 
in mouse microglia cells (Schaafsma et al. 2015). To determine if DMSO affects LPS-induced 
pro-inflammatory gene expression by microglia, RT-qPCRs were performed. LPS (100ng/
mL) significantly induced proinflammatory gene expression (Il1β, Il6, and Cox2) in BV-2 cells 
compared to PBS-treated cells. In contrast, treatment with DMSO significantly attenuated 
the response of microglia to LPS: Il1β, Il6 and, Cox2 were all significantly less induced (Fig-
ure 2). This reduced LPS responsiveness was observed after 3 hours of LPS stimulation and 
DMSO treatment. The relative expression of the genes Il1β, Cox2 and Il6 decreased after 
3-hour DMSO treatment and stimulation with LPS. Importantly, the LPS-induced gene ex-
pression progressively decreased with increasing DMSO concentrations (Figure 2.A-C). Sim-
Figure 1: DMSO affects mitochondrial activity and microglia integrity. The graphs depict MTT conversion and LDH 
activity of BV-2 cells (A-B) and primary microglia (C-D) treated with different concentrations of DMSO. Mitochon-
drial activity was measured by MTT conversion and cellular integrity by LDH release in the medium. P values were 
calculated by a two-way ANOVA followed by a Tukey post-hoc test (***: p < 0.001). Data is represented in dot-plots 
with mean ±
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ilar, but less pronounced, anti-inflammatory effects of DMSO were observed in primary mi-
croglia cells. The induction of Il1β expression by LPS was not modulated by DMSO, even at 
the high concentrations (1%) (Figure 2.D). However, the LPS-induced expression of Cox2 and 
IL6 were significant decreased when treated with 1% DMSO (p≤0.005) (Figure 2E-F). These 
results show that DMSO has anti-inflammatory activity in BV-2 cells and primary microglia.
Low concentration of DMSO has an anti-inflammatory effect on microglia cells
In order to confirm the anti-inflammatory effect of low DMSO concentrations on BV-2 cells 
and primary microglia, these cells were treated for 3 h with LPS (100 ng/ml) and/or DMSO 
(0.8 %). Gene expression of pro-inflammatory genes Il1β, NF-κb1 (p50), Cox2 and iNos was 
quantified by RT-qPCR assay. LPS increased the expression of all these genes compared with 
the control group. Interestingly, simultaneous treatment of microglia with LPS and DMSO 
significantly reduced the induction of all evaluated genes in both cells type (Figure 3A-H) (p≤ 
0.001) with the exception of iNos in BV-2 cells (Figure 3.D). The attenuation of LPS-induced 
gene expression by DMSO was more also detected in primary microglia (Figure 3 E-H). These 
results correlated with our previous results suggesting that DMSO has an anti-inflammatory 
effect on microglia cells by negatively modulating the LPS-induced expression of pro-inflam-
matory genes.
Figure 2: DMSO reduces LPS-induced pro-inflammatory gene expression in BV-2 cells and primary microglia. Graphs 
depict the fold induction in gene expression of the Il1β, Cox2, and Il6 genes in BV-2 cells (A-C) and primary microglia 
(D-F). The data is depicted as a percentage of the fold induction of the LPS-treated group. Data were analyzed with 
a two-way ANOVA followed by a Tukey post-hoc test (**P < 0.01, ***P < 0.001). Data is represented in dot-plots 
with mean ± SEM.
DMSO suppresses LPS-induced cytokine secretion by microglia
To assess if the effect of DMSO on pro-inflammatory gene expression after inflammatory 
stimulus also translated into decreased cytokine secretion, protein levels in the supernatant 
of BV-2 and primary microglia cells treated with PBS, LPS (100ng/mL) or increasing concen-
trations of DMSO were performed. In both cell types, DMSO decreased the LPS-induced 
secretion of Il-6 and Il1β, which was already observed at the lowest DMSO concentration 
(0.2%) used (Figure 4 A-D). DMSO reduced the abundance of Il-6 and Il1β protein and mRNA 
levels in both microglia cell types.
Discussion
DMSO is frequently used as a solvent and as a compound with anti-inflammatory proper-
ties for the treatment of various inflammation-associated diseases including osteoarthritis, 
rheumatoid arthritis, systemic sclerosis, chronic pancreatitis, ulcerative colitis, and neuro-
logical disorders (Santos et al. 2003). However, little is known about how DMSO acts on 
inflammation in the central nervous system, and most notably what its effect is on the prin-
cipal CNS immune cells, microglia. This study was aimed to assess the anti-inflammatory ef-
fect of DMSO on microglia, the resident tissue macrophages of the CNS (Colucci et al. 2008). 
Using an in vitro approach, we show that DMSO has an anti-inflammatory effect on micro-
glia. Primary microglia cultures and BV-2 cells were immune activated with LPS and treated 
with a different concentration of DMSO (0.2-10% v/v). This concentration range was tested 
as these were used in studies to solubilize and deliver bioactive compounds to cells (Colucci 
et al. 2008) . According to our results obtained in microglia cultures, DMSO did not induce 
any cytotoxicity up to 5% v/v. At higher concentrations however, decreased cell integrity 
(LDH release) and reduced mitochondrial activity (MTT conversion) were observed after 3 
hours incubation. Similar observations were reported for astrocytes, where DMSO concen-
trations of ≥5% v/v reduced mitochondrial activity, cell viability and promoted apoptosis. 
Starting from 1% v/v, DMSO progressively reduced MTT conversion and caused mitochon-
drial swelling in cultured astrocytes (C. Yuan et al. 2014). DMSO concentrations ≥1% v/v in-
duced a progressive loss of viability and NeuN expression in cultured neurons, already after 
12h exposure (C. Zhang et al. 2017). Finally, recently a study showed that DMSO starting at 
1% v/v induces cytotoxicity in monocytes (Elisia et al. 2016). DMSO-induced cytotoxicity was 
resulted in decreased cell membrane thickness and the formation of transient water pores 
at concentrations ranging from 2.5-7.5% and 10-20%, respectively (Gurtovenko and Anwar 
2007). In summary, these data indicate that DMSO, has cytotoxic effects on all CNS cells like 
astrocytes, neurons and microglia as well as other myeloid cells, monocytes. 
The address the potential anti-inflammatory effects of DMSO, we performed RT-qPCR for 
5 proinflammatory genes (Il1β, Il-6, NF-κB, Cox2, and iNOS) on LPS-treated microglia. LPS 
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enhanced the mRNA expression of these genes, and DMSO treatment attenuated this induc-
tion in primary microglia and BV-2 cells. DMSO already displayed anti-inflammatory proper-
ties at concentrations as low as 0.2% up to 1%. Importantly, not cytotoxic effects of DMNSO 
were observed at these concentrations. IL-6 and Il1β are both pro-inflammatory cytokines 
with important roles in the CNS inflammation response and are released by microglia (Krase-
mann et al. 2017). Several studies have indicated that DMSO is able to reduce the expression 
of pro-inflammatory cytokines via inhibition of transcription factors such as NF-κB. LPS inter-
acts with membrane receptors such as toll-like receptor 4 (TLR4) and induces the activation 
of NF-κB, leading to the production of reactive oxygen species (ROS) and inflammatory gene 
expression (Ahn et al. 2014). This process is reversed by DMSO via ROS scavenging and NF-
κB inhibition, since, the results showed that DMSO reduced the expression of NF- κB, Il1β, 
Il-6, and Pro-IL-1 in bone marrow-derived macrophages stimulated by LPS (Ahn et al. 2014). 
In a different study, low concentrations of DMSO (0.1 and 0.5% v/v) attenuated the intesti-
nal inflammatory response through reduction of mRNA expression and secretion of IL6 and 
IL1β by intestinal cells via inhibiting inflammasome activation (Hollebeeck et al. 2011b). Our 
findings in microglia agree with these results, as DMSO reduced LPS-induced secretion of in-
flammatory cytokines by microglia. The observed DMSO effects on mRNA and protein levels 
Figure 3: DMSO attenuates pro-inflammatory gene expression induced by LPS in BV-2 cells and primary microglia. 
The graphs depict the fold induction in gene expression of Il1β, Nfκb1, Cox2, and iNos in BV-2 cells (A-D) and prima-
ry microglia (E-F), respectively. Cells were treated with LPS (100 ng/mL) and/or DMSO (0.8% v/v) as indicated. Fold 
induction of gene expression was calculated using the delta-delta CT method with Hmbs expression as a reference 
and an untreated sample as controls. Data were analyzed with two-way ANOVA followed by a Tukey post-hoc test 
(*P < 0.05, **P < 0.01, ***P < 0.001). Data is represented in dot-plots with mean ± SEM.
Figure 4: DMSO reduces LPS-induced secretion of IL-6 and Il1β by BV-2 cells and primary microglia. Concentration 
of IL-6 and Il1β in the supernatant of primary microglia (A-B) and BV- cells (C-D) are depicted. Data were analyzed 
with two-way ANOVA followed by a Tukey post-hoc test (**p < 0.01, ***p < 0.001). Data is represented in dot-plots 
with mean ± SEM. 
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suggest that DMSO is involved in both transcriptional and post-transcriptional regulation of 
the inflammatory response in microglia.
NF-κB plays a pivotal role by modulating expression of several genes related with inflamma-
tory pathways including cytokines, and pro-inflammatory enzymes (COX2 and iNOS), which 
facilitates the production of pro-inflammatory mediators such as prostaglandins (PGs) and 
NO, respectively (Shabab et al. 2017). As expected, LPS increased the expression of COX2 
and iNOS in microglia, which was reduced by DMSO.
In summary, our data indicate that DMSO, at low concentration 0.1-0.8% v/v, has an an-
ti-inflammatory activity on primary microglia and BV-2 cells, by reducing pro-inflammatory 
cytokine gene expression and secretion. In addition, the induction of inflammatory medi-
ators such as PGs and NO are likely reduced by DMSO due to attenuated COX2 and iNOS 
gene expression. The anti-inflammatory effects of DMSO in microglia are likely caused by 
reduced activation of the transcription factor NF-kB and as a consequence its downstream 
target gene by DMSO.
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Alzheimer disease is an irreversible, progressive brain disorder with progressive deterio-
ration of memory and cognitive skills, which affect the simple and functional tasks of the 
AD patients. In the most of AD cases, the clinical symptoms first appear around 60 years 
old (The Lancet 2016). Several estimations indicate that AD may rank third, behind heart 
disease and cancer, as a cause of death in elderly people. AD is characterized by progressive 
neuron loss and microgliosis and caused by a combination of environmental and genetic 
factors. (Reitz and Mayeux 2014). In AD many molecular lesions are observed, and accord-
ing to multiple observations, the accumulation of misfolded proteins in the AD brain cells 
results in oxidative and inflammatory damage, which induces to synaptic dysfunction, met-
abolic alterations, energy failure and finally cell death (Cuervo, Wong, and Martinez-Vicente 
2010). Misfolded proteins bind to surface receptors from microglia and astrocytes and trig-
ger the innate immune response, characterized by the release of pro-inflammatory media-
tors which exacerbates these alterations and increases AD severity (Hong 2015b). Genomic 
studies identified several AS risk genes, and these genes encode enzymes like BACE1 in neu-
rons, APOE4 in astrocytes and transcription factors that increase pro-inflammatory cytokine 
production.
External high risk factors for AD include hypertension, dyslipidemia and obesity at midlife, 
diabetes mellitus, smoking, physical inactivity, depression and low levels of education (Ud-
din et al. 2018). Interestingly most of these external factors are related to systematic in-
flammation and lipid metabolic alterations which likely affect the immunological processes 
favoring the AD progress in the CNS.
In Chapter 2. we showed that microinjections of RNAi to silencing of BACE1 protein in the 
CA1 hippocampal area induced cognitive recovery and restored the fatty acid composition 
of lysophosphatidylethanolamine (LPE) and etherphosphatidylethanolamine (ePE) in aged 
3xTg-AD mice after 6 and 12 months of gene therapy treatment. These changes were re-
lated with pro-inflammatory pathways, since cPLA2 phosphorylated enzyme levels were 
reduced, how has been shown that their activity produces arachidonic acid we observed 
this fatty acid was reduced as well, subsequently we measured the levels of COX2 due AA 
is their main subtract, interestingly the levels significantly decreased. Together, our results 
show, for the first time, that BACE1 levels are not only related to amyloid production, but 
also control of pro-inflammatory response through restoration of phospholipid composi-
tion which downregulated specific proinflammatory agents at the hippocampus promoting 
cellular homeostasis and cognitive function recovery AD model mice. Those results showed 
that endogenous lipids are important mediators of AD not only because they are involved in 
all phases of inflammation, but also involved in the regulation and fine-tuning of its course 
and cessation. However, as little is known about the brain lipid profile in human AD, we 
performed a complete phospholipid profile analysis of brain human tissue  diagnosed with 
familial Alzheimer disease (FAD) and sporadic Alzheimer disease (SAD), which were com-
pared with healthy human tissue in Chapter 3. We performed a comparative analysis of the 
phospholipid composition of temporal cortex from FAD, SAD and, healthy human brains. A 
significant alteration between poly and unsaturated fatty acids was observed for both types 
of AD, and the phospholipid composition was different. The levels of polyunsaturated fatty 
acids were increased in both AD types, and two unsaturated lipids (PE-Cer and PG were sig-
nificantly increased in SAD, which confirmed that AD cortex has an unbalanced proportion 
of phospholipids associated to mitochondria impairment. These changes are different be-
tween FAD and SAD, in addition, these fatty acid changes suggested that neuroinflammation 
pathways were activated due to altered lipid metabolism. 
To understand how lipid metabolism and inflammatory pathways are affected in AD, we 
performed in vitro experiments described in chapter 4. We observed membrane lipid alter-
ations triggering the over activity of membrane proteins such as BACE1 suggesting a strong 
link between the Inflammation and AD pathogenesis through AA fatty acid metabolism 
(cPLA2/arachidonic acid/COX2) (chapter 2). In this chapter, we analyzed the role of cPLA2 
and fatty acid desaturases such as SCD1 and FAD6 in primary cortical neuron cultures with 
BACE1 knock-down in a glutamate excitotoxicity model. This model induced hyperphos-
phorylation of tau, increased apoptotic nuclei, LDH release, and cPLA2 expression, which 
were all reversed by BACE1-KD. In addition, co-silencing of BACE1 and cPLA2 improved the 
neuroprotective effects. However, co-silencing of BACE1 and SCD1 or FAD6 reduced these 
pro-survival effects. These results are supported by overexpression of SCD1 and FAD6, which 
resulted in a recovery of the neuroprotective effect by BACE1 silencing, but not by each 
desaturase alone. These findings suggested that BACE1 and lipid metabolism both play an 
important role in AD pathogenesis due to the over activation of BACE1 which can reduce the 
processing of fatty acids by desaturases exacerbating neuronal excitotoxicity.
In chapter 5, we describe the anti-inflammatory effect of dimethyl sulfoxide (DMSO) on 
primary microglia and BV-2 cells. We observed that DMSO did not affect cell viability at low 
concentrations (0.1-1% v/v), however, cell viability was altered at high concentrations of 
DMSO (5-10% v/v). Interestingly, lipopolysaccharide (LPS) -induced activation of microglia 
was reduced by DMSO at low concentrations. LPS stimulation resulted in increased gene ex-
pression of IL-1Β, IL6, NF-κB, iNOS and, COX2, which was significantly attenuated by 0.4-1% 
v/v DMSO. In agreement with these results, we also observed that DMSO significantly re-
duced LPS-induced IL-1Β and IL6 protein levels. We conclude that DMSO has in vitro anti-in-
flammatory effects, at low concentrations, by the reducing mRNA and protein expression of 
pro-inflammatory genes in microglial cells, but more mechanistic investigations would be 





De ziekte van Alzheimer (AD) is een ongeneeslijke hersenaandoening die gekenmerkt wordt 
door progressieve achteruitgang van het geheugen en cognitieve vaardigheden. Hierdoor 
kunnen AD-patiënten eenvoudige en functionele taken niet meer uitvoeren. In de meeste 
gevallen van AD, beginnen de klinische verschijnselen rond de leeftijd van 60 jaar (The Lancet 
2016). Onder ouderen is AD een veel voorkomende ziekte en geschat wordt dat AD, na hart-
falen en kanker, de derde meest voorkomende oorzaak voor het overlijden van ouderen is. 
AD wordt gekenmerkt door progressief verlies van zenuwcellen en activatie van glia cellen, 
de steuncellen in het centrale zenuwstelsel. AD wordt veroorzaakt door een combinatie van 
erfelijke en omgevingsfactoren (Reitz and Mayeux 2014). In de hersenen van AD-patiënten 
ontstaan gebieden, seniele plaques, waarin onjuist gevouwen eiwitten zich ophopen. Dit 
resulteert in een verstoorde functie van zenuwcellen, glia cellen en de communicatie daar-
tussen, veranderingen in de energiehuishouding van zenuwcellen en uiteindelijk celdood 
(Cuervo, Wong, and Martinez-Vicente 2010). Onjuist gevouwen eiwitten binden aan recep-
toren op de buitenkant van twee soorten glia cellen: microglia en astrocyten die daardoor 
geactiveerd raken. Hierdoor worden ontstekingsmoleculen vrijgelaten die het ziekteproces 
verergeren (Hong 2015b). DNA is het erfelijk materiaal en de erfelijke informatie op ons 
DNA ligt vast in genen. Genen bevatten informatie voor eiwitten, en deze eiwitten vervullen 
belangrijke functies in cellen. Veranderingen in genen kunnen leiden tot verstoorde functies 
in cellen met zelfs ziekten als gevolg. Met behulp van genetische studies zijn een aantal 
genen (en veranderingen in deze genen) geïdentificeerd die betrokken zijn bij AD. Een van 
de bekendste genen die gemuteerd is bij mensen met AD is het Amyloid Precursor Protein 
(APP) gen, en deze mutaties leiden tot foutieve vouwing en ophoping van het APP-eiwit. 
¬¬¬Een ander gen dat betrokken is bij AD is het BACE1 eiwit. BACE1 is een enzym dat het 
APP-eiwit klieft. Verstoorde activiteit van het BACE1 enzym leidt tot verhoogd productie 
van een APP-fragment dat samenklontert in zenuwcellen. Het BACE1 eiwit wordt als een 
mogelijk therapeutisch aanknopingspunt beschouwd om AD te behandelen en uitgebreid 
onderzocht in dit proefschrift.
Externe, hoge risicofactoren voor AD zijn onder andere hoge bloeddruk, verstoringen in de 
vethuishouding, suikerziekte op middelbare leeftijd, roken, gebrek aan lichamelijke activi-
teit, depressie en een laag opleidingsniveau (Uddin et al. 2018). Opvallend is dat de meeste 
van deze externe factoren gerelateerd zijn aan systemische ontsteking en veranderingen in 
het vet-metabolisme, wat waarschijnlijk leidt tot ontstekingsreacties die AD bevorderen.
In Hoofdstuk 2 hebben wij laten zien dat het verlagen van de hoeveelheid BACE1 eiwit in 
een deel van de hippocampus in een muismodel voor AD, een hersengebied dat wordt aang-
etast in AD, beschermend werkt. Een herstel van cognitieve functies en in de samenstel-
ling van fosfolipiden lysofosfatidylethanolamine (LPE) en etherfosfatidylethanolamine (ePE) 
werd waargenomen in oude AD muizen, 6 en 12 maanden na gentherapie. Deze veranderin-
gen in fosfolipiden hielden verband met ontsteking stimulerende signaaltransductie routes. 
Onze resultaten laten voor het eerst zien dat BACE1 niveaus niet alleen samenhangen met 
amyloïde productie, maar ook de productie van ontsteking stimulerende processen con-
troleren. Mogelijk gebeurt dit door herstel van de samenstelling van fosfolipiden wat leidt 
tot vermindering van bepaalde ontsteking stimulerende moleculen in de hippocampus en 
herstel van cognitieve functies in dit AD-muis model.
De resultaten in hoofdstuk 2 lieten zien dat fosfolipiden belangrijke factoren zijn in AD, en 
dat ze betrokken zijn bij de productie van ontstekingsmoleculen. 
Momenteel is er weinig bekend over de (fosfo)lipiden samenstelling van het brein van hu-
mane AD-patiënten. Daarom hebben we een complete fosfolipide profielanalyse gedaan 
van humaan hersenweefsel dat gediagnosticeerd is met familiaire Alzheimer (FAD) en spo-
radische Alzheimer (SAD) en dat vergeleken met gezond humaan hersenweefsel (Hoofdstuk 
3). Deze analyse is uitgevoerd op weefsel van de temporale cortex. Een significant verschil 
tussen meervoudig onverzadigde vetzuren werd waargenomen bij beide vormen van AD en 
ook de fosfolipiden samenstelling was anders. Het niveau van de meervoudig onverzadigde 
vetzuren was verhoogd in beide vormen van AD en twee onverzadigde lipiden fosphatidy-
lethanolamine-ceramide (PE-Cer) and fosfoglycerol (PG) waren significant verhoogd in SAD. 
De disbalans in fosfolipiden is geassocieerd met verstoorde mitochondriale functie en speelt 
dus mogelijk een rol in de pathologie van AD in de cortex. Daarnaast wijst de veranderde 
lipidensamenstelling op een potentiële rol van lipiden-metabolisme in de activatie van neu-
rale ontsteking bij AD.
Om te begrijpen hoe lipiden-metabolisme en ontstekingsroutes aangedaan zijn in AD, heb-
ben we in vitro experimenten gedaan die in Hoofdstuk 4 beschreven staan. We hebben 
onderzocht of veranderingen in de samenstelling van lipiden in het membraan tot een ver-
hoogde activiteit van membraaneiwitten zoals BACE1 leidt. De resultaten suggereerden dat 
er een sterk verband is tussen ontsteking en arachidonzuur metabolisme in AD-pathogen-
ese. In dit hoofdstuk analyseerden wij de rol van cPLA2 en vetzuur desaturases (zoals SCD1 
en FAD6) in gekweekte primaire corticale neuronen door het remmen van BACE1 eiwit-
productie. In dit model leidde een overdadige hoeveelheid glutamaat tot hyperfosforylatie 
van tau en een toename van apoptotische cellen, lactaat dehydrogenase uitscheiding, en 
cPLA2 expressie. Verlaging van de hoeveelheid BACE1 eiwit herstelde deze effecten. Daar-
naast zorgde de gelijktijdige varlaging van BACE1 en cPLA2 voor nog grotere neuron-bes-
chermende effecten. Daarentegen, de gelijktijdige uitschakeling van BACE1 met SCD1 of 
FAD6, leidde voor verminderde neuron-beschermde effecten van BACE1 uitschakeling. 
Deze observaties werden bevestigd in experimenten waarin de expressie van SCD1 en FAD6 
verhoogd werd, wat resulteerde in nog meer bescherming tegen glutamaat dan bij BACE1 




op als beide eiwitten aanwezig zijn. Deze resultaten suggereren dat BACE1 en lipiden-me-
tabolisme alle twee een belangrijke rol spelen in AD-pathogenese. Overactiviteit van BACE1 
kan leiden tot een verminderde omzetting van vetzuren door desaturasen wat neuronale 
excitotoxiteit versterkt. 
In Hoofdstuk 5 beschrijven we het ontstekingsremmende effect van dimethyl sulfoxide 
(DMSO) op primaire microglia en BV-2 cellen. We hebben waargenomen dat DMSO geen 
effect had op cellulaire levensvatbaarheid bij lage concentraties DMSO (0.1-1% v/v), maar 
wel bij hoge concentraties (5-10% v/v). Opvallend is dat activatie van microglia door lipopol-
ysaccharide (LPS) werd verminderd door DMSO bij lage concentraties. Stimulering door LPS 
resulteerde in toegenomen expressie van IL-1B, IL6, NFκB, iNOS en COX2, wat significant 
minder was bij concentraties van 0.4-1% v/v DMSO. DMSO verlaagde ook de door LPS ver-
hoogde eiwitniveaus van IL-1B en IL6 significant.  We concludeerden dat lage concentraties 
DMSO in vitro een ontstekingsremmend effect hebben wat zorgt voor verlaagde produc-
tie van ontstekingsfactoren microgia. Er zijn echter meer mechanistische studies nodig om 
beter te begrijpen hoe DMSO deze ontstekingssignalen remt.
Conclusies en perspectieven
De resultaten beschreven in dit proefschrift laten zien dat het remmen van BACE1 in de 
hippopcampus, de AD-geassocieerde degeneratie in AD-model muizen verbetert. Dit werk 
geeft aan dat BACE1 betrokken is bij de vetzuursamenstelling van fosfatidylethanol-derivat-
en, aangezien BACE1-remming bij AD-muizen de niveaus van deze lipide-derivaten herstelt, 
wat geassocieerd kan zijn met leer- en geheugenverbetering. Deze verandering in lipiden 
samenstelling werd ook waargenomen in de hersen van mensen met erfelijke en spora-
dische AD. De positieve effecten van BACE1 remming hingen af van de activiteit van de-
saturases, enzymen die pro-inflammatoire signalen verminderen, wat suggereert dat lipide 
metabolisme een belangrijke regulator is van het neurodegeneratieve proces. De progressie 
van AD is afhankelijk van de productie van bèta-amyloïd maar tegelijkertijd speelt het ver-
anderde lipide metabolisme en de inflammatoire respons in de hersenen van AD-patiënten 
een rol. Deze observaties illustreren dat er een grote behoefte is aan nieuw goed opgezet 
onderzoek naar combinatietherapieën tegen AD.
De mogelijkheid om de TAU- en Aβ-pathologie te verbeteren, biedt potentieel enorme 
voordelen voor mensen met AD, hopelijk leidt het tot een omkering van het pathologische 
proces. Niettemin, gezien het functionele belang van BACE1 in het volwassen brein, moet 
aanvullend onderzoek worden uitgevoerd die de mogelijke gevolgen van de lang termijn 
reductie in BACE1 hoeveelheden op de functie van zenuwcellen en glia cellen vast te stellen. 
Evenzo moeten de implicaties van BACE1 reductie in termen van hersenfunctie bij AD muizen 
worden bepaald door een nauwkeurigere evaluatie van meer cognitieve vaardigheden die 
zijn aangedaan in AD. Tenslotte is er nog steeds een grote beperking in de beschikbaar-
heid van een betrouwbaar afleveringssysteem dat in staat is om de bloed-hersenbarrière te 
doorkruisen om een systemische behandeling te bewerkstelligen en daarmee een effectieve 





BACE1 gene silencing reduces tauopathy by regulating the inflammatory response.
Neurodegeneration is considered the main public health problem for the XXI century, and 
among neurodegenerative diseases, Alzheimer’s disease (AD) is the most abundant and 
best studied. However, despite intense scientific research, at the moment there is no effec-
tive and definitive therapeutic strategy for its treatment (Mandler et al. 2014; Heneka et al. 
2015c). In this thesis, we show a novel approach, employing RNA interference (RNAi) as a 
tool for the treatment of neurodegeneration. As a therapeutic target, we selected the β-site 
amyloid precursor protein cleaving enzyme 1 (BACE1), a family member of transmembrane 
aspartic proteases. BACE1 exhibits all the functional properties of beta-secretase, and as it 
is the key enzyme that initiates the formation of Aβ, it is an attractive drug target for AD.
BACE1 is a potential drug target for AD. There were and are several clinical trials with multi-
ple BACE1 inhibitors focused on small molecules or anti-Aβ immunotherapy with the main 
objective to inhibit BACE1 activity to clean the brain of aggregated Aβ, respectively. How-
ever, these trials have been challenging and several have failed during clinical implemen-
tation (Vassar 2014; Koelsch 2017a). Last year, three clinical trials with BACE1 inhibitors 
were stopped due to collateral adverse events due to a specific effect of these inhibitors. 
Merck ended phase III studies of Verubecestat and APECS, as well as AstraZeneca/Eli Lilly 
with phase III trial of Lanabecestat, mainly because all of those studies failed to reduce 
cognitive decline in AD patients. On the other side BACE1 knockout studies in mice failed as 
well because of adverse side effects, such as demyelination and reduced muscle spindles, 
which is related with the physiological function of BACE1. Together these results showed 
that effective therapies require an exquisitely safe and specific therapeutic agent (Vassar 
2014; Koelsch 2017a). Problems that can potentially be overcome with the specific BACE1 
knockdown by shRNA-BACE1 (BACE1miR). In chapter 2, our data showed, for the first time, 
that BACE1 targeting-induced neuroprotection, cognitive recovery, reduces soluble hyper-
phosphorylated tau, modulating proinflammatory pathways through lipid metabolism mod-
ification in the hippocampi of aged 3xTg-AD mice.
Another possible problem to create successful therapies is the time factor, since, the failure 
to be efficient in stopping or preventing cognitive decline might be related with the starting 
time of treatment, if the AD stage is too advanced, the Aβ and tau accumulation and neu-
rodegeneration might be irreversible. However, our results showed that BACE1 knockdown 
by shBACE1miR is effective at different stages of AD in mice. The long-term therapy started 
in young mice (6 months) when proteinopathies and cognitive decline are in an early stage 
and these mice were evaluated 12 months later, and on the other hand, we included a 
short-term therapy group where BACE12 was knocked down in 12 months old mice, when 
the proteinopathies and cognitive decline are in a more advanced stage, and this group was 
evaluated 6 months later. In both groups, a neuroprotective effect including cognitive recov-
ery and decrease of tau aggregation by BACE1-RNAi was observed.
Previously, Piedrahita et al, validated that silencing of BACE1 in 3xTg-AD mice reduced the 
CTF (carboxy-terminal fragment) and 1–42 Aβ and hyperphorylated tau levels in the hip-
pocampus by autophagy. However, this effect was stopped by the autophagy inhibitor 3MA, 
which blocks PE lipidation, avoiding autophagosome formation (Piedrahita et al. 2016). This 
result opened new questions about the role of lipids in AD, therefore we performed a deep 
lipidomic analysis of hippocampi from AD model mice to evaluate if BACE1 silencing had an 
effect on brain lipid composition. Interestingly our results showed different lipid composi-
tions between control and AD model mice. AD mice had significantly higher concentrations 
of unsaturated lipids which is widely described as a risk factor on AD, since, these lipids 
reduce the cell membrane fluidity, increasing activity of membrane proteins such as BACE1 
favoring the processing of APP and subsequently Aβ production (Hirsch-Reinshagen, Bur-
gess, and Wellington 2009). 
Interestingly, the short- and long-term treatment with shBACE1miR changed the profiles 
of mainly phospholipid (PL) levels, by regulation of PL levels and specific subspecies com-
position of PE plasmalogens as LPE and ePE, which were mainly composed of unsaturated 
fatty acid chains in AD brains.  BACE1 silencing balanced their levels to control levels, in 
agreement with the findings of Piedrahita et al, where PE played an important role to de-
crease the protein accumulation by the silencing of BACE1 (D Piedrahita, Castro-Alvarez, 
Boudreau, Villegas-Lanau, Kosik, Gallego-Gomez, and Cardona-Gomez 2015). In addition, 
those findings were confirmed by the lipid profile evaluation of two types of the human AD 
(SAD and FAD), where the levels of phospholipids in subspecies PE and PG, both mainly com-
posed by unsaturated fatty acids, increased. In addition, we detected that PE-Cer increased 
in SAD group, suggesting PE-Cer as a marker of chronic impairment in SAD patients. Differ-
ent studies reported alterations of PL brain levels in neurodegenerative diseases, PL species 
such as PI (Whiley et al. 2014), PC (Araki and Wurtman 1997; Whiley et al. 2014) PE and its 
derivatives, such as LPE and ePE (Nesic et al. 2012), PS (Shea 1997); and, PE-Cer (Chan et al. 
2012) seeming to have multifactorial origins, including the hyperactivation of phospholipas-
es, mitochondrial stress, peroxisomal dysfunction and irregular FA composition of PLs. Ac-
cordingly, it has been shown that phospholipids participate in numerous cellular functions 
such as inflammatory processes, intracellular signaling, trafficking, cell growth, survival and, 
pro-apoptotic pathways. Recently, a specific receptor for phosphatidyl serine was reported 
which is related to the pathologic over activation of microglia (Krasemann et al. 2017).
The role of PL in chronic inflammation has been extensively investigating and is mainly asso-
ciated with immune-dependent and vascular-related chronic inflammatory diseases, includ-
ing diabetes, obesity and neurodegenerative disorders such as AD (Dorninger et al. 2015). 
This link is mediated by the fatty acid composition of PL as PE, since it has the ω-6 PUFA 




brane lipids by PLA2 and used as a substrate for three different enzymes: COX 1 and 2, Lipox-
ygenases and epoxygenases. In our study, we reported increased levels of PLA2 and COX2 in 
AD brains which is tightly linked with the production of prostaglandins (PG)(Abdullah et al. 
2017a). Indeed, PGs are associated to the inflammation process, mostly with the transition 
from acute to chronic inflammation; in general, through activation of the cytokine cascade, 
amplification of innate immune response, exacerbated recruitment of immune cells (micro-
glia) and an increase of pro-inflammatory genes induced by cytokines (Zárate et al. 2017b). 
Our findings showed that silencing of BACE1 decreased the concentration of AA together 
with a reduction of PLA2 and COX2 levels supporting these associations between specific 
PLs, inflammatory processes and neurodegenerative diseases as AD. 
We also observed modifications in essential fatty acids such as Docosahexaenoic acid (DHA), 
an omega-3 fatty acid essential for normal brain growth and cognitive function, which acts 
as a neurotrophic factor and modulates synaptic activity (Kuratko et al. 2013). DHA is highly 
enriched in brain PLs, which is consistent with its importance in brain function (Sherratt et 
al. 2016). The present work indicates that a misbalanced fatty acid composition in AD also 
includes DHA. The DHA levels increased, in the form of PE and LPE, while in the form of 
ePE, DHA levels decreased, those changes were observed in AD brains. Interestingly, DHA 
levels were restored to basal levels by BACE1 gene therapy in AD model mice. Pro-survival 
properties of DHA by down-regulation of the chronic inflammatory response under neu-
rotoxic conditions was demonstrated in cellular and animal models (Zárate et al. 2017a; 
Heras-Sandoval, Pedraza-Chaverri, and Pérez-Rojas 2016b). This effect is associated with 
two physiological properties in animal and in vitro models: DHA increases membrane lipid 
fluidity due to its chemical structure (Sherratt et al. 2016), which reduces the overactivity 
of membrane enzymes such as BACE1, and on the other hand, DHA decreases the produc-
tion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, inhibiting the activity of 
mitogen-activated protein kinases (MAPK), which promotes the activation of enzymes (de-
saturases) to regulate fatty acid storage and glucose metabolism in neurons and glia cells 
(Heras-Sandoval, Pedraza-Chaverri, and Pérez-Rojas 2016a). These results together suggest 
that PL play an important role in AD progress, highlighting that specific lipid species as PE 
could be promising molecular targets either as a biomarker or therapy in neurodegenerative 
processes. (Figure 1).
Saturation balance of fatty acids play key role in the control of AD inflammation  
Phospholipids are the major component of cell membranes, source of energy and, key 
pathophysiological mediators of several cell signaling pathways. In fact, they are “bioactive 
lipids” with a pivotal role in immune regulation, inflammation, and cell homeostasis. Lipids 
can be classified according to the number of double bonds presents in their fatty acid car-
bon chain, into three lipid categories: unsaturated, monounsaturated and polyunsaturated, 
which determines their specific role in cell signaling (Fahy et al. 2005). The bioactive lipids 
mostly are composed of mono and polyunsaturated fatty acids which are processed by cat-
alytic enzymes such as stearoyl-CoA desaturase (SCD) and fatty acid desaturases (FADS) re-
spectively (Tosi et al. 2014). 
The diverse roles of both enzymes have an impact on cell physiology, and their unbalanced 
activity leads to pro-inflammatory disorders such as neurodegenerative diseases. However, 
little is known about the interaction between those lipid enzymes and other proteins such 
as cPLA2 and BACE1 involved in the neuro-inflammation process in AD. Therefore, in chap-
ter 4, considering cPLA2 is the main enzyme involved in the production of plasmalogens 
(Makide et al. 2009) and that SCD1 and FADS6 are responsible for fatty acid unsaturation; 
we analyzed the role of cPLA2, COX2 and desaturases (SCD1, FADS6) in BACE1-KD-induced 
in neuron cultures. We observed protective action and a reduction in tau hyperphosphoryl-
ation in a model of glutamate excitotoxicity. Moreover, a synergic neuroprotective effect of 
BACE1 silencing was observed when simultaneously SCD1 and FADS6 were overexpressed 
through downregulation of pro-inflammatory cascade (AA, CPLA2, and COX2). Which was 
reverted when SCD1 and FADS6 were silencing together with BACE1.
SCD1 is the rate-limiting enzyme catalyzing the monounsaturated fatty acids (MUFA), mainly 
oleate (18:1) and Palmitoleate (16:1), which are the major FA of membrane conforming PL 
and TG (Lavandera et al. 2017). The conversion-ratio of saturated to MUFA determine the 
PL composition, consequently, the alteration of this ratio affects cell homeostasis triggering 
a variety of diseases including cardiovascular diseases, obesity, diabetes, cancer, and neuro-
logical disorders (Ntambi and Miyazaki 2004). Our results showed, that SCD1 expression im-
proved the neuroprotective effect of BACE1 silencing, which is supported by studies where 
SCD1 significantly inhibited caspase activation, ceramide synthesis, apoptotic cell death and 
mitochondrial reactive oxygen species (ROS) generation by cardiac myocytes (Matsui et al. 
2012). In addition, oleic acid synthetized by SCD1 mediates neuronal growth, migration, and 
arrangement of synapses (Polo-Hernandez et al. 2014). Although, in our experiments, over-
expression of SCD1 alone did restore cellular homeostasis under glutamate excitotoxicity. 
However, its synergistic effect with the BACE1-KD -mediated neuroprotection clearly sug-
gested an important role of SCD1 in neurons. These data suggest that the activity of SCD1 in-
creased MUFA levels and reduced the high concentration of saturated FA and their adverse 
catabolism (pro-inflammatory cascade), and eventually preventing glutamate excitotoxicity.
Polyunsaturated fatty acids (PUFAs) are considered to be critical molecules to regulate cell 
homeostasis, brain development, and cognition, as well as several neurological diseases. 
Their metabolism is regulated by numerous fatty acid elongases and desaturases play key 
roles in synthesizing PUFAs. They are precursors of eicosanoids which modulate immune 
responses by pro and anti-inflammatory pathways; DHA (22:6) is the most described pre-
cursor of anti-inflammatory FA (Lavandera et al. 2017). Thereby, it has been established 




is synthesized by FADS6, which introduce a double bond at carbon position 6 and work co-
operatively with elongases to extend the carbon chain. In our study the role of FADS6 was 
assessed on primary neuron cultures, we observed that the silencing of FADS6 diminished 
the neuroprotective effect of BACE1 silencing, which was reverted by FADS6 overexpression 
through downregulation of pro-inflammatory proteins such as cPLA2 and COX2.
Deletion of FADS6 gene expression abolishes the initial step in the enzymatic cascade of 
PUFA synthesis in mouse (Stoffel et al. 2008), resulting in low concentrations of DHA, and 
high concentrations of saturated FA (palmitic and stearic acids) and an increase in AA, which 
together are risk factors for AD. In contrast, the expression and activity of FADS6 is essential 
to maintain tissue homeostasis through the DHA synthesis, promoting pro-survival molecu-
lar pathways, such as increased expression of extracellular signal-regulated protein kinase 1 
and 2 (ERK1/2), brain-derived neurotrophic factor (BDNF), and anti-apoptotic Bcl-2, reduced 
expression of cPLA and COX2 proteins in cultured cortical neurons (Figueroa et al. 2012). 
FADS6 activity promotes neuronal activity and prevents memory deficits (Bazinet and Laye 
2014). Levels of neuronal activity indicators such as c-Fos are decreased in neurodegener-
ative diseases, which alters the action potentials and the synaptic connections. Interest-
ingly, the synthesis of DHA restored c-Fos expression and enhanced neuronal activity in 
the hippocampus leading to the recovery of memory deficits in mice (Hussain et al. 2013). 
FADS6 is also important for the regulation of proinflammatory proteins, such as cPLA and 
COX2. These results are supported by several gene expression studies performed on mouse 
brain deficient for DHA that revealed a loss of synaptic proteins. In AD, the proteinopa-
thies induce apoptosis through multiples phosphorylation of kinases such as c-Jun N-ter-
minal kinase (JNK) and cyclin depend on kinase 5 (CDK5) and, consequently, triggering the 
phosphorylation of tau protein (Yarza et al. 2016; Bhounsule et al. 2017). The induced ex-
pression of FADS6 in 3xTg-AD mice prevents the hyperphosphorylation of kinases and ulti-
mately protected neurons from apoptosis. Since lower levels of hyperphosphorylated tau 
and improved brain function were observed in in vitro and in vivo experiments due to the 
enhanced endogenous production of DHA (Lebbadi et al. 2011), which is consistent with 
our results. Finally, it is noteworthy that the beneficial actions of BACE1 silencing and FADS6 
overexpression on cortical neurons cultures might be associated with an increase in the 
expression of transcription factors, which are involved on differentiation and survival path-
ways of neurons. (Figure 1).
DMSO inhibit the inflammatory response on microglia cells
Microglia has been widely described as a potential source and target of important neuropro-
tective as well as neurotoxic factors, since their activation may keep CNS homeostasis. How-
ever, their uncontrolled activation contributes to neurotoxicity in brain disorders (Hickman, 
Allison, and El Khoury 2008c). The over-activation of microglia triggered the production of 
inflammatory mediators such as cytokines (IL-1β and IL-6), prostaglandins (PGE), and nitric 
oxide (NO) through enzymatic activity of COX2 and iNOS respectively. Furthermore, nuclear 
factors such as NF-kB is also overexpressed (Shabab et al. 2017). All these molecules are 
involved with neuroinflammation in several neurological diseases. Thus, intervention with 
microglia over activation could be a therapeutic target against multiple neuroinflammatory 
diseases.
IL-1β and IL-6 are two main pro-inflammatory cytokines overproduced by activated micro-
glia during the course of neuroinflammation (Zheng, Zhou, and Wang 2016a). In the brain, 
several stimuli, such as bacterial infections and LPS, β-amyloid and acute traumatic injuries 
have been shown to increase IL-1Aβ and IL-6 levels (W. Y. Wang et al. 2015). Which is tightly 
related to detrimental effects such as mitochondrial dysfunction, oxidative stress and apop-
tosis pathways in neuronal cells. This study investigates whether DMSO inhibits LPS-induced 
production of inflammatory cytokines in primary microglia and BV2 cells, a microglia cell 
line. Our data indicate that DMSO inhibited LPS-induced mRNA expression and protein se-
cretion of IL-1β and IL-6 in activated primary microglia and BV-2 cells in a dose-dependent 
manner. These results indicate that DMSO is able to modulate the expression of inflamma-
tory cytokines in over activated microglia. After LPS challenge, microglia increased COX-2 
levels, which is the main enzyme for the production of PGE during inflammation, contribut-
ing to the development of chronic neurological disorders such as stroke, multiple sclerosis, 
Alzheimer’s disease and Parkinson’s disease (Ferrer et al. 2018; Phillis, Horrocks, and Faroo-
qui 2006) In this study, DMSO inhibited LPS-induced PGE2 production by reducing the COX-2 
mRNA expression in activated primary microglia and BV-2 cells in a concentration-depend-
ent manner. This result indicates that the inhibition of PGE2 production by DMSO might be 
due to the suppression of COX2 up-regulation in activated microglia.
Another important pro-inflammatory molecule released by activated microglia is NO, which 
is known (Hickman, Allison, and El Khoury 2008a; Jay, von Saucken, and Landreth 2017) to 
be involved in the neuroinflammation processes (Gu, Nakamura, and Lipton 2010). NO is 
synthesized by the iNOS enzyme, and their levels and activity are significantly induced in ac-
tivated microglia after the exposure to various stimulators such as LPS (Gu, Nakamura, and 
Lipton 2010  Saini and Singh 2018). For that reason, therapeutic agents targeted to inhibit 
the iNOS expression are potentially beneficial in the treatment of inflammatory diseases, 
since, down-regulation of NO production reduced the over activated microglia phenotype. 
Our results suggest DMSO decreased LPS-induced NO production by down-regulation of 
iNOS mRNA expression in microglia. That result indicates DMSO has anti-inflammatory 




Finally, we evaluated the mRNA expression of NF-kB which is a key regulator of inflamma-
tory response in microglia cells, since, it is a pleiotropic regulator of several genes involved 
in the synthesis of inflammatory cytokines (IL-1β and IL-6) and enzymes related to the in-
flammatory process (COX2 and iNOS) during microglia responses to activating LPS stimu-
li (Kopitar-Jerala 2015). Hence, this transcription factor plays an important role in several 
pathologic conditions, and it makes NF-kB a potential target in multiples diseases (Saini and 
Singh 2018). The molecular activation of NF-kB starts at the cytoplasm with the activation 
of IκB kinase (IKK) and followed by I-κBα phosphorylation allowing NF-kB translocation and 
activation into the nucleus (Sarnico et al. 2009). Thus, activation is crucial to triggering the 
expression of pro-inflammatory genes in microglia cells. We showed that DMSO at 0.8% may 
prevented LPS-induced activation of NF-kB. Therefore, inhibition of NF-kB signaling path-
ways in microglia by DMSO results in the down-regulation of inflammatory mediators, which 
result in a strong anti-inflammatory effect on stimuli-LPS microglia. 
In this, study, we observed that an in vitro LPS challenge on microglia cells DMSO exert an 
anti-inflammatory effect at low concentrations (0,8% v/v). DMSO down-regulated the mRNA 
and protein secretion of proinflammatory cytokines such as IL-6 and IL-1β. In addition, our 
data showed that DMSO decreased the mRNA expression of COX2 and iNOS enzymes, which 
have been associated with inflammatory pathways in microglia. Furthermore, DMSO treat-
ment was able to reduce the mRNA expression of NF-κB a central regulator of microglial 
responses to activating stimuli as LPS. This results together indicate for the first time the fact 
that DMSO has anti-inflammatory properties on microglia and could provide a beneficial 
effect against inflammatory brain disorders. 
Conclusions and perspectives
The data presented in this thesis show that the silencing of hippocampal BACE1 by RNAi 
ameliorates AD degeneration in 3xTg-AD mice. This work indicates that BACE1 is involved in 
the FA composition of PE-derivates, since BACE1 silencing in 3xTg-AD mice restores the lev-
els of lipid subspecies that are altered in AD mice, which might be associated with learning 
and memory improvement. This alteration in PE composition was also observed in human 
EOAD and LOAD CNS tissue. The positive effects of BACE1 silencing depended on the activity 
of desaturases enzymes to reduce the proinflammatory signals, suggesting lipid metabolism 
is a key regulator of the neurodegenerative process. Showing that the progression of AD 
depends on beta-amyloid production but at the same time altered lipid metabolism and 
inflammatory response from CNS. These observations illustrate that there is a great need for 
new well-designed research on combination therapies against AD.
The possibility of ameliorating tau and Aβ pathology poses potentially enormous bene-
fits for people affected with AD, hopefully offering a reversion of the pathological process 
(Figure 1). Nonetheless, given the functional importance of BACE1 in the adult brain, addi-
tional studies should be carried out analyzing the possible consequences of its long-term 
down-regulation on neuronal and glia function and eventually compare these findings with 
the already demonstrated benefits of pharmacological inhibitors. Likewise, the implications 
of silencing in terms of brain function in wild type and 3xTg-AD mice should be determined 
by evaluation of more cognitive skills implied in AD. Finally, there is still great limitation in 
the availability of a reliable delivery system that is able to cross the blood brain barrier in 
order to achieve a systemic treatment of neurotropic action and, therefore, deliver an effec-
tive therapy to the patient with neurodegeneration.
Figure 1. BACE1 silencing has an anti-inflammatory effect through FA metabolism regulation. Following the red 
arrow: In AD the levels of BACE1 enzyme are elevated which increases the processing of APP by this enzyme. Fur-
thermore, the levels of SFA at the cell membrane system also are increased, which favors the activity and stability 
of BACE1. The increased levels of SFA change the rate balance between saturated and unsaturated fatty acids (FA), 
due to both low activity levels of desaturated FA enzymes such as SCD1 and FADS6, and high levels and activity of 
cytoplasmatic enzymes such as cPLA2 and COX2, which synthesize AA and pro-inflammatory mediators, respective-
ly. Finally, all those events together trigger aggregation of Tau protein, diminished beta oxidation, and excitotoxicity 
in AD brains. Following the blue arrow: in the nucleus, shBACE1miR is processed by RNAi maturation enzymes to 
induce the silencing of BACE1 gene expression. Consequently, the levels of BACE1 enzyme and the Aβ and tau 
aggregation process decreased, as well as the levels of SFA, due the activity of the desaturases SCD1 and FADS6, 
which led to up-regulation of unsaturated FA levels and plasmalogens derivates from the FA phosphatidylcholine 
(ePE and LPE). These plasmalogens are mainly composed by DHA, which is not a substrate of COX2 protein, sug-
gesting the production of pro-inflammatory mediators from COX2 activity are reduced as a consequence of BACE1 
silencing. All these findings together suggest that BACE1 silencing restore the cell homeostasis by lipid metabolism 
and inflammatory response down-regulation. Source Graphic templates (CREATIVE COMMONS LICENCE and Servi-
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AA: Arachidonic acid 
AAV:  Adeno associate virus




AICD: intracellular APP fragment
APOE: apolipoprotein
APP: amyloid precursor protein
ASC: Apoptosis-associated speck-like protein 
containing a CARD 
ATP: Adenosine triphosphate
Aβ: Amyloid Beta
BACE1: Beta secretase 1
BBB: blood-brain barrier
CDK5: Cyclin dependent of kinase 5
Cer: ceramide 
CNS: Central nervous system














LPA: lysophosphatidic acid  
LPC: lysophosphatidylcholine
LPE: lysophosphatidylethanolamine
LTP: long-term potentiation 
MHC-II: major histocompatibility class 2 
complex
NFT: neurofibrillary tangles 
NF-κB: nuclear factor-κB 
NMDA: N-methyl-D-aspartate 





PGE2: prostaglandin E2 receptors 
PI: phosphatidylinositol
PI3K: phosphatidylinositol-3 kinase
PKC: protein kinase C 






RNA: Ribonucleic Acid 
RNAi: RNA interference 
ROS: Reactive oxygen species
sAPP: soluble amyloid protein precursor 
sAPPα
shBACE1miR: short hairpin BACE1 micro 
RNA





TNF-α: Tumoral Necrosis Factor- alpha 
TREM2: triggering receptor expressed by 
myeloid cells 2 
βMCD: β-methyl cyclodextrin 
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